An Evolving Epigenome that Determines Tissue and Cell Specificity by Sears, Renee Louise
Washington University in St. Louis 
Washington University Open Scholarship 
Arts & Sciences Electronic Theses and 
Dissertations Arts & Sciences 
Winter 12-15-2019 
An Evolving Epigenome that Determines Tissue and Cell 
Specificity 
Renee Louise Sears 
Washington University in St. Louis 
Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds 
 Part of the Biology Commons, Developmental Biology Commons, Evolution Commons, and the 
Genetics Commons 
Recommended Citation 
Sears, Renee Louise, "An Evolving Epigenome that Determines Tissue and Cell Specificity" (2019). Arts & 
Sciences Electronic Theses and Dissertations. 2018. 
https://openscholarship.wustl.edu/art_sci_etds/2018 
This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open 
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an 




WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Human and Statistical Genetics 
 
Dissertation Examination Committee: 








An Evolving Epigenome that Determines Tissue and Cell Specificity 
by 
Renee Louise Sears 
 
 
A dissertation presented to  
The Graduate School  
of Washington University in 
partial fulfillment of the 
requirements for the degree 





















© 2019, Renee Louise Sears
ii 
 
Table of Contents 
List of Figures ................................................................................................................................. v 
List of Tables ............................................................................................................................... viii 
Acknowledgments .......................................................................................................................... x 
Abstract of the Dissertation ........................................................................................................ xiv 
Chapter 1: Introduction ................................................................................................................. 1 
1.1 The Transcriptome ........................................................................................................................ 2 
1.1.1 Cell Type-Specific Neural Transcriptome Studies ...................................................................................3 
1.1.2 The bacTRAP System ..............................................................................................................................6 
1.2 The Epigenome .............................................................................................................................. 7 
1.2.1 Chromatin Structure .................................................................................................................................8 
1.2.2 CpG DNA Methylation ..........................................................................................................................10 
1.2.3 Neural CpG DNA Methylation ..............................................................................................................11 
1.2.4 Non-CpG DNA Methylation ..................................................................................................................12 
1.3 Comparative Genomics ............................................................................................................... 14 
1.3.1 Comparative Epigenomics .....................................................................................................................14 
Chapter 2: Epigenome Atlas of Mouse Astrocytes, Oligodendrocytes, and Motor Neurons .... 18 
2.1 Abstract ........................................................................................................................................ 19 
2.2 Introduction ................................................................................................................................. 19 
2.3 Results .......................................................................................................................................... 21 
2.3.1  Isolation of Nuclei to Create Epigenomic and Transcriptomic Maps ....................................................21 
2.3.2  RNA-Seq Re-Captures Neural Cell Type Markers ................................................................................22 
2.3.3  Identifying Novel and Putative Cell Type-Specific Circular RNAs ......................................................23 
2.3.4 Open Chromatin Signatures Define Cell Type/Lineage-Specific Distal and Shared Proximal 
Regulatory Regions ................................................................................................................................24 
2.3.5  TF Binding in Open Chromatin Regions ...............................................................................................26 
2.3.6  DNA Methylation Differentiates Between Glial and Neuronal Cell Types ...........................................26 
2.3.7  Proximal Regulatory Regions are Shared across Neural Cell Types .....................................................28 
2.3.8  Common and Distinct Glial Epigenetics ................................................................................................30 
2.3.9 Sex-Specific Epigenomic Differences ....................................................................................................30 
2.3.10 Oligodendrocyte-Specific Epigenetic Patterns Revealed at the QK Locus ............................................33 
2.4 Discussion and Conclusions ........................................................................................................ 35 
2.5 Methods ........................................................................................................................................ 38 
2.5.1 Mice ........................................................................................................................................................38 
2.5.2 Nuclei Isolation and Sorting ...................................................................................................................38 
2.5.3 RNA Extraction and library generation ..................................................................................................38 
2.5.4 DNA Extraction and Bisulfite Sequencing library generation ...............................................................39 
2.5.5 ATAC-Seq library generation ................................................................................................................39 
iii 
 
2.5.6 mESC Culture .........................................................................................................................................40 
2.5.7 RNA-Seq data processing ......................................................................................................................40 
2.5.8 Bisulfite Sequencing data processing .....................................................................................................41 
2.5.9 ATAC-Seq data processing ....................................................................................................................42 
2.5.10 General Processing .................................................................................................................................43 
2.5.11 Hi-C Data Visualization .........................................................................................................................43 
2.5.12 Accession Numbers ................................................................................................................................43 
2.6 Acknowledgements and Funding ............................................................................................... 44 
2.7 Author Contributions ................................................................................................................. 44 
2.8 Figures & Tables ......................................................................................................................... 45 
Chapter 3: bacTRAP mESC Creation ......................................................................................... 60 
3.1 Abstract ........................................................................................................................................ 61 
3.2 Introduction ................................................................................................................................. 61 
3.3 Results .......................................................................................................................................... 63 
3.3.1  Successful Differentiation of Astrocytes, Oligodendrocytes, and Neurons ...........................................63 
3.3.2  bacTRAP mESC Creation ......................................................................................................................64 
3.3.3  Assessing Differentiation of bacTRAP mESCs .....................................................................................65 
3.4 Discussion and Conclusions ........................................................................................................ 66 
3.5 Methods ........................................................................................................................................ 67 
3.5.1 RW.4 mESC Culturing and Differentiation ...........................................................................................67 
3.5.2 Cell Staining Methods ............................................................................................................................68 
3.5.3 MEFs ......................................................................................................................................................69 
3.5.4 Mice ........................................................................................................................................................69 
3.5.5 bacTRAP mESC Creation ......................................................................................................................69 
3.5.6 Nuclei Extraction and FANS ..................................................................................................................70 
3.6 Acknowledgements ...................................................................................................................... 71 
3.7 Figures and Tables ...................................................................................................................... 72 
Chapter 4: Tissue-specific DNA methylation is conserved across human, mouse, and rat, and  
driven by primary sequence conservation ............................................................... 77 
4.1 Abstract ........................................................................................................................................ 78 
4.2 Introduction ................................................................................................................................. 78 
4.3 Results .......................................................................................................................................... 82 
4.3.1 Up to 37% of rat tissue-specific differentially methylated regions are epigenetically conserved in 
mouse and human ...................................................................................................................................82 
4.3.2 Epigenetically conserved tsDMRs exhibit distinct genomic and epigenomic features as compared to 
epigenetically non-conserved tsDMRs ...................................................................................................85 
4.3.3 Epigenetic conservation is associated with genetic conservation ..........................................................87 
4.3.4 Epigenetic conservation can be explained by conservation of TF binding sites ....................................88 
4.3.5 Evolutionary dynamics of tsDMRs ........................................................................................................89 
iv 
 
4.4 Discussion and Conclusions ........................................................................................................ 93 
4.5 Methods ........................................................................................................................................ 98 
4.5.1 Animals ..................................................................................................................................................98 
4.5.2 Processing MeDIP-seq and MRE-seq data ............................................................................................99 
4.5.3 Processing histone modification data .....................................................................................................99 
4.5.4 Processing whole-genome bisulfite sequencing data .............................................................................99 
4.5.5 Defining tissue-specific hypomethylated DMRs .................................................................................100 
4.5.6 Obtaining genomic distribution-matched control set ...........................................................................100 
4.5.7 Mapping orthologous regions ...............................................................................................................101 
4.5.8 Defining three-way orthologous regions ..............................................................................................101 
4.5.9 Defining epigenetic conservation .........................................................................................................101 
4.5.10 Calculating the distance to the TSS ......................................................................................................102 
4.5.11 Genomic features ..................................................................................................................................103 
4.5.12 Calculating genetic conservation at tsDMRs .......................................................................................103 
4.5.13   Calculating epigenetic conservation enrichment ..................................................................................103 
4.5.14   Motif analysis .......................................................................................................................................104 
4.5.15   Data Availability ..................................................................................................................................104 
4.6 Acknowledgements and Funding ............................................................................................. 105 
4.7 Author Contributions ............................................................................................................... 105 
4.8 Figures & Tables ....................................................................................................................... 106 
Chapter 5: Conclusions and Future Directions ....................................................................... 132 
5.1 Significance ................................................................................................................................ 133 
5.2 Future Directions ....................................................................................................................... 135 
5.2.1  Regulation of Qk ..................................................................................................................................135 
5.2.2  Cell Type Specificity of Circular RNAs ..............................................................................................136 
5.2.3  Central Nervous System Epigenetics ...................................................................................................136 
5.2.4  Epigenetics in vivo versus in vitro ........................................................................................................138 
5.2.5  Epigenome Evolution ...........................................................................................................................142 
5.3 Summary .................................................................................................................................... 143 
Appendix A: Gene Sets from Epigenome Atlas of Mouse Astrocytes, Oligodendrocytes, and 
Motor Neurons ........................................................................................................ 144 
A.1 Astrocyte Expressed Gene Set ................................................................................................. 145 
A.2 Oligodendrocyte Expressed Gene Set ..................................................................................... 153 





List of Figures 
Chapter 2 
Figure 1. Nuclei Isolation from bacTRAP Transgenic Mice. . . . . . . . . . . . . . . . . . . . . . . . . . . . .45 
Figure 2. Identifying Differentially Expressed Genes and Assessing Lineage. . . . . . . . . . . . . . .46 
Figure 3. Differentially Accessible Regions and Their Role as Regulatory Regions. . . . . . . . . . 47 
Figure 4. Profiling DNA Methylation and the Relationship between Methylation and Expression. 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 
Figure 5. Shared Proximal and Cell Type-Specific Regulatory Regions defined by DNA 
Methylation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 
Figure 6. Sex-Specific Epigenetic Differences. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 
Figure 7. Clustered Cell Type-Specific DARs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 
Supplementary Figures 
Supplementary Figure 1. CSEA Analysis of Gene Sets. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 
Supplementary Figure 2. Clustering of Cell Types by DNA Methylation. . . . . . . . . . . . . . . . . . 53 
Supplementary Figure 3. ATAC Signal over Promoter Regions and Overlap with Chip-Seq 
Experiments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54 
Supplementary Figure 4. DNA Methylation Distributions and Integration with Expression Data. . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 
Supplementary Figure 5. Sex-Specific Gene Expression and X Inactivation Escape Genes. . . . 56 
Supplementary Figure 6. Accessing the Data through the WashU Epigenome Browser. . . . . . . 57 
Chapter 3 
Figure 1. Cell Staining of Cells Differentiated from RW.4 mESCs. . . . . . . . . . . . . . . . . . . . . . . 72 
Figure 2. Creation of bacTRAP mESCs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 
Figure 3. Cell Staining of Cells Differentiated from bacTRAP mESCs . . . . . . . . . . . . . . . . . . . 74 
Supplementary Figures 
Supplementary Figure 1. Additional Cell Staining of Cells Differentiated from RW.4 mESC. . 75 
vi 
 
Chapter 4  
Figure 1. Rat tissue-specific DMRs (tsDMRs) and their orthologous regions in mouse and 
human. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .106 
Figure 2. Epigenetically conserved rat tsDMRs and epigenetically non-conserved rat tsDMRs 
show distinct patterns. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .107 
Figure 3. Epigenetically conserved tsDMRs and epigenetically non-conserved tsDMRs show 
distinct genetic conservation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 
Figure 4. TF motif analysis of rat tsDMRs and their orthologous regions in mouse and human. . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109 
Figure. 5. Evolutionary dynamics of tsDMRs and transcription factor binding sites. . . . . . . . . 110 
Supplementary Figures 
Supplementary Figure 1. Genome-wide methylation distribution across the three tissue types in 
the three species. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .111 
Supplementary Figure 2. Genomic distribution and locations of rat tsDMRs. . . . . . . . . . . . . . .112 
Supplementary Figure 3. Views of TE copies in LTR subfamilies that are significantly enriched 
for rat sperm tsDMRs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .113 
Supplementary Figure. 4. Percentage of rat regions in different genomic features. . . . . . . . . . .114 
Supplementary Figure 5. Genomic distribution of epigenetically conserved and non-conserved 
tsDMRs in rat and human. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 
Supplementary Figure 6. Genomic distribution of mouse and human orthologous regions of 
epigenetically conserved and non-conserved tsDMRs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 
Supplementary Figure 7. Genomic distribution of epigenetically conserved and non-conserved 
tsDMRs associated with promoters in rat and human. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .117 
Supplementary Figure 8. Histone modification signatures at human orthologous regions of rat 
tsDMRs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118 
Supplementary Figure 9. Epigenetically conserved and epigenetically non-conserved rat 
intergenic tsDMRs show distinct genetic conservation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .119 
Supplementary Figure 10. Epigenetic conservation status of tsDMRs shows distinct genomic 
distributions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .120 
vii 
 
Supplementary Figure 11. Histone modification signatures at mouse and human orthologous 
regions of rat tsDMRs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121 
Supplementary Figure 12. Epigenetic conservation status of tsDMRs shows distinct genetic 
conservation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .122 
Supplementary Figure 13. Epigenetic conservation status of tsDMRs shows distinct transcription 




List of Tables 
Chapter 2 
Supplementary Tables 
Supplementary Table 1: Astrocyte Expressed Gene Set. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145 
Supplementary Table 2: Oligodendrocyte Expressed Gene Set. . . . . . . . . . . . . . . . . . . . . . . . . 153 
Supplementary Table 3: Motor Neuron Expressed Gene Set . . . . . . . . . . . . . . . . . . . . . . . . . . .161 
Supplementary Table 4: Number of Genes Upregulated in Pairwise Comparisons. . . . . . . . . . . 58 
Supplementary Table 5: Circular RNA Supporting Reads. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58 
Supplementary Table 6: CpG Methylation Coverage Per Sample. . . . . . . . . . . . . . . . . . . . . . . . 59 
Chapter 3 
Table 1: Genotypes of bacTRAP mESCs Generated. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76 
Supplementary Tables 
Supplementary Table 1: Primary Antibodies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76 
Supplementary Table 2: Secondary Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 
Chapter 4 
Table 1: tsDMRs by epigenetic conservation status (2-way analysis). . . . . . . . . . . . . . . . . . . . 124 
Table 2: Summary of overlap between histone mark peaks and mouse and human orthologous 
regions of rat tsDMRs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125 
Table 3: Rat tsDMRs with various epigenetic conservation status (3-way analysis) . . . . . . . . .125 
Supplementary Tables 
Supplementary Table 1: Datasets used in this study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126 
Supplementary Table 2: Summary of rat tsDMRs overlapping TEs. . . . . . . . . . . . . . . . . . . . . .128 
Supplementary Table 3: Enrichment of TE subfamilies overlapping rat sperm tsDMRs. . . . . .128 
ix 
 
Supplementary Table 4: Summary of three-way orthologous rat tsDMRs. . . . . . . . . . . . . . . . . 129 
Supplementary Table 5: Rat EC and ENC tsDMR distance from the nearest TSS to the start of 
the tsDMR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 
Supplementary Table 6: Genomic coordinates and motif sequences of the TF binding sites shown 






I would not be the person I am today without my mother, Laure Sears. As a child my 
mom largely (there was the occasional required dress) allowed me to be who I wanted to be. She 
supported my love of nature, allowed me to be a tomboy without feeling ashamed, and let me 
read long after bedtime. She instilled in me a creative mindset, love of learning, appreciation of 
the arts, and foremost gave me the confidence to be myself. Until higher education, the concept 
that women were supposed to have different occupations than men or that we were supposed to 
be worse at science or math was foreign to me because I was simply not raised in that 
environment. She has continued to support and encourage me even when it meant living more 
than a thousand miles away and only seeing each other a few times a year. To my biggest 
defender and greatest friend, thank you.   
My research experience in both the laboratories of Dr. Andrew Clark and Dr. Giovanni 
Coppola gave me the credentials and experience to get into my choice of graduate programs, but 
I am not sure I would have picked WashU without the “intervention” of Dr. Ting Wang. I 
distinctly remember talking to Ting while sitting on the floor of John Rice’s house during 
recruitment dinner; perhaps he knew right then that I would end up joining his lab although it 
took me a year to figure that out. I have been lucky to work under an advisor who allowed me to 
shape my own thesis, supported my decisions, and introduced me to new scientific avenues. Ting 
is really good at honoring the importance of life events and publications which in turn has 
fostered a supportive lab environment that extends to external float trips, happy hours, game 
nights, and outings to new restaurants. My lab family past and present introduced me to new 
xi 
 
concepts, provided a fun work environment, and gave me a safe place to bounce ideas around for 
which I am thankful.  
The strong scientific environment of WashU allowed me to seek knowledge from other 
leading scientists. I am especially thankful for my third rotation mentor and later committee chair 
Dr. Joseph Dougherty for supporting my project, which would not have been possible without 
the combined resources of his and Ting’s laboratories. He has helped me to become a better 
critical thinker and made crucial suggestions in editing my latest paper. I am also indebted to 
Harrison Gabel, Rob Mitra, and Kyunghee Choi for using their valuable time to answer my 
questions and advise me on potential analysis directions. Jeanne Silvestrini was a great program 
coordinator for most of my graduate career and Sara Holmes has helped with the final push. I 
would also like to thank my funding and additional education provided by the Lucille P. Markey 
Special Emphasis Pathway in Human Pathobiology.    
I started graduate school with a number of classmates who remain my friends six years 
later. My HSG cohort of Nathan Kopp, Beth Ostrander, Matt Bailey, and myself became really 
close. Nathan, Beth, and I even managed to conquer all seven books of the Harry Potter 
Hogwarts Battle game. Janet and Amy were my HSG elders and while I started by just asking 
them for advice we evolved into soccer watching and kickball playing friends. I got to see some 
of my friends (Kristina, Alex, and Jeanette) get married, attended numerous symphonies with 
Angela, and created cool new crafts with Melanie. Reyka became my co-captain of the Lethal 
Mutants and Sohini became my roommate. I played softball on the Lethal Mutants with many 
more of my friends including Drew, Joey, Josh, Mayank, and Luis. With some other HSGers I 
founded the Open Reading Frames Book Club, which quickly became HSG plus friends 
xii 
 
including Mary, Madi, Ju Heon, Hyo, Miriam, Steven, and Kayla. Without these friends, and 
more, graduate school would have been a struggle. 
Lastly, I would like to thank more of my family including my aunt Nina who helped me 
stay connected to New Jersey and my Nana and Pop. My Grandma and Grandpa have listened 
and patiently tried to understand my scientific ramblings over numerous phone calls. Halfway 
through graduate school my sister Nicole and her husband Sven moved to St. Louis, ultimately 
forcing my mother to come out for Christmas, and have since introduced me to numerous board 
games and trusted me with watching their corgi Bella. These dog-sitting sessions convinced me 
that I was ready to get my own dog, Maximus, who has completely changed my work life 
balance and sleeping situation. 
Renee Louise Sears 





























ABSTRACT OF THE DISSERTATION 
 
An Evolving Epigenome that Determines Tissue and Cell Specificity 
by 
Renee Louise Sears 
Doctor of Philosophy in Biology and Biomedical Sciences 
Human and Statistical Genetics 
Washington University in St. Louis, 2019 
Professor Ting Wang, Ph.D. Chair 
 
 
Understanding the mechanisms driving phenotypic variation is a major goal of biology that 
unifies classical genetics with the emerging fields of genomics and epigenomics. Human and 
mouse share over 90% of genes and global tissue-specific patterns of expression are maintained 
between the species. Thus, it is hypothesized that gene expression is influenced through 
distinctive regulation among species in order to account for the unmistakable phenotypic 
divergence. DNA methylation, histone modifications, open chromatin patterns, transcription 
factor binding, and other epigenetic factors are all associated with shaping, maintaining, and 
repressing regulatory regions which in turn coordinate gene expression. It is vital to first 
understand if epigenetic mechanisms are impacting gene expression concordantly across species 
and second discern how epigenetic regulation is conserved at the tissue level. Furthermore, cell 
types even within the same tissue diverge in their transcriptomic and epigenomic profiles. Thus, 
third we must deconvolute tissue-level epigenetics through the study of individual cell types. 
Here we work towards the goal of a more complete understanding of epigenetic regulation 
through 1) an epigenome evolution DNA methylation study across blood, brain, and sperm in 
xv 
 
human, mouse, and rat and 2) assessment of distinct and shared epigenetic profiles of mouse 
astrocytes, oligodendrocytes, and motor neurons. We find that while tissue-specific regions of 
hypomethylation are more likely to have orthologous counterparts than expected, less than half 
maintained tissue-specific hypomethylation within the compared species. For regions that are 
epigenetically conserved, there is evidence for enrichment of active histone marks and regulatory 
function along with higher overlap with genetically defined conserved regions. Transcription 
factor motif maintenance is seen for epigenetically conserved regions and turnover of binding 
sites could account for tissue-specific hypomethylation that is not epigenetically conserved. We 
find that epigenetically, glia are more similar to each other than to compared neuronal 
populations and that motor neurons are distinct from other neurons in their relative lack of 
hypomethylated regions. Cell type-specific open chromatin patterns and CpG hypomethylated 
regions track well with increased cell type gene expression. In addition, non-CpG methylation     
is enriched in neurons, but also seems to retain a putative repressive role in glia. Clustered open 
chromatin regions function in gene regulation as exemplified through our discovery of putative 
oligodendrocyte-specific enhancers that overlap a deletion in quakingviable mice; which are 
known to have oligodendroglial defects and aberrant Qk protein expression. Collectively, these 
data suggest general paradigms of epigenetics that are shared across species, tissues, and cell 
types, but only partial maintenance of tissue-specific regulatory regions across species and both 
shared and cell type-specific epigenetic regulation even within the same tissue. 
1 
 
Chapter 1: Introduction 
 
An individual’s genome is largely stagnant. Mutations may lead to various disease states, 
but for the most part every cell contains the same genetic code. This code has changed over 
evolutionary time, giving rise to unique traits such as speech in humans, but has also been 
tweaked slightly within different populations for classic population genetics examples such as 
beak type in Darwin’s finches or body color in Peppered moths. Both the understanding of how 
traits are inherited and how different genes interact in pathways to create a certain function have 
been vital stepping blocks for the fields of genetics and genomics. Genomics, in particular, has a 
knack for creating multiple new questions for each study produced and this search to discover 
has led to additional fields of study. 
Epigenomics is one of these relatively new fields of study and helps to account for how 
one code, stagnant, is interpreted in numerous ways. The prefix epi- means “upon”, “over”, or 
“above” and thus epigenetics can be summarized as the study of features that contribute to a 
heritable phenotype outside of changes to the DNA. More recently, the epigenome has been 
defined as chemical modifications and proteins binding to the genome which alter gene 
expression1. Epigenetic modifications, transcription factor binding, gene expression, and 
chromatin structure all change over developmental time and influence one another. The 
multitude of signals and interpretations allows for distinct tissues and disparate cell types even 
within a tissue.  
The research presented in this dissertation focuses on understanding epigenetics in the 
context of comparative analyses among species and neural cell types. I generate transcriptomes, 
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methylomes, and open chromatin maps across mouse astrocytes (ASTs), oligodendrocytes 
(OLs), motor neurons (MNs), and embryonic stem cells (mESCs). These data are used to 
discover putative cell type-specific clustered enhancers, regulatory regions with a 
hypomethylated state, and novel circular RNAs. Further, all data are carefully curated into a 
public data hub to facilitate future research. I go on to generate mESCs from the AST, OL, and 
MN transgenic lines for direct use in in vitro experiments. Broadening the scope of epigenetic 
comparison, I investigate DNA methylation patterns across three species and tissues in the 
context of sequence conservation concluding that tissue-specific hypomethylation is both 
epigenetically and genetically more conserved than expected and that transcription factor binding 
site turnover (TFBS) could play a role in epigenetic conservation. The overall goal of my work 
was to better understand epigenetic regulation both in a species-specific and cell type-specific 
manner.  
1.1 The Transcriptome 
 Using DNA as a template, RNA is catalyzed by RNA polymerase during transcription 
and messenger RNAs (mRNA) later get translated into proteins via translation. Three main tools 
are used for expression analysis; Real Time Quantitative PCR2, microarrays3, and RNA 
Sequencing (RNA-Seq)4,5. RNA-Seq not only allows for the detection of novel transcripts, but 
also can detect smaller differences in gene expression and allows for a greater dynamic range of 
expression values6. The more recent advent of strand-specific sequencing preserves a transcript’s 
direction and detangles reads from overlapping genes7. Past RNA-Seq experiments have been 
used to assemble reference transcriptomes for each species which include annotations from 
UCSC, Ensembl, and Gencode8–10. These references transcriptomes allow for three main types of 
analysis; 1) the relative quantification of transcript amounts, 2) the comparison of transcript 
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abundance between two or more conditions, and 3) the discovery of novel gene isoforms. Tissue-
, cell-, or region-specific gene expression profiles can be compared using statistical methods to 
define differentially expressed genes11,12 and curate gene sets. Researchers can interpret these 
large gene sets by feeding them into programs that integrate functional gene annotations through 
the use of Gene Ontology (GO) terms13,14. These annotations can highlight molecular functions, 
cellular components, and biological processes that a gene set is enriched for, thus pointing out 
potential research directions of interest15. GO resources are continually improved16 enabling 
easier interpretation of gene sets in different disease states or across species. There are now 
thousands of RNA-Seq experiments per year (a PubMed search of “RNA-Seq” in 2018 reveals 
6,315 results) and our understanding of gene expression will only continue to grow in the 
budding age of Long-read Sequencing.  
1.1.1 Cell Type-Specific Neural Transcriptome Studies 
 Santiago Ramon y Cajal was the first individual to understand and demonstrate the 
complexity of the Central Nervous System (CNS) through his cell staining17,18. He found that 
brain cells varied in shape and size, and thus initiated the practice of defining different CNS cell 
types through their morphological differences. However, the Golgi method of staining does not 
capture most cells in a tissue and cannot target specific cells19. Thus came the advent of 
immunostaining to mark both specific cell types and cell structures20. Today, hundreds of cell 
types are known to make up the CNS21, each with its own distinct function and morphology, and 
given this diversity cell type-specific studies are warranted within the field. 
 The Allen Brain Atlas took a systematic approach to understanding where different genes 
were expressed in the adult mouse brain by using in situ hybridization (ISH) to comprehensively 
assay >20,000 genes in individual sections. These sections were reassembled into an anatomy-
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centered database that allows for visualization of gene expression across the entire brain. By 
using known major cell class expressed genes to target specific coordinates of interest it is 
possible to return additional genes co-expressed with these marker genes, but only for cells types 
that do not overlap other distributions of cells. It is relatively easy to use this resource to map 
region-specific gene expression, but tying this to cell type-specific expression in more difficult22. 
This resource has since been expanded to include humans23, developmental stages24, and 
disease25 and remains a fundamental tool in the neuroscience field.  
 Cell type-specific studies have primarily been limited by the difficulty in isolating 
individual cell types from the CNS and some methods such as laser capture microdissection26 are 
not conducive to acquiring the number of cells needed for transcriptome analysis. Additional 
Fluorescence-activated cell sorting (FACS) methods27,28, while incredibly useful for some cell 
populations, utilize antibodies that recognize cell surface targets which do not exist for all neural 
cell types. Another related method fixes nuclei allowing for the isolation of cell types without 
cell-surface markers but with nuclear expressed cell type-specific genes29, however it is unclear 
the affect fixation has on genomic assays. Immunopanning techniques that negatively select a 
cell type of interest have previously been used to isolate rat astrocytes30, but have to be carefully 
designed to successfully deplete all other cell types. Transfection-based in vitro methods have 
been used to create specific cell lines with GFP expression under the control of cell type-specific 
genes31,32 which was later extended into the creation of transgenic animals33 (see The bacTRAP 
Project Section 1.1.2). More recently, an affinity-based method was developed to purify nuclei 
through use of magnetic beads34. Thus, current methodologies allow for the isolation of specific 
cell types.  
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 In the neuroscience field, astrocytes and oligodendrocytes are traditionally understudied 
in comparison to neurons. Decades of research have helped to define astrocytes, the most 
abundant glial cell, as important for synapse maintenance and homeostasis of the interstitial fluid 
while the main function of oligodendrocytes is to insulate axons allowing for increased 
conduction velocity35. In 2008, Cahoy et al.36 profiled mouse astrocytes, oligodendrocytes, and 
neurons using a microarray platform and unexpectedly found that pairwise correlations did not 
cluster glia together, but instead clustered OLs and neurons. They created cell type-enriched and 
cell type-specific gene sets that are still used for GO analysis today and a subset of these genes 
were experimentally validated with ISH. Importantly, they highlight Aldh1l1 as an AST-specific 
marker that re-captures all cells positively labeled with Gfap, but also captures more ASTs and 
ASTs in gray matter36. In 2014, Zhang et al.6 employed RNA-Seq to assay polyadenylated RNA 
from brain ASTs, OLs, microglia, neurons, endothelial cells, and pericytes to create a complete 
transcriptome dataset available as a website that allows for direct comparison between cell types. 
RNA-Seq consistently identified more differentially expressed genes in ASTs, OLs, and neurons 
than had been previously identified with microarray analysis and was also able to identify long 
non-coding RNAs (lncRNAs) expressed in these different cells. The authors also found that 
6,588 genes were alternatively spliced in at least one cell type with a similar distribution of 
splice event types (e.g. cassette exons, mutually exclusive exons, and alternative 5’ splice sites) 
across cell types6. Further work37 has profiled the nuclear transcriptome of ASTs, OLs, and 
neurons highlighting ncRNAs of interest such as Malat1, transcribed in all cell types, and Dlk1-
Dio3 locus ncRNAs enriched in neuronal nuclei. Additionally, the authors were able to identify 
circular RNAs (ciRNAs) at low levels in the nucleus with preferred detection in specific cell 
types37. While many neuronal populations have been previously assessed through 
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microarrays33,38 and RNA-Seq39, mouse in vivo MNs have yet to be fully profiled using RNA-
Seq.  
1.1.2 The bacTRAP System  
 Bacterial artificial chromosomes (BACs) have previously been used to study 
morphological differences of CNS cell types40. In 2008, the Heintz and Greengard laboratories at 
The Rockefeller University introduced BAC transgenic mice in conjunction with the translating 
ribosome affinity purification (TRAP) method33,41. In these mice EGFP has been fused to the N-
terminus of the ribosomal protein L10a (EGFP-L10a) which can be expressed under the control 
of cell type-specific promoters allowing for isolation of these cell types. Additionally, these mice 
provide a tool to study a specific cell type’s response to environmental or pharmacologic changes 
as exemplified by medium spiny neurons’ transcriptional response to cocaine administration41. 
Furthermore, bacTRAP lines can be crossed with disease model mouse lines to study 
transcriptomic changes in disease as typified by the cross of AST, OL, and MN bacTRAP lines 
with LoxSOD1G37R to study this ALS-linked point mutation in the context of spinal cell type-
specific mRNA changes42. Originally, 16 CNS bacTrap mouse lines were published33, but that 
has since been expanded to 34 (http://www.gensat.org/TRAP_listing.jsp; accessed 7/29/19). 
TRAP microarray data not only re-identified known cell type markers, but elucidated thousands 
of novel cell type-specific mRNAs that were not seen in whole tissue level analysis. 
Combinatorial analysis of bacTRAP microarray results have led to the definition of a specificity 
index, which is used to define genes enriched in specific cells43 and was later extended into a 
framework to help identify cell populations disrupted in disease states44. One technical limitation 
of the TRAP method is that it cannot assay RNA that is not translated and thus the RNA profile 
of any cell type is incomplete. However, bacTRAP lines can be used in conjunction with 
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fluorescent-activated nuclei sorting (FANS) and RNA-Seq to fully assess the transcriptional 
landscape of a given cell type37.  
1.2 The Epigenome 
 Epigenetics is defined by heritable phenotypic differences that are not a result of changes 
to the genetic code (DNA). Classically, the Waddington model described cell fate commitment 
as a ball rolling down a hill with irreversible changes along the way45. The epigenome has been 
re-defined as chemical modifications and proteins that bind to the genome altering transcription1. 
Within a person, epigenetic changes are important for normal development and cell type 
specificity but can also occur aberrantly in disease46 or due to environmental factors47. Here we 
define the epigenome as measurable patterns of epigenetic information such as transcription 
factor binding, DNA methylation, chromatin structure, and histone modifications across the 
genome.  
 Large-scale surveys of epigenetic profiles in different tissues and primary cells types 
have occurred in the context of three main consortium efforts; the NIH Roadmap Epigenomics 
Consortium, the Encyclopedia of DNA Elements (ENCODE) Project, and the Mouse ENCODE 
Consortium. These projects have played vital roles in understanding the epigenetic landscape 
across species and tissues and continue to provide a framework for comparative studies and data 
integration. Roadmap focused on creating a Human Epigenome Atlas containing genome-wide 
datasets for RNA-Seq, DNA methylation, DNase, and histone modifications (2,804 datasets in 
Release 9). Data can be broken down into four main types including adult tissues, brain regions, 
fetal tissues, and stem cell derived cells1. Thus, while a large number of relevant data sets have 
been created, many of these are in vitro primary cells or tissues leaving a gap in research for 
more cell type-specific studies.  
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 The ENCODE Project’s initial focus was figuring out the purpose of the non-genic 
human genome48. This project later spawned Mouse ENCODE to profile the regulatory 
landscape of Mus musculus and modENCODE for profiling Caenorhabditis elegans and 
Drosophila melanogaster. Today the ENCODE portal hosts data for long range interactions 
(chromosome conformation capture carbon copy (5C), Chromatin Interaction Analysis by 
Paired-End Tag Sequencing (ChIA-PET), and genome-wide chromatin conformation capture 
(Hi-C)), chromatin structure (DNase I hypersensitive site sequencing (DNAse-Seq), 
Formaldehyde-Assisted Isolation of Regulatory (FAIRE-Seq), and an assay for transposase-
accessible chromatin using sequencing (ATAC-Seq)), Chromatin Immunoprecipitation followed 
by sequencing (ChIP-Seq), DNA Methylation (Whole Genome Bisulfite Sequencing, Reduced 
Representation Bisulfite Sequencing (RRBS), and methyl array), RNA-Seq, and protein-RNA 
interactions (High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation 
(CLIP-Seq) and RNA immunoprecipitation sequencing (RIP-Seq)). The portal (accessed 8/7/19) 
hosts 9,617 ENCODE and 1,095 modENCODE datasets, 1,677 of which are generated from 
mouse which fall into four main types including tissue, cell line, primary cell, and in vitro 
differentiated cells. The mouse data was previously used across tissues to annotate 11% of the 
genome as putative cis-regulatory sequences49, but the deconvolution of tissue samples studied, 
such as cerebellum, cortex, and embryonic brain still needs to be performed in an in vivo cell 
type-specific manner.  
1.2.1 Chromatin Structure 
One level of epigenetic information comes from how genomes are packaged into 
chromatin, and this compaction plays a key role in gene expression50,51,52. About 146 bp of DNA 
wraps around each nucleosome, structures consisting of an octamer of histone proteins, making 
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the DNA harder to access53. Many assays for nucleosome occupancy require long preparation 
times or large amounts of cells54,55, which has inhibited research for cell types that are difficult to 
isolate or in low abundance within a tissue. Recently, ATAC-Seq56 was developed, which allows 
rapid library preparations from small numbers of cells. Tn5 transposase fragments and tags the 
genome with adapters preferentially at open chromatin sites creating sequences with a distinct 
periodicity of ~200 bp that can be sequenced, aligned, and then used to call peaks representing 
open chromatin regions56. Nucleosome occupancy has been found to be anti-correlated with CpG 
DNA methylation (mCG), although this may be context dependent57. Open chromatin regions 
can be used to predict enhancers58 and assays including, DNase I hypersensitive site (DHS) 
sequencing54, FAIRE-Seq55, and ATAC-Seq56 have been used to define enhancers and potential 
transcription factors (TF) binding sites across cell types39,59. Transcription Start Sites (TSSs) 
have been found to be highly accessible across cell types while more distal open chromatin 
regions are more cell type-specific60. Profiling of the open chromatin landscape has occurred 
across many cell and tissue types to locate regulatory regions including enhancers and 
promoters60–62. These accessible sites also overlap with ChIP-Seq data which are indicative of TF 
binding60,62. While many promoter elements are evolutionary constrained, the majority of DHSs 
are not61. Recently, three neuronal populations showed widespread differences in open chromatin 
through ATAC-Seq; only 13% of peaks were shared across all three neuronal types and tens of 
thousands of regions were cell type-specific39. This highlights the need for cell type-specific 
instead of tissue-specific studies as even closely related cells can differ vastly in their chromatin 
landscape.   
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1.2.2 CpG DNA Methylation 
 DNA methylation is found primarily in a CpG context across the genome63. Perhaps the 
clearest example of phenotypic differences due to mCG is the case of coat color in mice over the 
agouti gene. In this case an intra-cisternal A particle (IAP) retrotransposon becomes 
hypomethylated upstream of the agouti gene leading to distinguishable yellow fur64. mCG is 
necessary for proper development as homozygous knockout (KO) of Dnmt1, a maintenance 
DNA methyltransferase, causes embryonic lethality. Examination of KO embryos reveals that 
they are smaller and have morphological differences including lack of forelimb buds65. Likewise, 
KO of Dnmt3b is embryonic lethal and Dnmt3a KO mice die at 4 weeks66. ESCs remain viable 
in the absence of DNA methyltransferases (DNMTs)67, but the resulting hypomethylation 
inhibits differentiation within these cells68. While these phenotypic examples serve as interesting 
anecdotes, much of the study on DNA methylation is focused on elucidating the role of mCG in 
gene regulation and expression. CpG Islands (CGIs) have long been of interest to the research 
community as they are generally hypomethylated, coincide with promoters, and faithfully 
maintain their methylation levels during development69. Indeed, 5’ region mCG is inversely 
correlated with gene expression70 while gene body methylation is associated with increased 
transcriptional activity71. mCG is critical for its repressive role in repetitive element silencing72, 
X chromosome inactivation73 where it helps to stabilize the repressed state of the inactive X 
chromosome74,75, and imprinting76 where it is associated with parental-specific expression 
through repression of either the paternal of maternal allele. Importantly, cell type-specific 
differential methylation has been linked to enhancers77 and increased methylation has an inverse 
correlation with chromatin accessibility60.  
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1.2.3 Neural CpG DNA Methylation  
 Early studies showed that DNMTs are highly expressed in the CNS as compared to other 
tissues78–80 which hastened research into the role of mCG in normal CNS development and its 
perturbation in disease. In rats, increased Dnmt3a and Dnmt3b expression has been seen in the 
CA1 region of the hippocampus after exposure to associative context-plus-shock training. 
Subsequently, rats treated with DNMT inhibitors had significantly lower time spent displaying 
freezing behavior than their untreated counterparts indicating that DNMT activity is necessary 
for memory formation81. Conditional double knockouts (DKOs) of Dnmt1 and Dnmt3a under 
control of a postmitotic gene promoter have smaller hippocampi probably due to a size reduction 
in dentate gyri neurons, impaired neural plasticity in terms of long-term potentiation and 
depression, and deficits in learning and memory82. An additional conditional KO of Dnmt1 in 
neural precursor cells (NPCs) found that after hypomethylation changes in embryonic days 9-10 
astrocytes precociously differentiated with GFAP detectable as early as embryonic day 12, but 
below detection levels until embryonic day 14 in wildtype mice. This same astrocyte early 
differentiation phenotype was observed in vitro83. Taken together maintenance of mCG by 
DNMTs is critical for standard CNS regulation.   
 DNA methylation has been linked to neurodevelopmental disease, for example aberrant 
hypermethylation of the FMR1 promoter has been found in Fragile X Syndrome patients84 and 
Rett syndrome (RTT) patients have mutations in MECP285, a methyl-CpG-binding protein. 
Moreover, in Parkinson’s disease, hypomethylation of SNCA leads to aberrant upregulation of 
the gene86,87 and in amyotrophic lateral sclerosis (ALS) hypermethylation of the repeat expansion 
in C9orf72 is associated with decreased C9orf72 expression and increased disease severity88 
demonstrating that epigenetic perturbations can impact both early and late life disease 
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progression. The epigenomic landscape of many neural diseases is still under active investigation 
including Alzheimer’s disease89, drug addiction90, and Posttraumatic stress disorder91. 
 In order to interpret disease-related mutations in epigenetic machinery genes and DNA 
methylation variation differences between controls and patients it is imperative to understand the 
normal developmental trajectory and the tissue/cell type distribution of DNA methylation. mCG 
is associated with repression as exemplified by 1) highly expressed neuronal genes are 
hypomethylated within neurons (NeuN+), but not glia (NeuN+) and 2) genes associated with 
astrocyte function gain mCG in frontal cortex tissue, display hypermethylation in neurons, and 
are hypomethylated in glia. However this association is not a completely linear relationship as 
developmentally up-regulated neuronal genes that are no longer highly transcribed still show 
hypomethylation in neurons and not glia; perhaps as a remnant of their expression in earlier 
development92. Hypomethylated differentially methylated regions (hypo-DMRs) are associated 
with DNAse I hypersensitive regions suggesting an inverse relationship between mCG and 
genome accessibility92. Similar to open chromatin, there are tens of thousands of hypo-DMRs 
that are cell type-specific even among three closely related neuronal cell types39 further calling 
attention to the need for cell type-specific research to deconvolute CNS epigenetics.   
1.2.4 Non-CpG DNA Methylation  
 While DNA methylation generally occurs at CpG dinucleotides, non-CpG methylation 
(mCH) has been shown in ESCs primarily in a CAG context and in brain samples primarily in a 
CAC context93. mCH levels in mESCs have been demonstrated to be higher than many other 
somatic DNAs (liver, kidney, spleen, and lung) and Dnmt1-null mice have similar mCA when 
compared to wildtype mice94. This is congruent with the observation that mCH is seen at 
relatively high rates in hESCs and induced pluripotent stem cells (iPSCs), but is reduced in 
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embryoid bodies (EBs), NPCS, muscle, and blood cells. The same study used a linear model to 
determine Dnmt3a and Dnmt3b expression were most associated with mCA levels and 
experimentally validated this computation finding through an hESC knockdown of Dnmt3a 
which led to global reduction of mCH95. Interestingly, mCH is lost upon hESC differentiation77 
and EB formation95 which led to doubts when it was first discovered in CNS samples.  
 ESC and brain mCH are posited to have opposite functions with ESC mCH associated 
with gene expression95 while brain mCH both in promoters and gene bodies is associated with 
repression92,96. Lister et al.92 demonstrate that mCH accumulates in mouse and human brain from 
the postnatal stage to adolescence initially paralleling synapse density increase but continuing 
even after the onset of synaptic pruning. At a population level, neurons (NeuN+) are enriched for 
mCH as compared to glia (NeuN-) and mCH accounts for the dominant form of methylation in 
the genome of these human neurons. Highly expressed neuronal genes show mCH 
hypomethylation in neurons while genes associated with astrocyte function are mCH 
hypomethylated in glia92. Similarly, highly cell type-specific genes expressed in Parvalbumin 
(PV)-expressing neurons are mCH hypomethylated in PV neurons, but mCH hypermethylated in 
Excitatory (Exc) neurons and Vasoactive intestinal peptide (VIP)-expressing interneurons. The 
same relationship is seen for genes specifically expressed in VIP and Exc neurons39. Neuronal 
mCG levels track well with mCH levels as mCG hypermethylated DMRs also show high mCH92, 
but there is only a moderate correlation genome-wide96. Thus, while CpG and non-CpG 
methylation are related they can tell non-overlapping stories about genome regulation. 
Interestingly, MeCP2 has been shown to bind methylated CA (mCA) sites thus repressing gene 
expression in long genes, which are as a class enriched for neuronal functions, and thus in RTT 
these genes are de-repressed leading to reduction in cellular health97. Lastly, in three neuronal 
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cell types among mCH, mCG, and open chromatin, gene body mCH was the most informative 
linear model feature deducing RNA abundance39 and therefore may be more important than 
initially realized for neuronal cells.  
1.3 Comparative Genomics 
 The Human Genome Project’s first draft was completed in 200198 and a year later the 
mouse genome was released99. The list of reference genomes keeps expanding with the 
Vertebrate Genomics Project aiming to sequence 70,000 vertebrate species100. Even before 
whole genomes were available, the basic local alignment search tool (BLAST) allowed for the 
assessment of sequence homology to known proteins with cross-species mappings101, but the 
advent of whole genome sequencing has permitted more global comparisons such as gene 
content across species98 and regions under purifying selection102. Vertebrates share analogous 
collections of protein-coding genes103; humans share over 90% of their genome with mice99 and 
>98% for chimpanzees and bonobos104,105 which motivates the question: How can phenotypic 
diversity be accounted for in the context of genetic similarity? One hypothesis is that differential 
regulation of genes106 could account for species divergence which can be assessed in the context 
of comparative epigenomics.  
1.3.1 Comparative Epigenomics  
There are multiple ways that one can compare epigenomes across species. Are the same 
epigenetic marks seen in different species? Is the genomic context (i.e. promoters, TSSs, gene 
bodies, etc.) of these marks similar across species? Are the regulatory consequences of the 
epigenetic marks the same across species? At a more nuanced level, researchers can analyze 
comparative epigenomics in a fourth way by first identifying homologous regions between 
15 
 
species and then determining whether these regions having matching or contrasting epigenetic 
patterns. 
DNA methylation has been found in plants107, chickens108, mammals109, and even slime 
mold110 with very low levels also present in Drosophila111. Transposon defense through 
methylation is seen in Neurospora crassa (a bread mold), Arabidopsis thaliana (a small 
flowering plant), mice, and humans109, but not in Ciona intestinalis (a sea vase)112. mCG profiles 
over genes and gene proximal regions look very similar between Chlorella (green algae) and 
Tetraodon nigroviridis (puffer fish) (both of which look similar to humans), but while the 5’ 
profile of genes looks similar to that in Chlorella, the rice genome shows noticeable mCG 
depletion also at the 3’ end of genes. Contrastingly, Selaginella moellendorffii (a lycophyte) does 
not have mCG over its gene bodies109. Evidence from both warm and cold-blooded vertebrates 
representing major evolutionary branches (humans, mouse, platypus, bird, lizard, frog, and 
zebrafish) points to the conservation of non-methylated islands across species which are 
predicted poorly by CGIs in lower vertebrates and are a conserved feature of gene promoters113. 
Pai et al.114 reconfirmed the negative correlation between gene expression and promoter mCG 
and revealed that in chimpanzee-human comparisons, mCG variance was primarily accounted 
for by tissue of origin instead of species consistent with gene expression studies that demonstrate 
clustering by tissue instead of species115,116. In each tissue there were more human and 
chimpanzee-shared tissue-specific DMR (T-DMR) CpG sites than expected by chance (18-26%) 
and these conserved T-DMRs enriched for developmental process genes. Lastly, interspecies 
differences in mCG underlie up to 12-18% of gene expression differences depending on the 
tissue analyzed114. Thus, while some patterns of mCG are shared across species there are also 
differences in the levels and targets of this methylation117. However, some studies provide an 
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incomplete genome-wide picture by focusing on individual CpGs in close proximity to 
TSSs114,118 which may give a disparate picture of the true levels of epigenetic conservation given 
the results of another study that uses 20 mammalian species to conclude that enhancers are rarely 
conserved across species while promoters are often conserved119. 
 In an extensive whole-genome study, Xiao et al.120 were the first to quantify epigenetic 
conservation in the context of sequence evolution using orthologous regions defined by 
liftOver121, PhyloP scores to determine fast and slow evolving sequences122, and sequence 
conservation level estimated by Phastcons123. First the authors found that for mCG and eight 
histone modifications the distributions of relative epigenetic modifications across genomic 
elements was similar in human, mouse, and pig (e.g. histone 3 lysine 26 trimethylation 
(H3K36me3) was found predominately over coding exons124 in all species). Second, certain 
epigenetic marks have conserved co-occupancy across species such as the active enhancer mark 
histone 2 lysine 27 acetylation (H3K27ac) and enhancer associated (me1/me2) or promoter 
associated (me2/me3) histone 3 lysine 4 mono-, di-, and trimethylation (H3K4me1/2/3). With the 
exception of H3K9me3, regions with one or two epigenetic modifications are correlated with 
conserved genomic sequences. Additionally, between species orthologous regions share marks 
for histone 3 lysine 27 trimethylation (H3K27me3), H3K36me3, and H3K4me1/2 more often 
than expected by chance. Interestingly H3K36me3, mCG, and H3K27ac all exhibit increased 
epigenetic conservation both in regions with an accelerated or a reduced substitution rate while, 
more in line with expectation, H3K27me3 and H3K4me3 are only epigenetically conserved in 
the slowest changing regions. Thus, for H3K36me3, mCG, and H3K27ac epigenetic 
conservation is not completely affiliated with sequence similarity among the species studied. 
Lastly, a conserved set of epigenetic marks are found to be predictive of gene expression in both 
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human and mouse and interspecies epigenetic changes predict changes in gene expression and 
TF binding120. In sum, many marks are epigenetically conserved, genetically conserved, and are 
associated with gene expression across three mammals. However, conservation of sequence 
similarity does not account for the total sum of epigenetic conservation which could in part be 
mediated by TFBS turnover as significant divergence in tissue-specific regulation has been 
previously noted between mouse and human125. 
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Within the neural lineage, glial cell types have been understudied while motor neurons are 
difficult to isolate and at low proportion within the brain stem and spinal cord, thus limiting 
epigenetic studies of these important and disease-implicated cell types in vivo. Transgenic mouse 
lines provide an in vivo opportunity to profile whole transcriptomes, DNA methylomes, and open 
chromatin maps for mouse astrocytes, oligodendrocytes, and motor neurons. We define cell type 
expressed gene sets, find sex-specific epigenetic patterns, and discover thousands of shared glial 
and cell type-specific hypomethylated regions, cell type-specific accessible regions, and novel 
circular RNAs along with hundreds of putative cell type-specific clustered enhancer regions. 
Through integration of our data sets, we unearth putative oligodendrocyte-specific enhancers that 
may be perturbed in quakingviable mice leading to the observed oligodendroglial defects and 
aberrant Qk protein expression. Importantly, all data are provided as a public datahub through 
the WashU Epigenome Browser. 
2.2 Introduction 
 Within an organism, one genetic code contains the instructions to build the central 
nervous system (CNS) tissues and organs containing hundreds of cell types with unique function 
and morphology21,98. Studies in the context of transcription have defined developmentally-
regulated22,23, tissue-regulated126,1, and cell type-regulated gene expression33,36,37. Gene 
expression in turn, is orchestrated by epigenetic marks and DNA-protein interactions. Recent 
genomic analysis has sought to create parallel epigenomic references for many cell types and 
tissues1 with the goal of functionally annotating the genome and identifying disease-relevant, cell 
type-specific epigenetic abnormalities127,128.  
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 DNA methylation is one of the best-studied epigenetic marks and is critical for repetitive 
element silencing72, X chromosome inactivation73 , imprinting76, memory formation81, and helps 
drive a cell’s fate129. CpG methylation (mCG) correlates with gene expression73,71 and 
progressive changes signify regulatory regions including enhancers1,130–134. Non-CpG 
methylation (mCH) in embryonic stem cells (ESCs) positively correlates with gene 
expression94,95. Contrastingly, during brain development mCH dramatically remodels and 
correlates with transcriptional repression92.   
 How genomes are packaged into chromatin also plays a key role in gene expression50–52. 
Nucleosome occupancy is anti-correlated with mCG, although this may be context-dependent57. 
Open chromatin regions can be used to predict enhancers58 and assays including, DNase I 
hypersensitive site sequencing54, Formaldehyde-Assisted Isolation of Regulatory Elements55, and 
Assay for Transposase-Accessible Chromatin using sequencing (ATAC-Seq)56 have been used to 
define enhancers and potential transcription factors (TF) binding sites across cell types39,59.  
 Epigenetic codes between cells even within the same tissue can vary greatly39,135. Thus, 
epigenomic profiling at the cell type level is needed to deconvolute total brain epigenome 
signals. Within the neural lineage, glial cells have been understudied while motor neurons are 
difficult to isolate as they are found at low proportion and only within the brainstem and spinal 
cord; thus, epigenetic studies have been limited. There is a pressing need to understand 
mechanisms of gene regulation in these specific cell types, in light of their relevance to disease 
and critical roles in the CNS. Indeed, Amyotrophic Lateral Sclerosis (ALS)136, Spinal Muscular 
Atrophy, and other motor neuron diseases have been associated with motor neuron 
dysfunction137, both astrocytes and oligodendrocytes have been associated with 
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neurodegeneration138,139 , and both motor neurons and glia have been implicated in ALS42, 
making these data of high interest to the neurological disease/disorder research community. 
 Here we profile gene expression, open chromatin, and DNA methylation in motor 
neurons, astrocytes, and oligodendrocytes from the mouse CNS. We present all data as a public 
data hub through the WashU Epigenome Browser140. We believe this will be an invaluable 
resource for researchers studying epigenetics of specific neural cell types, epigenetic regulation 
through developmental time, and epigenetic mis-regulation during disease. Finally, to 
demonstrate the potential utility of the resource, we highlight exciting avenues of analysis 
including circular RNAs, sex-specific epigenetic differences, and putative cell type-specific 
clustered enhancer regions exemplified by putative oligodendrocyte enhancers regulating Qk as 
examples of the utility of the data. 
2.3 Results 
2.3.1  Isolation of Nuclei to Create Epigenomic and Transcriptomic Maps 
 We used bacTRAP lines with GFP fused to Ribosomal Protein L10a (Rpl10A) expressed 
under cell type-specific promoters to extract pure populations of astrocytes (ASTs) (Aldh1L1-
eGFP-Rpl10A), oligodendrocytes (OLs) (Cnp-eGFP-Rpl10A), and motor neurons (MNs) (Chat-
eGFP-Rpl10A)33 (Figure 1A). GFP fluorescence is present in the nucleus of these lines since 
ribosomes are assembled in the nucleolus37. In addition, we cultured mouse embryonic stem cells 
(mESCs) as an outgroup from neural cell types. Nuclei were purified from fresh brains, spinal 
cords, or culture (mESCs) using a density gradient, underwent fluorescence activated nuclei 
sorting (FANS)141, and were then used for RNA extraction, DNA extraction, or ATAC-Seq as 
outlined in Figure 1B. Stringent gating was used to collect GFP+ nuclei (Figure 1C). While 
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RNA-Seq has previously been published for some of these lines37, this is the first use of ATAC-
Seq and Bisulfite Sequencing (BS-Seq) in bacTRAP lines to our knowledge. 
2.3.2  RNA-Seq Re-Captures Neural Cell Type Markers 
We created gene sets (Supplementary Tables 1-3) through pairwise comparisons for 
each neural cell type to substantiate cell type identity, re-confirm previously identified 
expression33,37,43, and provide a resource. At least 3,000 genes were differentially expressed (≥ 2-
fold change, p-value < .05, Bonferroni corrected) in each pairwise comparison (Figure 2A). 
6,051 genes show ≥ 2-fold change across the neural cell types and over 11,000 genes are found 
when mESC pairwise comparisons are included (Supplementary Table 4). There are numerous 
genes with upregulation shared between ASTs and MNs as compared to OLs and in ASTs and 
OLs as compared to MNs, but not in MNs and OLs as compared to ASTs (Figure 2B). We 
implemented the cell type-specific expression analysis tool (CSEA)44 to verify appropriate 
enrichment in each of our GFP+ nuclear RNA samples (Supplementary Figure 1A-C). 
Established cell type expressed genes (e.g Nefm, Nefl, and Meg3 in MNs; Slc1a3, Slc1a2, and 
Atp1a2 in ASTs; and Mag, Mog, and Olig1 in OLs) were enriched in our gene sets as in prior 
studies43,44,6,142 and affirm individual cell type identities.  
As our study is the first to profile the nuclear transcriptome of mouse MNs in vivo, we 
examined their expression profiles more deeply. Genes within the MN gene set enrich for ion 
channel activity (ID: GO:0022891) including three glycine receptor subfamily genes (Glra1, 
Glra2, and Glra3), three glutamate ionotropic receptor genes (Grik1, Grin2d, and Grin3b), six 
potassium voltage-gated channel genes (Kcna1, Kcnh2, Kcnip1, Kcnk3, Kcnk9, and Kcnq2), and 
three sodium voltage-gated channel genes (Scn3a, Scn7a, and Scn9a). We also see enrichment 
for genes involved with transmission of nerve impulse (ID: GO:0019226); notably Chat our MN 
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marker gene, Nrg1 which has been implicated in bipolar disorder and schizophrenia143, and Sv2c 
which has been implicated in Parkinson disease144. Unsurprisingly, Malat1 was the most highly 
expressed lincRNA across our neural cell types37. Dlk1-Dio3 locus-derived lincRNAs and Miat 
are at least 4-fold enriched in MNs as compared to all other cell types consistent with mESC 
differentiated mouse spinal MN data142,145. LincRNAs with unknown function, such as 
9530059O14Rik and 5330434G04Rik, are also upregulated in MNs and could offer avenues for 
further research opportunities. Thus, we have created a novel gene set for MNs that can serve as 
a resource for future studies. 
2.3.3  Identifying Novel and Putative Cell Type-Specific Circular RNAs  
Circular RNAs (ciRNAs) are enriched in brain tissues146 and could serve as biomarkers 
for disease147. We sought to discover previously identified ciRNAs with putative cell type-
specific expression and novel ciRNAs and provide our ciRNA annotations as a resource 
available through the WashU Epigenome Browser. We found evidence for 3,000 ciRNAs 
(ciRNAs described below in Supplementary Table 5). First, we verified expression of the well 
characterized miRNA regulating Cdr1as ciRNA, known to be important for brain function148. 
Thirteen of our neural samples, but none of our mESC samples, had Cdr1as expression 
consistent with previous work146. Two previously reported ciRNAs were also seen in thirteen of 
our samples; a ciRNA at the 3' end of Apoe, previously reported in hindbrain149, was identified in 
all cell types except MNs while a Ssbp2 ciRNA, previously found in neural tissues149, was never 
seen in mESCs. Surprisingly, the majority of our ciRNAs were not previously found in 
Circbase150 (79.67%) and many did not even overlap ciRNA annotations (55.63%). These 
included a Gm21168 antisense ciRNA identified in five OL samples, a Pde4b antisense ciRNA 
found in one AST and three OL samples, and a GM21738 antisense ciRNA in three MN samples. 
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We also note ciRNAs overlapping gene set genes including a novel Snhg11 antisense transcript, 
a novel Plp1 antisense transcript, and a known Sparcl1 antisense transcript. Lastly, we see a 
novel 48KB ciRNA downstream and in the antisense direction of Cnp but overlapping and sense 
to Dnajc7 and Zfp385c in five of our OL samples. Thus, by focused sequencing on these cell 
types, we have expanded the number of ciRNAs described in the CNS and provide this as a 
resource. We next profile our cell types via epigenetic assays and relate this back to the RNA-
Seq resources created.  
2.3.4 Open Chromatin Signatures Define Cell Type/Lineage-Specific Distal 
and Shared Proximal Regulatory Regions  
First, clustering was used to evaluate signal reproducibility across replicates and assess if 
the relationship among cell types based on RNA-Seq was maintained across epigenetic assays. 
First, we clustered reads per kilobase million (RPKM) of RNA-Seq signal across protein-coding 
and lncRNA genes (Figure 2C). We then used epigenomic data in the form of %mCG in 500 bp 
bins (Figure 2D), %mCG in 3KB promoters (Supplementary Figure 2A), %mCH in 500 bp 
bins (Supplementary Figure 2B), and ATAC-signal over ATAC peaks (Figure 2E). In each 
case mESCs separated from glial cells, which were separate from MNs consistent with shared 
glial epigenetic programming.  
 In other cell types, open chromatin is positively correlated with gene expression59, so we 
next tested the hypothesis that promoters of our neural gene set genes would likewise contain 
open chromatin signatures within the cell type they were defined from. Both ASTs and OLs had 
the highest read pileup over their own gene sets and higher expressed genes tend to have a more 
conspicuous open chromatin signature (Supplementary Figure 3A). However, OL gene set 
promoters that intersected CpG Islands (CGIs) had noticeably high pileups in all cell types 
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studied. We reasoned that this pattern might reflect shared expression, albeit at least 4-fold less, 
of OL gene set genes. Indeed, OL gene set genes with a CGI promoter were moderately 
expressed in our other cell types (median transcripts per million (TPM) of 7.8, 37.6, and 45.1 in 
mESCs, MNs, and ASTs respectively). Unexpectedly, MNs have a more pronounced signature 
over the OL gene set than their own gene set which may be reflective of alternative epigenetic 
regulation (Supplementary Figure 3A). To examine this more deeply, we next sought to 
analyze open chromatin regions in an unbiased manner and create a genome-wide resource of 
open chromatin patterns in our cell types.  
Open chromatin regions are biologically active, available for TF binding, and can be 
assayed through ATAC-Seq56. We discovered 159,830 autosomal peaks of chromatin 
accessibility across our cell types and categorized these peaks into distal (81.8%) and proximal 
annotations based on proximately to the nearest transcription start site (TSS). Our analysis 
focused on differentially accessible regions (DARs), previously used to define regulatory regions 
and putative cell type-specific TF binding patterns39,59. The largest peak categories consisted of 
shared peaks which were common across all four cell types, mESC-specific DARs, OL-specific 
DARs, AST-specific DARs, MN-specific DARs, and neural-specific DARs which were found in 
all three of our neural cell types, but not within mESCs (Figure 3A; Supplementary Figure 
3B). A much larger proportion of shared peaks were classified as proximal (53.02%) as 
compared to peaks within the other five classes (4.09%-16.78%) (Figure 3B). Shared proximal 
peaks also overlapped with CGIs (81.55%) much more frequently than any of the other five 
classes (3.13%-34.80%), while no class of distal peaks overlapped with CGIs more than 10% of 
the time (0.11%-6.09%) (Figure 3C). These results are reflective of the shared regulation of 
housekeeping genes (GREAT Gene Ontology (GO) of shared proximal peaks, binomial p-
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value=1.37-70, binomial fold enrichment 3.23, Molecular Signatures Database (MSigDB) gene 
set) that often have CGIs in their promoters. In contrast, cell type-specific peak classes enrich for 
cell type-relevant GO categories (Figure 3D). In sum, cell type-specific DARs are associated 
with cell type-specific GO terms and more likely to be distal, while shared peaks are associated 
with CGI promoters.   
2.3.5  TF Binding in Open Chromatin Regions  
As an example of the utility of our peak sets, we address potential TF binding by 
examining motif enrichment within distal peaks of each categorical context (Figure 3E) and 
through overlap with Chromatin Immunoprecipitation Sequencing (ChIP-Seq) peaks 
(Supplementary Figure 3C). Neural peaks were enriched for the CCCTC-binding (CTCF) 
motif, well known for its role in chromatin loop formation. Shared peaks enriched for BORIS 
(CTCFL), a paralog of CTCF, known to be found at active enhancers and promoters151. Indeed 
50.3% of distal neural peaks overlapped with CTCF ChIP-Seq peaks (SRX2916323) in mESC 
derived neural cells and 91.5% of shared distal peaks overlapped with CTCF ChIP-Seq peaks 
(SRX143822) in embryonic brain. These results suggest a coordinated topologically associating 
domain (TAD) structure across cell types and also a remodeling in a more CNS-specific manner, 
but limited cell type-specific TAD structures.  
2.3.6  DNA Methylation Differentiates Between Glial and Neuronal Cell Types 
We next sought to profile DNA methylation in our cell types to create a resource for 
comparative analysis. We achieved approximately 30X coverage for each cell type-by-sex group 
(Supplementary Table 6) for BS-Seq. As expected, bimodal distributions are observed for each 
cell type in the context of mCG (Supplementary Figure 4A). We observed the highest level of 
mCG and mCH in MNs as compared to our two glial cell types and mESCs (Figure 4A). mCH 
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has been shown to accumulate in the adult brain specifically in NeuN+ neurons, but not in glia as 
characterized through isolation of NeuN- nuclei and nuclei with GFP fluorescence under control 
of the S100B promoter92. We profile MN mCH levels for the first time and find that concordant 
with other neuronal types, mCH is most prevalent in MNs where it makes up 46.6% of mC calls 
while in OLs, ASTs, and mESCs it constitutes 24.5%, 22.1%, and 17.0% of mC calls 
respectively (Figure 4B). This mCH order is not completely consistent with human data where 
the male H1 hESC line has higher mCH than glia152 and instead flips the ESC glia mCH 
paradigm in mice. mCH levels in glia are also noticeably higher than previously published neural 
NeuN- nuclei92.  
As a demonstration of the utility of our data, we re-analyze DNA methylation data from 
previously published mouse neuronal types39 in comparison to our MN data. The mCG and mCH 
level in MNs is similar to that of cortical neuron types39 (Supplementary Figure 4B). In fact, 
the mCH level in MNs is comparable to PV neurons which have the highest mCH level as 
compared to other neuronal types studied. As previously established, mCH is primarily in a 
methylated CAC (mCAC) context for neurons93,153–155, and the mCH methylation level in MNs 
fits this paradigm. When considered at the trinucleotide level, there are more mCAC calls in both 
MNs and PV neurons than in any CpG context. Contrastingly, both excitatory neurons and VIP 
neurons have more mCG calls than mCAC. We also note that mCAC is the dominant mCH type 
in ASTs and OLs; mCAC calls make up 28.31% and 31.75% of mCH calls in ASTs and OLs 
respectively which is consistent with mCAC calls contributing to 28.74% of mCH calls in 
S100B+ glia [data reanalyzed from GSE47966]. In contrast to the prevalence of mCAC in neural 
cell types, mCAG constitutes the largest portion of mCH calls in mESCs (22.96% as compared 
to mCAC with 21.11%) in agreement with previously published human reports77,95,156.   
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Given that hypomethylation is found primarily at the 5’ end of genes (promoter, 5’UTR, 
and first exon) (Figure 4C and Supplementary Figure 4C), and is indicative of a permissive 
state for gene expression, we wanted to view DNA methylation patterns across genes in our cell 
type expressed gene sets. Within our gene sets we observe absence of mCG over the promoter 
extending into the gene body within the cell type the gene set was originally called in (i.e. our 
OL gene set has depletion of mCG within OLs, but not ASTs). This phenomenon is most notable 
for ASTs and OLs in the context of mCG depletion extending into the gene body and for MNs in 
the context of mCH (Figure 4D). mCH has been studied in neuronal populations, but it is likely 
functional within glia as well. Bmi1, the gene with the highest level of mCH in ASTs, is known 
to be important for neural stem cell renewal and loss results in an increase of ASTs157. Thus, 
Bmi1’s relatively high mCH in ASTs could indicate cell type-specific repression. While ASTs 
and OLs have similar levels of mCH, their profiles are distinct with only 10% of the top 30 genes 
sorted by %mCH shared, implying different mCH usage in distinct glial cell types. 
 To investigate whether mCG depletion was modulated by binary gene expression (i.e. 
off/on) or by a gradient of gene expression we plotted median mCG levels across genes within 
different bins of expression (Supplementary Figure 4D). There is a clear inverse relationship 
between expression and promoter mCG, but only in the context of genes without a CGI in their 
promoter. While the association between gene expression and mCG in ASTs, OLs, and mESCs 
is more binary, the gradient seen in MNs suggests that a permissive expression state can exist 
even when mCG depletion is not complete. We next sought to define regulatory regions by 
examining hypomethylation in an unbiased manner.    




To identify regulatory regions in the context of mCG that might be shared across cell 
types we called unmethylated regions (UMRs) and lowly methylated regions (LMRs), associated 
with promoters and enhancers respectively, across the genome158. While the number of UMRs 
was relatively similar across all cell types, a paucity of LMRs in mESCs and MNs was observed 
(Figure 5A). This dearth in MNs was unexpected given the number of LMRs in the other three 
neuronal cell types. UMRs were further classified into DNA methylation valleys (DMVs), 
domains that have previously been shown to be conserved across species and shared among cell 
types132,39,159. We checked the overlap of DMVs among our samples and three additional 
neuronal cell types (Figure 5B). 144 DMVs were shared among all cell types and 205 were 
shared among all neural cell types. As expected132, the majority (88-93%) of DMVs overlapped 
with promoter regions. DMVs shared across all seven cell types were enriched for GO molecular 
functions such as sequence-specific DNA binding, nucleic acid binding TF activity, and 
transcription regulatory region DNA binding. Almost half (282/609, 46.3%) of DMVs found 
within mESCs were found in no other DMV set of any cell type included in this study. 
Conversely, this same trend was not seen for AST (116/840, 13.8%), OL (154/808, 19.1%), or 
MN (14/649, 2.16%) -specific DMVs. The top mouse phenotype associated with mESC-specific 
DMVs is embryonic lethality, highlighting the importance of these large regulatory regions. 
Figure 5C presents four examples of large proximal mESC-specific DMVs that are associated 
with genes important to embryonic development. The vast majority (580/609, 95.2%) of DMVs 
found within mESCs intersect with a UMR found within one or more cell type consistent with 
the fact that most DMVs intersect a CGI (86%-93%) and that CGIs are generally unmethylated. 
Meanwhile, the top mouse phenotypes associated with OL-specific DMVs include abnormal 
myelination, abnormal OL morphology, and abnormal myelin sheath morphology. Examples of 
30 
 
OL-specific DMVs are presented in Figure 5D. We provide UMR, LMR, and DMV annotations 
for all cell types as a resource on the WashU Epigenome Browser.  
2.3.8  Common and Distinct Glial Epigenetics   
In addition to UMRs and DMVs which occur largely at promoters, we wanted to further 
identify putative distal regulatory regions in the context of mCG that were distinct among our 
cell types and often correspond to LMRs. We employed a conservative approach92,160 to identify 
differentially methylated regions (DMRs) across our four cell populations and three neuronal cell 
populations and provide this as a resource for the community. Shared glia, OL-specific, and 
AST-specific hypomethylated-DMRS (hypo-DMRS) were the largest three classes of 275,506 
DMRS identified (Figure 5E), consistent with the relatively large number of LMRs in the glial 
lineages as compared to mESCs and MNs. Unlike DMVs, a vast majority of autosomal DMRs 
did not intersect CGIs (3,745/274,184, 1.4%) nor overlap promoter regions (13,616/274,184, 
5.0%) consistent with the majority of DMRs corresponding to distal regulatory regions. 
Additionally, we assessed mCG differences between previously described S100B+ glia [data 
reanalyzed from GSE47966] and our ASTs, finding only 121 DMRs, reflective of largely similar 
astrocytic populations despite different methods of isolation. Surprisingly, in the context of DMR 
numbers in other neurons, but consistent with the low number of LMRs detected, MNs have only 
a modest number of hypo-DMRs.    
2.3.9  Sex-Specific Epigenomic Differences 
Our sex stratified study design allows us to both verify known patterns associated with X-
chromosome inactivation (XCI) and discover novel transcriptomic and epigenetic sex-specific 
differences across our cell types. Xist, a gene within the X-inactivation center expressed from the 
inactive X chromosome (Xi), is necessary for XCI in females161,162. mCG helps stabilize the 
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repressive state of the Xi74,75. Concordantly, Xist’s promoter is hypermethylated in male samples, 
but has 50.1%-68.9% mCG in females, congruent with hypomethylation and expression from the 
Xi and hypermethylation and repression from the active X chromosome (Xa) (Figure 6A). 
Parallel to autosomes, males have bimodal distributions of chrX mCG in contrast to females 
where the bimodal distribution is lost, and their %mCG is shifted downward across all three cell 
types (Figure 6B). In accordance with mCG’s repressive stabilization of the Xi, CGIs on the Xi 
are hypermethylated163 in contrast to CGIs genome-wide. Within chrX CGI containing 
promoters, females have more mCG than males (Figure 6C) across all three cell types. Mean 
mCG of these CGI-containing promoters ranges from 42.9% - 44.4% in females, close to what 
we’d expect with a fully methylated Xi and unmethylated Xa.  
 Some genes have been found to escapee XCI164 which happens in a tissue-specific 
manner165. CGIs of genes escaping XCI are hypomethylated not only on the Xa, but also on the 
Xi166 and could be diagnostic of escape genes in a cell type-specific manner. All three cell types 
had chrX female hypomethylated CGIs in the promoter or gene body of Ddx3x, Kdm6a, Eif2s3x, 
Ftx, and Kdm5c (previously identified in brain165), Pbdc1 (identified in spleen and ovaries, but 
not brain165), Jpx167, and Tmem29 (shown to partially escape XCI in embryonic fibroblasts168). 
Several escape genes have higher gene body mCH in females (Supplementary Figure 5A), 
perhaps as an alternative means to repression, as previously observed in NeuN- and NeuN+ 
nuclei92. Unexpectedly, we see a shift in ASTs towards males having more mCH than females 
over gene bodies, which is also true over other genomic contexts. Interestingly, Bcor has chrX 
female hypomethylated CGIs in its promoter, internal region, and downstream and while it was 
previously implicated as an escape gene does not seem to escape XCI in the brain169. We decided 
to visualize escape genes previously reported in the brain165 that were not found in the above 
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analysis. With the exception of 5530601H04Rik, females had higher mCG than males over the 
promoters of these genes (Supplementary Figure 5B) implying that while they might escape 
XCI in other CNS cell types, they do not demonstrate epigenetic signs of XCI escape in ASTs, 
OLs, or MNs. Thus, mCG information can be used in a cell type-specific manner to deconvolute 
XCI escape gene results at the tissue level. We next sought to identify transcriptomic and 
epigenomic differences between sexes in an unbiased manner not solely focused on sex 
chromosomes.  
  Sexual differences have been implicated in AST number and complexity170, disease 
prevalence and physiology171,172, microglia gene expression173, adult human cortex gene 
expression174, brain volume and white matter proportion175, and even OL turnover rates176. 
However, it is important to take into account the magnitude of these differences and the 
differential environments and experiences of sexes177. We sought to identify transcriptomic and 
epigenomic differences between sexes outside the sex chromosomes but didn’t find any. In all 
our neural cell types, even with a relaxed p-value adjustment178 and only requiring a 1.2-fold 
change, we only detected female upregulation of Xist and male expression of chrY genes Kdm5d, 
Uty, Ddx3y, and Eif2s3y concordant with data from whole brain179, but in contrast to higher 
powered studies174,180 (Supplementary Figure 5C). Previously, sex-specific mCG differences 
have been identified at individual CpG sites within the brain181,182 and at the DMR level in a very 
high powered human brain study183. For each cell type, we called DMRs between females and 
males using Methylpy160 and a pairwise DMR caller DSS184,185. In all three cell types, DMRs 
were restricted solely to chrX. Female hyper-DMRs were overrepresented (>95% in all three cell 
types for Methylpy) which was expected given that mCG helps inactivate the Xi161. For neural 
cells, female hypo-DMRs were found over Firre, 4933407k13Rik, Bcor, and Xist. Glial cells also 
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had female-specific Mid1 hypo-DMRs, perhaps indicating differences in neuronal versus glial 
regulation of this gene. Given the lack of mCG differences on autosomes we wanted to assess 
whether sex-specific DARs gave us redundant or new information. DARs were assessed both at 
the cell type level and with all female replicates versus all male replicates. When all female 
samples were treated as replicates and all male samples were treated as replicates, DARs were 
only present on chrX and chrY, with a large portion (28/45) within 15KB or overlapping the 
gene Firre and another grouping (7/45) overlapping 4933407k13Rik (the mouse homolog of 
Dxz4186), both implicated in anchoring the Xi to the nucleolus through CTCF which acts as a 
chromatin insulator186–188. These genes were also identified in the sex-specific DMR analysis. 
Sex-specific DARs in Firre and 4933407k13Rik overlap mouse ENCODE CTCF ChIP-Seq from 
neural tissues (forebrain, midbrain, and hindbrain), mESCs, and other tissues (Figure 6D). All 
three datatypes led to one concurrent conclusion; across the cell types studied there was a lack of 
autosomal epigenetic differences between sexes, but differential regulation on chrX.  
2.3.10 Oligodendrocyte-Specific Epigenetic Patterns Revealed at the QK 
Locus 
As an example of the utility of our combined resources we decided to look further at the 
Qk promoter region, a shared DMV across all cell types, that is expanded by >60KB to a region 
of 120KB when comparing ASTs to OLs and contains shared glial hypo-DMRs. Qk has 2-fold 
higher expression in both ASTs and OLs as compared to mESCs and MNs. The quakingviable 
(qkV) mutant mouse has previously been characterized to have a ~1 MB deletion on mouse chr17 
from ~.9KB upstream of Qk to within the fifth intron of Prkn. Qkv mice display seizures, 
tremors, male sterility, and oligodendroglial defects189–191. Three Qk isoforms are abundant in 
OLs of wildtype mice, and present in ASTs, but reduced in OLs, but not ASTs, of qkV mice191. 
We reasoned that if OL-specific enhancers were deleted in qkV mice this could account for the 
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discordant Qk expression, but the DMV expansion did not overlap the qkV deletion. Pressing on, 
we integrated our ATAC-seq data and noticed a shared Qk promoter open chromatin region, an 
AST-specific DAR, and a cluster of OL-specific DARs in Pacrg that did overlap the deletion 
(Figure 7A). We postulated that these OL-specific DARs may act as Qk distal enhancers and 
indeed Hi-C data from mouse brain192 is suggestive of an interaction between these peaks and 
Qk’s promoter (Figure 7B). Taken together, these data suggest that putative regulatory regions 
in OLs may be perturbed in qkV mice leading to their oligodendroglial defects and aberrant Qk 
protein expression. This analysis would not have been possible without the integration of our 
three assay types.     
2.3.11 Clustered Distal Cell Type-Specific Differentially Accessible Regions  
Given the cluster of OL-specific DARs associated with Qk, we decided to systematically 
locate similar regions across the genome and provide them as a final resource. We merged distal 
cell type-specific DARs into regions we call clustered putative enhancers. AST-specific clusters 
enriched for GO biological processes stem cell maintenance, somatic stem cell maintenance, and 
glial cell differentiation along with MSigDB genes enriched in ASTs in the adult mouse brain. 
OL-specific clusters enriched for GO biological processes axon ensheathment, regulation of 
membrane potential, and intracellular transport along with MSigDB genes downregulated during 
differentiation of oligodendroglial precursors and genes enriched in OLs in the adult mouse 
brain. MN-specific clusters enriched for GO biological processes axon part and neurofilament. 
We next searched within the putative clustered enhancers for those with the most individual 
peaks. Many of these were in close proximity or overlapping genes within our cell type enriched 
gene sets including Slc1a2, Fgfr3, and Sfxn5 for ASTs and Cldn11, Cd82, and Mbp for OLs. 
Interestingly, we also find two clusters in OLs with underlying OL-specific expression; a 26KB 
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cluster of six peaks overlapping Urm1 and two microRNAs (Figure 7C) and an 11KB cluster of 
five peaks overlapping an LTR element (Figure 7D). These two OL-specific putative regulatory 
regions may be permissive for the underlying expression seen. Our data sets allow for the 
discovery of putative cell type-specific clustered DARs which enrich for cell type-specific GO 
terms and are indicative of broader regulatory regions. 
2.4 Discussion and Conclusions 
Unique profiles of coordinated expression networks193–195 and tissue/cell type-specifically 
expressed genes33,36 have been fundamental to the understanding of cell fate and specificity. 
Many studies have delved into the epigenetics behind particular tissue types, including large 
scale consortium efforts such as ENCODE, Mouse ENCODE, and the Roadmap Epigenomics 
Project, adding to the genomics field a broad understanding of how epigenetics affect expression. 
However, tissue-level analysis can mask certain signals which deconvoluted cell type-specific 
analysis can find. 
Our study indicates that shared regulatory regions, defined by open chromatin signatures, 
are more likely to be proximal to the TSS and contain a CGI than those that are cell type-
specific. These regions and neural lineage DARs are enriched for CTCF and CTCFL, 
respectively, suggesting that TADs are established across cell types and tissues in a shared 
instead of cell type-specific manner. In contrast, cell type-specific DARs enrich for biological 
processes relevant to their derived cell type and contain putative binding sites for TFs that are 
more cell type-specific. Excitingly, we find regions with OL clustered putative enhancers of 
potential functional consequence upstream of Qk. Furthermore, two regions with clustered 
putative enhancers in OLs overlap regions with OL-specific expression from a non-protein 
coding or lincRNA locus.  
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 In each of our assays, ASTs and OLs cluster together, indicative of a shared glia 
epigenomic profile. Interestingly, OL differentiation is within the top 10 GO biological process 
terms for AST-specific DARs and both ASTs and MNs have ATAC-Seq signal over a large 
portion of promoters within the OL gene set. We believe this is driven by moderate expression of 
genes within the OL gene set in our other neural cell types and that they have shared patterns of 
regulation across these cell types. ASTs and OLs share many expressed genes as compared to 
MNs and form the largest class of hypo-DMRs. However, ASTs and OLs both have large sets of 
distinct DMRs and DARs along with largely non-overlapping top ranked genes in terms of 
%mCH. 
 MNs, like other neurons, are distinguishable from non-neurons by their high mCG and 
mCH levels. Unexpectedly, MNs can be distinguished from other neurons by their lack of LMRs 
and dearth of hypo-DMRs. They also exhibit more mCG over promoters of lowly expressed 
genes than their glial cell counterparts for TPM matched genes. Thus, we posit that permissive 
expression and regulatory states in MNs may not be marked by mCG changes at the same 
magnitude or length of other cells in this study. 
In the context of neurological sexual dimorphism170–176 it is perhaps surprising that none 
of our cell types show autosomal regulatory differences, but this could also be attributed to the 
power needed to see gene expression and mCG differences180,183.  While the vast majority of 
expression, open chromatin, and DNA methylation patterns are shared between our male and 
female samples, there are some notable exceptions to this paradigm on chrX. Two distinct 
clusters of ATAC peaks present in females and absent in males are within genes that anchor the 
Xi to the nucleolus through CTCF binding and overlap CTCF ChIP-Seq peaks. Some XCI 
escape genes can be distinguished by their relatively high mCH in females as compared to males 
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while others can be distinguished by mCG at proximal CGIs. Epigenetically, the neural cell types 
present in this study only support sex differences on chrX, but it is possible that sex differences 
do occur in these cell types at different developmental time points, during aging, under 
environmental conditions, or in disease. It is also possible that CNS sexual differences are 
attributable to other cell types, such as microglia173, or at a scale182 or epigenetic mark not 
studied.  
We report here three different assays (RNA-Seq, ATAC-Seq, and BS-Seq) from 
genetically defined in vivo extracted ASTs, OLs, and MNs all cell types that are important, but 
understudied or difficult to isolate. Additionally, each neural cell type has both male and female 
replicates and data was also generated from mESCs as a developmental outgroup. Data generated 
was extensively compared to three existing neuronal datasets39 and will serve as a valuable 
resource for future epigenetic and gene expression studies. All tracks and analyzed data are 
publicly available through the WashU Epigenome Browser as a public datahub (URL: 
https://epigenomegateway.wustl.edu/browser/) in the mouse mm10 genome. These rich datasets 
can be further used to validate and classify cell type specificity of ciRNAs, identify TFs 
expressed in development or specific cell types that interact with putative enhancers, and 
distinguish promoters and enhancers from larger regulatory regions in a cell type-specific 
manner. Our vignette on the cluster of Qk interacting OL DARs highlights how putative 
clustered enhancers as defined by ATAC-Seq can help interpret phenotypic data. Lastly, through 
the elucidation of cell type-specific epigenetic patterns we can assign disease-state mutations, 





Mouse procedures were approved by the IACUC at Washington University. Lines used 
included B6.FVB-Tg(Aldh1L1-eGfp/Rpl10a)JD130Htz/J, B6.FVB-Tg(Cnp-eGfp/Rpl10a)JD368Htz/J, and 
B6.FVB-Tg(Chat-eGfp/Rpl10a,Slc18a3)DW167Htz/J. Whole brains were used for the glial lines while 
pooled spinal cords were used for the ChAT line from mice 6-8 weeks of age in a sex stratified 
manner.  
2.5.2 Nuclei Isolation and Sorting 
Nuclei isolation was performed as previously described141 with the substitution of 35% 
Iodixanol as the lower layer in the density gradient. Additionally, after extraction, nuclei were 
pelleted at 3,000 rpm for 10 minutes at 4° in homogenization buffer to concentrate the sample 
and then incubated with 30 ul of carboxylic acid Dynabeads to remove free floating DNA. TO-
PRO-3 Iodide was added to each sample and gates were set for both TO-PRO-3 and GFP using 
wildtype mouse nuclei. FANS was performed with a Beckman Coulter MoFlo using 488 and 640 
nm excitation lasers. Nuclei were sorted into TRIzol LS, homogenization buffer, or DNA/RNA 
Shield buffer for RNA-Seq, ATAC-Seq, or Bisulfite Sequencing respectively.  
2.5.3 RNA Extraction and library generation 
GFP+ nuclei were sorted into TRIzol LS and stored at -80C. We randomly batched all 
RNA samples, started with the RNA purification from the aqueous phase after TRIzol LS 
extraction method, and then followed the standard protocol for Zymo’s RNA Clean & 
Concentrator Kit (R1013), which includes an in-column DNase 1 treatment. The Nugen Ovation 
Universal RNA-Seq System with mouse depletion targets (Nugen 0348) was used to create all 
strand-specific RNA libraries. We followed the standard protocol including an additional 
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integrated DNase treatment and a qPCR to determine the optical number of PCR cycles. 75bp 
paired-end sequencing of final libraries was performed on an Illumina NextSeq.  
2.5.4 DNA Extraction and Bisulfite Sequencing library generation 
GFP+ nuclei were collected into DNA/RNA Shield Buffer (Zymo Research R1200-125) 
and stored at -80C. DNA extractions were performed using the ZR-DuetTM DNA/RNA MiniPrep 
Plus (D7003) Kit’s Solid Tissue & Blood Cell DNA purification protocol with the following 
substitutions: 1) Zymo-Spin IC XM columns were used in lieu of Spin-Away columns to allow 
for elution of smaller volumes, 2) we added an additional 80% Ethanol wash step before the 
written wash steps, and 3) an elution volume of 20 μl was used. A Qubit was used to quantify all 
DNA concentrations. A spike-in of .1% phage-lambda DNA was added to each sample (50-200 
total nanograms of DNA) and bisulfite conversion was performed following the EZ DNA 
Methylation-DirectTM Kit (Zymo D5021) purified DNA protocol. The TruSeq DNA Methylation 
Kit (Illumina) Reference Guide Protocol was used to create libraries and 75 bp paired-end 
sequencing was performed on an Illumina NextSeq. 
2.5.5 ATAC-Seq library generation  
GFP+ nuclei were sorted into supplemented homogenization buffer, kept on ice, and 
processed directly after FANS. Tubes were centrifuged for 5 minutes at 500g at 4C, supernatant 
was removed, nuclei were transposed and purified, and then PCR was performed as previously 
described (with the exclusion of lysis buffer)56 using the Nextera DNA Library Prep Kit 
(Illumina) with cleanup steps performed with Qiagen’s MinElute PCR Purification Kit. 75 bp 
paired-end sequencing was performed on an Illumina NextSeq.      
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2.5.6 mESC Culture  
Bruce4 mESCs (Millipore Sigma SF-CMTI-2) were acquired at passage 12, thawed at 
37C, washed with ESGRO Complete Basal media (SF002-500), and expanded in ESGRO 
Complete Clonal Grade Medium (SF001-500P) supplemented with GSK3B inhibitor for two 
passages. Cells were then frozen using ESGRO Complete Serum-Free Cell Culture Freezing 
Media (SF005). Three vials of frozen Bruce4 mESCs were later thawed as above, cells were 
washed with PBS and media was replaced daily, and each vial was expanded for one passage 
with the use of Accutase (SF006) for detachment. Nuclei were isolated as in Nuclei Isolation and 
Sorting except homogenization was performed by hand instead of a drill and no sorting was 
necessary. ATAC-Seq was performed immediately after nuclei isolation and additional nuclei 
were stored in DNA/RNA Shield Buffer and placed at -80C. RNA extraction was processed in 
parallel with DNA extraction using the ZR-DuetTM DNA/RNA MiniPrep Plus Kit, which has 
identical steps to those in the Zymo’s RNA Clean & Concentrator Kit protocol after the DNAse 
1 treatment step.  
2.5.7 RNA-Seq data processing 
Reads were trimmed using cutadapt196 and genome indices were generated using 
STAR197 (2.5.4b) with the mm10 genome and Ensembl release 90 gene annotations. STAR’s 
two-pass method was used for read alignment and multi-mapping reads were excluded (--
outFilterMultimapNmax 1). For genes expressing multiple transcripts with disparate 5’UTRs, we 
retain transcripts displaying high coverage over the most upstream 5’UTR (non-exonic). 
Similarly, we excluded transcripts with low coverage over the most upstream 5’UTR (compared 
to other transcripts of the same gene). Reads were assigned to Gencode Basic Mouse M17 genes 
using HTSeq198 in a stranded manner. Counts were fed into EdgeR11,199 to call differentially 
expressed protein-coding or lincRNA genes in a cell type-specific and sex-specific manner. For 
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each cell type we took the intersection among the genes found in all paired cell type-specific 
expression comparisons (i.e. an AST-specific gene would be upregulated at least 4-fold in 
comparison to OLs, MNs, and mESCs) and filtered out genes that were 1) lowly expressed or 2) 
had a high coefficient of variation to create cell type expressed gene sets. All genome 
annotations were created in reference to the Gencode M17 Basic Gene gtf file. The online 
version of CSEA44, was used to look for overlap of our gene sets with known neurally expressed 
genes. Unmapped reads were extracted from STAR output and then split into anchors and used 
for circular RNA detection using scripts from find_circ146 using the –stranded option. Anchor 
fastqs were combined by cell type and re-run through find_circ to find the number of distinct 
reads in support of a junction site.  
2.5.8 Bisulfite Sequencing data processing  
Cutadapt was used to trim reads and Bismark200 was used for alignment (v0.18.1) with 
default parameters (mismatches was increased to 1). CpG conversion rates were assessed using 
the lambda genome and any libraries with <99% conversion were excluded. In a cell type-by-
sex-specific manner we combined de-duplicated aligned reads until we had approximately 1.2 
billion total reads (roughly 30X coverage) for each group’s BAM file. We further filtered out 
reads with mapping quality less than 10 and read pairs where one or both reads had >70% 
methylation in a non-CpG context with a minimum of 3 non-CPG methylation calls; likely 
representative of incomplete bisulfite conversion. MethylSeekR201 (1.18.0) was used to call 
UMRs and LMRs with a minimum of 5 CpGs per element and median methylation cutoff of .5. 
Methylpy160 was employed to call DMRs among the four cell types and in a sex-specific manner 
with default parameters except 1) minimum differentially methylated sites set to 5 and 2) number 
of simulations set to 5,000. Sex-specific DMRs were further filtered to have at least 5 unique 
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CpGs and 30% difference in methylation level. DSS184,185 was used to call DMRs in a pair-wise 
manner with default parameters except 1) delta was set to .2, 2) p-value threshold was set to 1e-
3, 3) minimum length was set to 200, and 4) minimum CpGs was set to 5. DMVs were 
categorized as UMRs with a minimum length of 5KB and maximum mean methylation of 15%. 
mCG was calculated over all chrX CGIs and CGIs with a mCG difference <=10% between 
males and females with <=30% mCG in females were called chrX female hypomethylated CGIs. 
Only genes where these CGIs were in the promoter or gene body and congruent with CGIs in the 
gene were maintained for further analysis. Deeptools202 computeMatrix scale-regions and 
plotHeatmap were used to visualize mCH and mCG as heatmaps. GREAT14 was used with the 
single nearest gene setting for GO biological process analysis. 
2.5.9 ATAC-Seq data processing 
Cutadapt was used to trim reads and Bowtie 2203 was used with a minimum fragment 
length of 38, maximum fragment length of 600, suppression of unpaired and discordant 
alignments for paired reads, and local alignment. Duplicate read pairs were removed, fragment 
files were created through conversion of the bam files to bed files, and sub-nucleosomal (<120 
bp) fragments were kept for further analysis. To ensure that peaks calling was not affected by 
differences in library sizes each fragment file was downsampled to 14 million fragments. These 
files were combined in a cell type-by-sex-specific manner and peaks were called for each group 
using the MACS2204 callpeak function in BEDPE mode. Peaks within 150 bp of each other were 
merged (bedtools merge) and we used bedtools multiinter to create a consensus peak set for 
Diffbind205 with a minimum allowable peak size of 100 bp. Diffbind was used for all samples to 
analyze differentially accessible regions. Deeptools202 computeMatrix scale-regions or reference-
point and plotHeatmap were used to visualize  subnucleosomal reads as heatmaps. GREAT14 was 
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used with the single nearest gene setting for GO biological process analysis. HOMER206 with 
default parameters except -size given and -S 100 was used to find de novo TF motifs in distal 
enhancers. Distal enhancers were defined as those outside of 2KB upstream or downstream from 
the TSS for all Gencode M17 basic annotation genes that were protein coding or lincRNAs. To 
find putative clustered enhancers we clustered distal cell type-specific ATAC-Seq peaks that 
were within 12.5KB of a neighboring peak, a distance previously used for calling super-
enhancers207. ChIP-Seq peaks were downloaded from ChIP-Atlas208 for all TFs with a Q-value 
threshold of significance of 1-5, liftover121 was used to convert coordinates from mm9 to mm10 (-
minMatch=.85), and bedtools fisher was used to define significant overlaps.  
2.5.10 General Processing 
We made extensive use of the bedtools209  suite including its closest, fisher, groupby, 
intersect, makewindows, multiinter, and subtract functions.   
2.5.11 Hi-C Data Visualization 
We made use of Juicebox210 version 1.9.8 for visualization of mouse brain data in the Hi-
C Data Archive (Deng and Ma et al. | Genome Biology 2015, Mouse brain combined 
replicates)192. We show observed/expected read values with balanced normalization for the 
image presented.   
2.5.12 Accession Numbers  
The accession number for the raw data files generated in this paper is GEO: GSE134357. 
Processed data files are available as a public data hub on the WashU Epigenome Browser 
(http://epigenomegateway.wustl.edu/browser/). We provide a supplementary tutorial to help 
users access the data seamlessly.  
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2.8 Figures & Tables 
 
 
Figure 1. Nuclei Isolation from bacTRAP Transgenic Mice. (A) Diagram of the bacTRAP mouse construct. 
Arrows indicate the promoters of the cell type-specifically expressed genes ChAT (Motor Neurons), Cnp 
(Oligodendrocytes), and Aldh1L1 (Astrocytes) driving expression of eGFP fused to L10a. Second diagram displays 
the 60S ribosomal protein L10a fused to GFP in an assembled translating ribosome. (B) Steps in the nuclei isolation 
protocol. Whole brains were used for the AST and OL lineages while pooled spines were used for the MN lineage. 
(C) Gates used for flow cytometry. Top Row: Gate 1 (Forward Scatter vs. Side Scatter) was used to distinguish size 
and complexity of nuclei thus excluding events deemed to be debris. Gate 2 (Forward Scatter vs. Pulse Width) was 
used to exclude nuclei duplets or clumps. Gate 3 (Forward Scatter vs. To-PRO-3) was used to select for nuclei 
exhibiting fluorescence for TO-PRO-3, a nuclear stain. Bottom Row: Representative gating for GFP+ nuclei from 
each transgenic mouse line. A wild-type (GFP-) mouse was used for each sorting session to determine the correct 




Figure 2. Identifying Differentially Expressed Genes and Assessing Lineage. (A) Scatterplots of all genes and 
differentially expressed genes for each neural comparison. Light colored points indicate >=2-fold change between 
cell types, while darker colored points indicate genes with >=4-fold change in all pairwise comparisons which are 
later termed gene sets. (B) Venn diagrams of shared >= 2-fold change genes in: 1) MNs and ASTs when each is 
compared pairwise to OLs, 2) OLs and ASTs when each is compared pairwise to MNs, and 3) MNs and OLs when 
each is compared pairwise to MNs. (C) Clustering of RPKM across protein coding and lincRNA genes by Pearson 
correlation. (D) Clustering of %mCG in 500bp bins by Pearson correlation. (E) Clustering of subnucleosomal 
ATAC-Seq reads over the consensus peak set by Pearson correlation. 
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Figure 3. Differentially Accessible Regions and Their Role as Regulatory Regions. (A) Heatmaps and plots 
show the subnucleosomal ATAC-Seq signal over the largest six classes of ATAC peaks for both proximal and distal 
peaks. (B) Violin plots indicating distance to the nearest TSS for each class of ATAC peaks. (C) Pie charts 
indicating the overlap of proximal peaks within each class of ATAC peaks with CGIs. (D) Top 10 GREAT GO 
biological terms enriched within each class of ATAC peaks using the single nearest gene setting. (E) Top 5 HOMER 




Figure 4. Profiling DNA Methylation and the Relationship between Methylation and Expression. (A) 
Percentage of BS-Seq calls supporting mCG and mCH for each group across sites with at least 5X coverage using 
autosomes. The top and bottom strand for CpG sites were merged into a single dinucleotide site while CH sites are 
not merged. (B) Percentage of BS-Seq calls supporting mCG and mCH as a proportion of total calls for each cell 
type. For each group all sites on autosomes were used. (C) Percentage of BS-Seq calls supporting mCG across 
autosomes in the context of different genomic elements. (D) Panel 1) Heatmaps and plots of mCG over gene bodies 
of genes within the defined gene sets divided by presence or absence of a CGI in the promoter region. Panel 2) 
Heatmaps and plots of mCH over gene bodies of genes within the defined gene sets divided by presence or absence 




Figure 5. Shared Proximal and Cell Type-Specific Regulatory Regions defined by DNA Methylation. (A) 
Lowly methylated regions (LMRs) and unmethylated regions (UMRs) found in each of our cell types along with 
three neuronal cell types. (B) Proportion of DNA methylation valleys (DMVs) shared among our cell types along 
with three neuronal cell types. DMVs were intersected both with DMVs and with UMRs. (C) WashU Epigenome 
Browser region set view of four DMVs found in mESCs that are important for embryonic development and (D) four 
DMVs found in OLs that are important marker genes. For each sample MethylC tracks and categorical tracks 
indicating the presence of a DMV, UMR, or LMR are displayed. (E) UpSet plot showing the relationship between 




Figure 6. Sex-Specific Epigenetic Differences. (A) WashU Epigenome Browser view of MethylC tracks for male 
and female samples from each of our cell types over the promoter of Xist. (B) Density plot of mCG on chrX for 
males and females of each cell type. (C) Density plot of the difference in %mCG between males and females of the 
same cell type for promoters with and without CGIs on chrX. (D) WashU Epigenome Browser view of MethylC 
tracks, ATAC subnucleosomal reads, and sex-specific DMRs for each of our neural cell types over Firre and 
4933407k13Rik. Below are Mouse Encode CTCF fold change over control tracks for three neural tissues, mESCs, 




Figure 7. Clustered Cell Type-Specific DARs. (A) WashU Epigenome Browser view of ATAC, MethylC, and 
categorical tracks for ASTs, OLs, and mESCs over Qk and the region deleted in qkV mutant mice. Zoomed-in region 
of OL-specific DARs within the above region. (B) Juicebox visualization of Hi-C data from mouse brain suggests an 
interaction between the OL-specific DARs and the Qk promoter. (C) WashU Epigenome Browser view of ATAC, 
RNA, and categorical tracks for ASTs, OLs, MNs, and mESCs over a cluster of OL-specific ATAC peaks with 
underlying expression within two microRNAs and (D) over a cluster of OL-specific ATAC peaks with underlying 




Supplementary Figure 1. CSEA Analysis of Gene Sets. CSEA diagrams for the A) MN gene set, B) AST gene 
set, and C) OL gene set. Smaller hexagons indicate more stringent thresholds of a Specificity Index and p-values are 
calculated from Fisher’s Exact test. Each gene list strongly highlights the most related cell type, across all thresholds 











Supplementary Figure 2. Clustering of Cell Types by DNA Methylation. (A) Clustering of %mCG in promoter 
regions (here defined as 2KB upstream and 1KB downstream of the TSS) by Pearson correlation (minimum 
coverage of 5X per CpG). (B) Clustering of %mCH in 500 bp bins across the autosomal genome by Pearson 




Supplementary Figure 3. ATAC Signal over Promoter Regions and Overlap with Chip-Seq Experiments. (A) 
Heatmaps and plots show subnucleosomal ATAC-Seq signal centered on the TSS of genes within cell type-specific 
gene sets divided by promoter CGI content. (B) Heatmaps and plots show the subnucleosomal ATAC-Seq signal 
over the largest six classes of ATAC peaks for only distal peaks. (C) Overlap of distal peals with public ChIP-Seq 
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Supplementary Figure 4. DNA Methylation Distributions and Integration with Expression Data. (A) Density 
plots of mCG for our four cell types and for MNs in comparison to three other neuronal cell types (minimum 5X per 
CpG). (B) Bar plots of genome-wide mCG for our combined cell types and for three neuronal cell types (minimum 
5X per CpG). (C) Percentage of BS-Seq calls supporting methylation in a CH context across autosomes in the 
context of different genomic elements. (D) Median mCG across genes binned by their TPM value and divided into 
genes with and without a CGI in their promoter. 
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Supplementary Figure 5. Sex-Specific Gene Expression and X Inactivation Escape Genes. (A) Scatterplots for 
mCH in males vs. females over gene body regions for autosomes (purple) and chrX (turquoise). chrX genes that fall 
outside the 1-1-10 confidence interval are marked in green and are all known escape genes. (B) WashU Epigenome 
Browser region set view of female and male MethylC tracks over the promoters of eight genes previously described 
as escaping XCI in the brain. (C) WashU Epigenome Browser region set view of five genes differentially expressed 




Supplementary Figure 6. Accessing the Data through the WashU Epigenome Browser (A) Access the WashU 
Epigenome Browser (http://epigenomegateway.wustl.edu/browser/), click on mouse, click the mm10 build, and then 
click Go. This will load a few default annotation tracks. (B) Click on the Tracks button and then click Public Data 
Hubs to access the browser’s public data hub collection. Click the + button next to the Neural Epigenome Atlas 
Collection. Below in green the user can see how many tracks are loaded and how many tracks are available. Click 
on the X in the top right to go back to the track view. (C) The user can easily relocate to specific places in the 
genome or to genes. Click the Genomic Region Locator and then type a query in the Gene search box. Multiple 
isoforms of a gene may appear; click one of the isoform annotations. To expand the view, click the -5 zoom out 
button. (D) Only a subset of the data within the Neural Epigenome Atlas Collection is presented on the browser by 
default. To view more data, click on the Tracks button and then click Track Facet Table. The table can be 
rearranged by setting a different metadata type in the column attribute and then expanded by clicking the + buttons 
next to the row and column displays. Clicking on the box at the intersection of categorical and Paired-End BS-Seq 
will bring up a table of all tracks available in the intersection (in this case tracks that display DMV/LMR/UMR 
annotations). Select tracks of interest by clicking the + button next to each one and then the X to go back to the track 
view. There is extensive documentation on additional functions of the browser available by clicking the Help button 






























Supplementary Tables 1-3 have been placed in Appendix A.   
Supplementary Table 4. Number of Genes Upregulated in Pairwise Comparisons. Pairwise comparisons were 
performed in EdgeR between each of the cell types for protein-coding genes and lincRNAs.  
# Upregulated Genes (2-fold, p < .05) 
Upregulated in Column Name as Compared to Row Name 
 Motor Neurons Astrocytes Oligodendrocytes mESCs 
Motor Neurons 0 1,850 2,295 4,150 
Astrocytes 1,243 0 1,405 3,737 
Oligodendrocytes 2,242 1,833 0 3,766 
mESCs 4,127 4,453 4,222 0 
 
Supplementary Table 5. Circular RNA Supporting Reads. Circular RNAs mentioned in the text annotated with 
the number of unique bridge reads and the number of samples with greater than 1 read stratified by cell type. 
CiRNAs were also annotated based on their overlap and relative direction with respect to gene[s]. 
Location (strand) Gene Type 
Cell Type 
# Samples Supported 
 (min 2 reads) # Unique Bridges 
chrX:61183247-61186174 (+) Cdr1 Antisense 
Astrocytes 4 15 
Oligodendrocytes 3 11 
Motor Neurons 6 32 
mESCs 0 0 
chr7:19696337-19697010 (-) Apoe Sense 
Astrocytes 6 41 
Oligodendrocytes 4 12 
Motor Neurons 0 0 
mESCs 3 30 
chr13:91524584-91564694 (+) Ssbp2 Sense 
Astrocytes 3 8 
Oligodendrocytes 4 19 
Motor Neurons 6 27 
mESCs 0 0 
chr5:25956739-26007120 (-) Gm21168 through Gm5067 Antisense 
Astrocytes 0 0 
Oligodendrocytes 5 31 
Motor Neurons 0 1 
mESCs 0 0 
chr4:102277046-102277610 (-) Pde4b Antisense 
Astrocytes 1 2 
Oligodendrocytes 3 9 
Motor Neurons 0 1 
mESCs 0 0 
chr14:19417219-19418853 (+) Gm21738 Antisense 
Astrocytes 0 0 




Supplementary Table 6: CpG Methylation Coverage Per Sample. Bisulfite libraries were combined in a cell 
type-by-sex-specific manner until they reached approximately 30X coverage for each merged CpG (+ strand and - 
strand calls were combined). Percent coverage was calculated using the total number of CpGs annotated in the 
mm10 genome excluding mitochondrial DNA and blacklisted regions.  
Group Number and (Percent) of CpGs covered at >= (1X-20X) Average Coverage 
Uncombined 
 
1x 5x 10x 15x 20x CpGs with at 
least 1X 



















































































(68.7%) 40.32X 38.06X 
Combined 1x 5x 10x 15x 20x CpGs with at 
least 1X 










(80.53%) 66.04X 62.77X 



















(80.85%) 73.24X 69.66X 
Motor Neurons 3 15 
mESCs 0 0 
chr2:158376304-158381442 (-) Snhg11 Antisense 
Astrocytes 0 0 
Oligodendrocytes 0 0 
Motor Neurons 3 3 
mESCs 0 0 
chrX:136832039-136833353 (-) Plp1 Antisense 
Astrocytes 0 0 
Oligodendrocytes 2 7 
Motor Neurons 0 0 
mESCs 0 0 
chr5:104092871-104093081 (+) Sparcl1 Antisense 
Astrocytes 2 4 
Oligodendrocytes 0 0 
Motor Neurons 0 0 
mESCs 0 0 
chr11:100589897-100637892 (-) Dnajc Sense 
Astrocytes 0 0 
Oligodendrocytes 5 30 
Motor Neurons 0 0 
mESCs 0 0 
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Chapter 3: bacTRAP mESC Creation  
 





With the invention of the microscope, scientists were able to morphologically define cell types 
and later define subcellular features and differences among cells through the use of cell staining. 
However, this presents an incomplete picture of cell state, as the regulatory landscape of the cells 
is not readily viewable. Aberrant DNA methylation has been observed in culture and whether 
this disruption is due to general culture environment or specific to cell lineage is an open 
question. Transgenic mouse lines previously provided us the opportunity to profile in vivo neural 
cell types and the derivation of mESCs from these lines coupled with differentiation allows for a 
direct cell type-specific resolution in vivo versus in vitro study without the complication of 
differing genetic background. Here we tested astrocyte, oligodendrocyte, and motor neuron 
mESC differentiation protocols in RW.4 mESCs and created transgenic mESCs from Aldh1L1, 
Cnp, and ChAT bacTRAP mice. For each line at least one male and one female line was created 
to allow assessment of a cell type’s sex on in vitro culture. Using our bacTRAP-Aldh1L1-mESCs 
we demonstrate that GFP+ cells can be isolated after differentiation proving the potential utility 
of these lines. 
3.2 Introduction 
Pluripotent stem cells, including induced pluripotent stem cells (iPSCs) and embryonic 
stem cells (ESCs), are powerful tools for research as they can become “any” cell type and 
potentially replace non-self-renewing cells in the human body or those that are damaged through 
the onset of disease or sudden trauma. Indeed, many protocols have been developed to generate a 
vast array of cell types including cardiomyocytes211, macrophages212,213, endothelial cells214, 
muscle cells215, glial precursors216, neurons217–221, oligodendrocytes222,223, astrocytes221, and 
erythroid cells224. They can also act as transplantable cells for diseases that would otherwise be 
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considered incurable or fatal, as exemplified by their potential role in replacing degenerated 
motor neurons of ALS patients225. Cell- and tissue- based in vitro models also inform drug 
development in disease state, but incomplete modeling of the original cell/tissue has contributed 
to the failure to clinically translate many of these findings226. Thus, it is vital that in vitro cell 
types behave in the same manner as in vivo counterparts.  
No studies have characterized in vivo versus in vitro whole genome epigenetic changes at 
the cell type level for neural differentiation. Hypermethylation has been observed in cells 
differentiated in vitro131,227, high-CpG density promoter methylation increases with passage 
number131, global patterns of 5-hydroxymethylcytosine can be lost in culture228,229, and aberrant 
changes in DNA methylation has been linked to tumorigenesis158,230,231. Certain culturing 
conditions have also been shown to affect epigenetic profiles of in vitro cells232. A recent study 
assessed the DNA methylation profile of cerebral organoids155 finding that patterns recapitulated 
those in the human fetal brain. For the first time, this paper directly gauged in vitro neural 
differentiation as compared to an in vivo model. However, although organoids may serve as 
valuable tools for functional testing and the brain as a whole, these systems still have limitations 
in studying and modeling epigenetics at the cell type level, which will be necessary for 
transplantable cells. 
Unsupervised hierarchical clustering on RRBS data reveals that non-cancer cell lines and 
normal human tissue form distinct clades93. We hypothesize that in vitro mESC differentiated 
cultures will have changes in accessibility underlain by cell type/lineage-specific transcription 
factors, coordinated changes in DNA methylation, chromatin accessibility, and gene expression 
at the local level, and loss of non-CpG DNA methylation. However, epigenetic identifiers vital 
for transformation into a specific cell type will be maintained across the in vivo and in vitro 
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systems. Thus, epigenomic profiles of in vitro cell types will incompletely model those of the 
reference in vivo epigenomes but maintain cell type-specific epigenetic identifiers. 
Here we test differentiation protocols for astrocytes (ASTs), oligodendrocytes (OLs), and 
motor neurons (MNs) in RW.4 mESCs. Often within neural cultures ASTs, MNs, and OLs are 
seen co-currently233 so a system was selected to minimize culture differences between 
differentiated cell types that will also maximize cell type-specific differences when compared to 
in vivo data. We then create mESCs from transgenic bacTRAP Aldh1L1, Cnp, and ChAT lines 
and re-test working cell type appropriate differentiation protocols. Lastly, we implement cell 
staining and FANS analysis to confirm cell identity and furthermore show the presence of GFP+ 
cells for bacTRAP-Aldh1L1-mESCs directed towards the AST cell identity.  
3.3 Results 
3.3.1  Successful Differentiation of Astrocytes, Oligodendrocytes, and Neurons 
Established protocols and kits are available for numerous differentiation systems, 
including systems for all cell types used in this project221,234,235. We tested protocols to terminally 
differentiate mESCs into populations of ASTs, OLs, and MNs (Methods). We tested numerous 
primary and secondary antibodies (Supplementary Tables 1 and 2) to verify identity over time 
for all three cell types. Cell staining revealed CNPase, GFAP, and Tuj1 presence in OLs, ASTs, 
and MNs at day 17 of the protocol respectively (Figure 1A-C). At terminal differentiation day 
20 we co-stained our OL directed culture with Olig2 and CNPase revealing many cells still 
expressing Olig2 perhaps indicating that longer culturing times could lead to more fully 
differentiated OL cells (Supplementary Figure 1A). We re-validated the ChAT antibody in 
sectioned mouse brain successfully (data not shown), revealing that while neurons formed in 
culture, MNs were at low proportion. Additionally, we co-stained for Nestin and Isl1 at terminal 
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differentiation day 17 for cells directed towards MNs which revealed a lack of neural precursor 
cells as expected and MN presence, but at very low abundance (Supplementary Figure 1B). 
Thus, we can differentiate astrocytes at high numbers and both oligodendrocytes and motor 
neurons albeit at lower numbers.  
3.3.2  bacTRAP mESC Creation 
 While readily accessible, RW.4 mESCs have a genetic background of 129X1/SvJ, which 
is distinct from our transgenic lines. Different mouse backgrounds can complicate research in at 
least two ways; 1) direct effects of variation on CpGs and CHs and 2) indirect effects of variation 
on the maintenance and control of regulatory regions which may have downstream consequences 
on gene expression and regulation. Genetic variation among strains has been previously 
characterized236, has been related to phenotypic differences237, and ultimately has led to UCSC 
builds of strain-specific mouse reference genomes238. This genetic background would further 
complicate an in vivo versus in vitro analysis and thus we decided to create mESCs with an 
identical genetic background so that data would be directly comparable to that created within 
Chapter 2. We first tested a mESC creation method based on a previous publication239 in the 
ChAT line and after successful application extended this to the Cnp and Aldh1L1 lines (Figure 
2A). Briefly, five timed pregnancies were setup per line, hormonal injections were given to 
female mice, and they were mated with males. Oocytes were extracted from fertilized mice and 
these were re-plated at the blastocyst stage. The inner cell mass attached to the plate creating an 
ESC-like colony that was later re-plated and grew into mESC lines (Figure 2B). mESCs were 
genotyped for presence of GFP and Sry (a chromosome Y located gene) which revealed the 
successful creation of at least one male and one female mESC line per bacTRAP line (Table 1). 
We next retested differentiation protocols especially the Embryoid Body (EB) formation steps, 
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as B6 background cells do not form EBs as well as different genetic backgrounds (personal 
correspondence Dr. Kyunghee Choi).  
3.3.3  Assessing Differentiation of bacTRAP mESCs  
 Initial testing of EB development from bacTRAP-ChAT-mESCs indicated that there were 
smaller and fewer EBs formed as compared to RW.4 EBs when 1 million cells were plated on 
100mm plates. We retested the protocol plating 1 million, 2 million, or 3 million cells and found 
that 3 million allowed for final EB size and numbers appropriate for further differentiation steps. 
In RW.4 test differentiations our AST cultures reliably gave us cells that we could positively 
identify as ASTs and a larger number of the cells than the OL and MN cultures. Thus, we used 
bacTRAP-Aldh1L1-mESCs for full protocol testing. 
bacTRAP-Aldh1L1-mESCs were differentiated towards ASTs (Methods) with the 
exception that 3 million instead of 1 million cells were used for EB creation. Fluorescence 
activated nuclei sorting (FANS) was employed to determine if GFP+ cells were present within 
our cultures. GFP was not readily viewable under the microscope for bacTRAP-Aldh1L1-mESCs 
directed towards ASTs for 16 days, but FANS analysis revealed the presence of GFP even with 
the high autofluorescence noted (Figure 2C). GFP was also not viewable under the microscope 
for bacTRAP-ChAT-mESCs directed towards MNs for 17 days and FANS analysis concurrently 
revealed the absence of GFP. This could be due to incomplete differentiation or some effect of 
the notable autofluorescence seen.  
Next, we stained fixed cells from each culture system for cell type markers and GFP. Cell 
type markers were present for each cultured system (CNPase for OLs, GFAP for ASTs, and Tuj1 
for neurons) (Figure 3A-C), but we could not distinguish Hb9 which marks MNs. GFP presence 
was noticeable in AST staining, could not be seen in MNs (data not shown), and was not visible 
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in OLs. While in MNs this matches with the perceived incompletely differentiated state of these 
cells for OLs it does not match our expectation based on presence of CNPase. We expect an 
additional OL differentiation and staining with the same GFP antibody used for ASTs will reveal 
GFP presence albeit in far fewer cells. Given these results we believe with certain protocol 
adjustments and additional testing that these lines can be successfully differentiated into ASTs, 
OLs, and MNs and data can be created and compared to the data in Chapter 2.      
3.4 Discussion and Conclusions 
Epigenetic profiles of cell lines and ESC/iPSC-derived cells are commonly published, 
they form a sizable sample set of the Roadmap data and both ENCODE and mouseENCODE 
contain ES derived neurons, but the scarcity of studies directly assessing the epigenetic 
concordance in vivo and in vitro places restrictions on interpretation of data and limits the 
applicability of ESC/iPSC derived cells within the medical field. Classically, serum with a 
combination of growth factors was used to drive cells towards their ultimate fate. However these 
experiments were hard to replicate and may not represent a biologically accurate environment for 
cell specification240. Here we create three cell lines that can be used to glean if there are shared 
or cell type-specific epigenetic perturbations in vitro. Eventual data can be directly compared to 
the data created in Chapter 2. In addition, data from other cell type-specific in vitro studies could 
be compared to our posed in vitro data to analyze contrasts among differentiation protocols. 
Indeed, two recent studies241,242, profiled chromatin accessibility and gene expression of 
transcriptionally reprogrammed MNs and thus could serve as a comparison group.  
There are several limitations to our current protocols that need to be overcome. Firstly, 
there is apparent lack of fully differentiated MNs in our system. Secondly OLs, while present, 
are not a large portion of their culture as previously observed (personal correspondence Justin 
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Melendez) and would require a lot of input cells for differentiation. Third, we were unsuccessful 
at visualizing GFP presence in OLs and MNs and while staining methodology might be at fault 
this could also be indicative of a larger problem. Lastly, there is noticeable autofluorescence 
even within our differentiated ASTs, which was not seen in our previous in vivo nuclei methods. 
This may be an effect of the dissociation protocols used for the large cell clumps and could 
indicate that a change is needed in the protocol at the plating EB stage. However there is hope as 
ASTs from our bacTRAP-Aldh1L1-mESCs very clearly show perinuclear staining of GFP which 
is how GFP distributes in the bacTRAP mice37. Additionally, these cells can be isolated through 
FANS for downstream data creation and analysis.     
3.5 Methods 
3.5.1 RW.4 mESC Culturing and Differentiation 
The RW4 cell line was cultured as previously described243. We used a modified 
protocol235 provided by the Rob Mitra and Shelly Sakiyama-Elbert laboratories for 
differentiations. Plates were coated with polyheme (Sigma-Aldrich P3932-10G) in 95% Ethanol. 
At 85% confluence RW.4 cells were washed with PBS (Gibco), trypsinized, incubated, and the 
reaction was quenched with DMEM (Corning). A million cells were added onto polyheme 
coated 100mm plates with DFK5 media219 (DMEM/F-12 (Thermo Fisher), 5% KO Serum 
Replacement (Thermo Fisher), 1% Insulin-Transferrin-Selenium (Thermo Fisher), .5% 
Nucleosides, .5% Nonessential amino acids, and .5% Beta-Mercaptoethanol (Thermo Fisher)) to 
form EBs. Two days later EBs were resuspended in DFK5 media supplemented with 1mM 
retinoic acid (RA) (Sigma-Aldrich) and 10 mM Smoothened Agonist (SAG) (EMD Millipore) 
which was repeated at day 4. On day 6, EBs were gently dissociated and placed on Poly-L-
Ornithine (Poly-O) (Sigma-Aldrich) and Laminin (Thermo Fisher) coated plates in DFKNB (1:1 
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DFK5 to Neurobasal medium (Thermo Fisher)) supplemented 1:50 with B-27 Supplement 
(Thermo Fisher) supplemented 1:10000 with Basic fibroblast growth factor (BFGF) (R&D 
Systems) and Epidermal Growth Factor (EGF) (PeproTech) for astrocytes and oligodendrocyte 
and in DFK5 1:50 with B-27 supplemented 1:20000 with each of Neurotrophin-3 (NT3) 
(PeproTech), Glial cell line-derived neurotrophic factor (GDNF) (PeproTech), and Brain-derived 
neurotrophic factor (BDNF) (PeproTech) for motor neurons. For MNs, media is switched to 
DFKNB with B-27 on day 7 with the same growth factors (GFs), switched to just NB media and 
GFs day 10 with the same media change on day 13. On days 7 and 8 BFGF and EGF are added 
again to the AST and OL cultures. For days 9-11 ASTs also get Ciliary Neurotrophic Factor 
(CNTF) (Peprotech) 1:5000 added daily, day 12 media was changed to NB with B-27 only 
supplemented with CNTF, and for the rest of the protocol CNTF was added daily with media 
changes as needed. For days 9-11 OLs also get Platelet-Derived Growth Factor (PDGF) 
(Peprotech) 1:5000 added daily, day 12 media was changed to NB with B-27 only supplemented 
with PDGF, PDGF was then added daily until day 16 where media was changed to NB with B-
27. Cell cultures end at days 17, 18, and 20 for MNs, ASTs, and OLs respectively.  
3.5.2 Cell Staining Methods  
At the stage where EBs were dissociated a subset of the cells are placed into 12-well 
plates with coverslips coated in Poly-O and Laminin and cultured as in RW.4 mESC Culturing 
and Differentiation. Cell staining was performed as previously described244 for a variety of 
antibodies listed in Supplementary Tables 1 and 2 and cells were also incubated with DAPI 
(Thermo Fisher) to visualize nuclei. Coverslips were mounted on slides and microscopy was 
performed with a Leica DM IL LED Fluorescence Inverted Microscope. Images were further 
processed when necessary with ImageJ245.      
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3.5.3 MEFs  
We obtained untreated CF1 Mouse Embryonic Fibroblasts Cells (MEFs) from Applied 
StemCell (ASF-1201) and expanded in media containing L-Glutamine, Nonessential amino 
acids, Heat-inactivated FBS (Thermo Fisher), and DMEM. Cells were passaged using trypsin, 
washed daily, and frozen using standard media with 20% DMSO (Sigma-Aldrich) and 20% FBS. 
MEFs were irradiated using an XCELL 50 X-Ray Irradiator in the bottom tray for 909 seconds 
(5,000 rads) and used as a feeder layer plated on gelatin plates for mESC creation.     
3.5.4 Mice 
Mouse procedures were approved by the IACUC at Washington University. Lines used 
included B6.FVB-Tg(Aldh1L1-eGfp/Rpl10a)JD130Htz/J, B6.FVB-Tg(Cnp-eGfp/Rpl10a)JD368Htz/J, and 
B6.FVB-Tg(Chat-eGfp/Rpl10a,Slc18a3)DW167Htz/J as described in Chapter 2. Female wildtype B6 
mice received an IP injection of 100 ul of Pregnant Mare Serum Gonadotropin (PMSG) followed 
48 hours later by and IP injection 100 ul of Human Chorionic Gonadotropin (HCG). Males were 
then set up with females overnight. Heterozygous male bacTRAP mice were used for the ChAT 
and Aldh1l1 lines while heterozygous female bacTRAP mice were used for the Cnp line due to 
known reproductive problems of Cnp males. Copulation plugs were checked the next day and 
successfully mated females were sacrificed.  
3.5.5 bacTRAP mESC Creation 
mESCs were generated from each transgenic mouse line based roughly on a previously 
published protocol239. The uterine horn was placed in M2 medium (Millipore/Sigma), oviducts 
were isolated, and each ampulla was punctured to release the cumulus-oocyte complex. 
Hyaluronidase was added to digest cumulus cells leaving only oocytes that were selected based 
on the presence of both a maternal and paternal pronuclei. These were transferred to a 35mm 
plate with KSOM media (Millipore/Sigma) overlaid with mineral oil and placed in the incubator 
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to culture until the blastocyst stage (~3 days). Blastocysts were transferred to ESM/3i media 
consisting KO DMEM (Thermo Fisher), 7.5% KO Serum Replacement (Thermo Fisher), 7.5% 
Hyclone ES Screened Fetal Bovine Serum (FBS) (GE Healthcare), 1% 100X Glutamax (Thermo 
Fisher), and 1% Nonessential amino acids supplemented 1:20000 Gentamicin (Thermo Fisher), 
1:5500 Beta-Mercaptoethanol (Thermo Fisher), 1:100000 LIF (EMD Millipore; LIF2050), 
1:10000 CHIR99021 (Sigma-Aldrich), 1:20000 PD 0325901 (Sigma-Aldrich), and 1:10000 SB 
431542 (Sigma-Aldrich) and plated one per well on a 24-well plate containing irradiated MEFs 
(iMEFs). At day 10 (3 days later) the blastocysts hatched out of the zona pellucida and the inner 
cell mass stably attached to the plate. One day later (day 11) media was carefully changed and 
changed daily after. Daily growth checks and visualization occurred. Depending on the growth 
rate, cells were ready to be trypsinized (TrypLE) and moved to a new well in 24-well plate 
containing iMEFs 4-7 days later. Extra media was added to the original 24-well plate and cells 
were left to grow for later GFP and Sry genotyping. Media was changed daily on 24-well plates 
and 3-4 days post-plating cell colonies were large enough to transfer to an iMEF coated well in a 
6-well plate with 2 ml ESM/3i media. Daily media changes occurred and 3-4 days later when 
80% confluent, cells were transferred to 100mm iMEF coated plates with 10 ml ESM/3i. Plates 
were expanded as necessary or frozen in ESM Freezing Medium (60% ESM media lacking 
inhibitors, 20% FBS, 20% DMSO). When possible three GFP+ Male and three GFP+ Female 
mESC lines were expanded per original bacTRAP construct. 
3.5.6 Nuclei Extraction and FANS 
Nuclei extraction was performed as previously described37 with the same modifications 
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3.7 Figures and Tables 
 
 
Figure 1. Cell Staining of Cells Differentiated from RW.4 mESCs. (A) Staining of directed differentiation 
towards oligodendrocytes with CNPase (green) and Dapi (blue). (B) Staining of directed differentiation towards 
astrocytes with GFAP (red) and Dapi (blue). (C) Staining of directed differentiation towards motor neurons with 









Figure 2. Creation of bacTRAP mESCs. (A) Steps in the mESC creation protocol. (B) Representative bright field 
images of stages in mESC creation including the blastocyst (top left), inner cell mass hatching out of the zona 
pellucida (top right), inner cell mass growth into an “ESC-like” colony (bottom left), and mESC colonies (bottom 
right). (C) Gating for nuclei from bacTRAP-Aldh1L1-mESCs directed towards ASTs reveals successful AST 




Figure 3. Cell Staining of Cells Differentiated from bacTRAP mESCs. (A) Staining of the bacTRAP-Cnp-
mESCs which were directed towards oligodendrocytes with CNPase (green), GFP (red), and Dapi (blue). Absence of 
GFP is noted. (B) Staining of the bacTRAP-Aldh1L1-mESCs which were directed towards astrocytes with GFAP 
(red), GFP (green), and Dapi (blue). (C) Staining of the bacTRAP-ChAT-mESCs that were directed towards motor 







Supplementary Figure 1. Additional Cell Staining of Cells Differentiated from RW.4 mESCs. (A) Staining of 
directed differentiation towards OLs with CNPase (red), Olig2 (green), and Dapi (blue). (B) Staining of directed 






Table 1. Genotypes of bacTRAP mESCs Generated. mESCs were created for three bacTRAP lines and 
genotyped for GFP presence and SRY presence.  
 
mESCs Created Per Line 
bacTRAP Line GFP+ Males GFP+ Females GFP- 
ALDH1L1 6 4 7 
CHAT 5 4 11 
CNP 13 1 6 
 
Supplementary Table 1. Primary Antibodies.  Several antibodies were used to stain for proper lineage 
commitment for astrocytes, oligodendrocytes, and motor neurons.  
Antibody Dilution Host Species Cell Types Stained Reference Company 
S100b 1:200 Rabbit Astrocytes ab52642 Abcam 
Oct4 1:250 Rabbit ESCs ab19857 Abcam 
Hb9 1:25 Mouse Motor Neurons 81.5C10 DSHB 
Isl1 1:50 Mouse Motor Neurons 39.4D5 DSHB 
Olig2 1:250 Rabbit pMN/pOL AB9610 Millipore Sigma 
Tuj1 1:250 chicken Neurons CH23005 Neuromics 
ChAT 1:500 Goat Motor Neurons AB144P Millipore Sigma 
GFAP 1:1000 Rabbit Astrocytes Z033429 Agilent 
Nestin 1:2000 Chicken NPCs ab134017 Abcam 
CNPase 1:500 Mouse Oligodendrocytes MAB326 Millipore Sigma 
Glt1 1:100 Rabbit Astrocytes NBP1-20136 Novus Biologicals 
 
Supplementary Table 2. Secondary Antibodies. Several secondary antibodies were used to visualize primary 
antibodies across three different channels.  
Host Target Conjugate Reference Company 
Donkey  anti-Goat IgG (H+L)   AlexaFluor® 350  A-21081 Thermo Fisher 
Donkey  anti-Goat IgG (H+L)   AlexaFluor® 488  A-11055 Thermo Fisher 
Donkey  anti-Mouse IgG (H+L)   AlexaFluor® 488  A-21202 Thermo Fisher 
Donkey  anti-Rabbit IgG (H+L)   AlexaFluor® 488  A-21206 Thermo Fisher 
Donkey  anti-Chicken IgY (IgG) (H+L)   AlexaFluor® 488  703-545-155 Jackson ImmunoResearch 
Donkey  anti-Goat IgG (H+L)   AlexaFluor® 546  A-11056 Thermo Fisher 
Donkey  anti-Mouse IgG   AlexaFluor® 546  A-10036 Thermo Fisher 
Donkey  anti-Rabbit IgG (H+L)   AlexaFluor® 546  A-10040 Thermo Fisher 
Donkey  anti-Chicken IgY (IgG) (H+L)   Rhodamine (TRITC) 703-025-155 Jackson ImmunoResearch 
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Chapter 4: Tissue-specific DNA methylation 
is conserved across human, mouse, and rat, 
and driven by primary sequence 
conservation 
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From: 
Tissue-specific DNA methylation is conserved across human, mouse, and rat, and driven by 
primary sequence conservation.  
Zhou, Jia and Sears, Renee L. et al. (2017). Tissue-specific DNA methylation is conserved 





Uncovering mechanisms of epigenome evolution is an essential step towards understanding the 
evolution of different cellular phenotypes. While studies have confirmed DNA methylation as a 
conserved epigenetic mechanism in mammalian development, little is known about the 
conservation of tissue-specific genome-wide DNA methylation patterns. Using a comparative 
epigenomics approach, we identified and compared the tissue-specific DNA methylation patterns 
of rat against those of mouse and human across three shared tissue types. We confirmed that 
tissue-specific differentially methylated regions are strongly associated with tissue-specific 
regulatory elements. Comparisons between species revealed that at a minimum 11-37% of tissue-
specific DNA methylation patterns are conserved, a phenomenon that we define as epigenetic 
conservation. Conserved DNA methylation is accompanied by conservation of other epigenetic 
marks including histone modifications. Although a significant amount of locus-specific 
methylation is epigenetically conserved, the majority of tissue-specific DNA methylation is not 
conserved across the species and tissue types that we investigated. Examination of the genetic 
underpinning of epigenetic conservation suggests that primary sequence conservation is a driving 
force behind epigenetic conservation. In contrast, evolutionary dynamics of tissue-specific DNA 
methylation are best explained by the maintenance or turnover of binding sites for important 
transcription factors. Our study extends the limited literature of comparative epigenomics and 
suggests a new paradigm for epigenetic conservation without genetic conservation through 
analysis of transcription factor binding sites. 
4.2 Introduction 
A fundamental yet unanswered question in biology is how epigenomes evolve. 
Comprised of an assortment of chemical modifications (including DNA methylation and histone 
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modifications), the epigenome describes the genome-wide epigenetic landscape of a cell246. 
Within the context of cellular state, identical DNA sequences can diverge in their epigenetic 
patterning leading to differential gene expression, which is fundamental for the development of 
multicellular organisms247. Thus, a single genome shared among all cells has the potential to give 
rise to many epigenomes248. The information contained within a single genome must direct the 
creation of multiple epigenomes, but how the generation of these epigenomes is regulated and 
how epigenomes among different species relate to each other, remains largely undefined. 
 Comparative genomics studies genome evolution through the analysis of primary 
sequence divergence across species over time. Using this powerful method, many principles of 
genome evolution, adaptation, and function have been discovered249, and functional regions of 
genomes identified102,250. Thus, we hypothesize that by comparing epigenomes of multiple 
species in the context of their genomic sequences, one might deduce rules connecting genome 
evolution with epigenome evolution. 
 Pioneer studies in comparative epigenomics have begun to unveil the fundamental 
principles of epigenome evolution. For example, the genome-wide pattern of DNA methylation 
for certain genomic elements is conserved in vertebrates as well as plants109,251 suggesting that 
the regulatory roles of DNA methylation are conserved252. Using pluripotent stem cells of 
humans, mice, and pigs, Xiao et al. discovered strong epigenomic conservation in both rapidly 
evolving and slowly evolving DNA sequences, but not in neutrally evolving DNA sequences120. 
These conserved epigenomic modifications mark regulatory DNA120,253. Using the Illumina 
HumanMethylation27 BeadChip microarray for human and chimpanzee liver, heart, and kidney 
samples, Pai et al. found that methylation variations were greater between tissues in the same 
species than between species for the same tissue114. Hernando-Herraez et al. compared DNA 
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methylation patterns between humans and great apes using the Illumina HumanMethylation450 
platform and found many genes with significantly altered methylation patterns. They discovered 
a positive relationship between the rate of coding variation and alterations of methylation at the 
promoter level118. Long et al. compared the location of non-methylated CpG islands (CGIs) in 
seven vertebrates and suggested that non-methylated regions are a conserved feature of 
vertebrate gene promoters113. In addition to DNA methylation, studies have associated the 
changes in other epigenetic marks between species with inter-species differential gene 
expression. One study examined the histone modification H3K4me3 in prefrontal cortex of 
human, chimpanzee, and macaque, and identified many sequences with human-specific 
enrichment or depletion254. Cain et al. investigated the contribution of H3K4me3 to regulatory 
differences between species and found strong evidence for conservation of H3K4me3 
localization in the species examined. They estimated as much as 7% of inter-species gene 
expression differences could be explained by changes in H3K4me3255. By comparing H3K27ac 
and H3K4me1 in livers across 20 mammalian species, Villar et al. demonstrated enhancer and 
slow promoter evolution119. Similarly, other assays that investigate differential chromatin states 
including Deoxyribonuclease I (DNase I) hypersensitive sites (DHSs), RNA polymerase II, and 
H3K4me1 have been found to be associated with gene expression among species256,257. Recently, 
Prescott et al. compared epigenomic profiles of human and chimp induced pluripotent cell-
derived cranial neural crest cells and revealed links between cis-regulatory divergence and 
quantitative expression differences of crucial neural crest regulators258. Together, these studies 
established the importance of epigenome conservation, and revealed that the relationship 
between genome conservation and epigenome conservation is not linear.  
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 In this study, we address outstanding questions in comparative epigenomics: to what 
degree are tissue-specific epigenetic patterns conserved, and to what degree does an underlying 
genomic sequence account for a conserved epigenomic pattern? We focused our study on 
genome-wide DNA methylation. DNA methylation is a key epigenetic mechanism and plays 
critical roles in diverse biological processes such as X chromosome inactivation, repression of 
transposable elements (TEs), genomic imprinting, and tissue-specific gene expression71,259. 
Disruption of normal DNA methylation is implicated in many diseases including cancer260. More 
recently, several studies have revealed that DNA methylation not only regulates promoters and 
CGIs, but plays a much larger role in regulation of tissue-specific expression130,133,261. However, 
the conservation of tissue and cell type-specific DNA methylation patterns across species has not 
been thoroughly assessed. This leaves a significant gap between our knowledge of genome 
evolution and epigenome evolution.  
 In our study, we compared DNA methylomes of multiple tissues (blood, brain, and 
sperm) from multiple species (human, mouse, and rat). We identified tissue-specific 
differentially methylated regions (tsDMRs) and compared their DNA methylation status as well 
as sequence conservation across species. We found that a significant proportion of tissue-specific 
DNA methylation is conserved. Conserved DNA methylation is associated with conservation of 
other epigenetic marks including histone modifications and conservation of primary genomic 
sequences. We found that the evolutionary dynamics of tissue-specific DNA methylation are best 
explained by maintenance or turnover of binding sites for important transcription factors (TFs). 
Our study extends the limited literature of Comparative Epigenomics and suggests a new 
paradigm for epigenetic conservation without genetic conservation through analysis of 




4.3.1 Up to 37% of rat tissue-specific differentially methylated regions are 
epigenetically conserved in mouse and human  
We first produced DNA methylomes from three rat tissues (whole blood, whole brain, 
and sperm) using two complementary, sequencing-based technologies (Methylated DNA 
immunoprecipitation followed by sequencing (MeDIP-seq)) and methyl-sensitive restriction 
enzyme digestion followed by sequencing (MRE-seq))252,262. MRE signal is indicative of CpGs 
that are not methylated while MeDIP-seq indicates a methylated state for CpGs contained within 
the reads. Using computational tools these two data types can be integrated to call DMRs 130 and 
read out a methylation state for each CpG genome-wide263. For a complete description of data, 
please refer to Supplementary Table 1. As expected, the global distributions of CpG 
methylation across these three rat tissues overlap each other and reproduce the bimodal 
distribution seen in all vertebrates to date (Supplementary Figure 1). Previously published 
work supports global hypomethylation of sperm within the primate lineage264. However, our rat 
sperm methylation dataset better recapitulates global CpG DNA methylation levels seen in 
mouse sperm samples265,266. Rat and mouse brain global CpG DNA methylation averages are 
similar to those previously published for human and mouse1,92. Lastly, previous work has 
assayed many cells in the blood lineage in both human1 and mouse267 and we find the global 
average CpG DNA methylation levels of our mouse and rat blood samples to be in line with 
these averages. Using these data and recently developed computational algorithms130,263 
(Methods), we defined tsDMRs for the three rat tissues. Previous research has indicated that the 
majority of tsDMRs are hypomethylated rather than hypermethylated in their respective 
tissues130, so we focused our analysis on hypomethylated tsDMRs. In brief, tsDMRs were 
defined as 500bp-sized genomic regions hypomethylated in one tissue, but hypermethylated in 
83 
 
the other two tissues. In total we identified 5,506 rat tsDMRs for blood, 6,861 for brain, and 
40,971 for sperm (Figure 1A). Consistent with previous genome-wide DNA methylation 
profiling of other species130, 91%-94% of tsDMRs were located in introns or intergenic regions 
(Supplementary Figure 2). Interestingly, even though global CpG methylation levels were 
comparable across the three rat tissues (Supplementary Figure 1A), there were considerably 
more tsDMRs in sperm, suggesting widespread local hypomethylation of the sperm methylome 
as compared to blood and brain methylomes. A higher proportion of sperm rat tsDMRs were in 
TEs when compared to blood and brain tsDMRs: 20% of sperm tsDMRs overlapped with TEs 
compared to 10% in blood and 5% in brain (Supplementary Table 2), including several TE 
subfamilies that were significantly enriched for hypomethylated DNA (Supplementary Table 3; 
Supplementary Figure 3). This result is consistent with a previous study showing repetitive 
elements in human sperm are frequently hypomethylated264.  
 We next identified orthologous regions of rat tsDMRs in the genomes of mouse and 
human based on the pairwise chain files provided by the UCSC Genome Browser268,269 
(Methods). For all subsequent analysis, only tsDMRs with orthologous regions are considered. 
Interestingly, rat tsDMRs were more likely to have orthologous counterparts in the mouse and 
human genomes than expected by chance (Figure 1A). Note that we included both a genome-
wide control and a control that matches the genomic distribution of tsDMRs within each tissue 
(Methods)(Figure 1A and Supplementary Figure 3). Overall, 88% of rat tsDMRs were mapped 
to orthologous sequences in the mouse genome and 57% were mapped to orthologous sequences 
in the human genome, whereas the random expectations were 64% and 34% for mouse and 
human, respectively. The difference was statistically significant (Figure 1A). Our strategy also 
allowed us to define regions that were orthologous in rat, mouse, and human (three-way 
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orthologous regions) (Methods). We found 24,592 (46%) rat tsDMRs that were in three-way 
orthologous regions when 25% were expected by chance (and Supplementary Table 4). To 
avoid potential bias from DMRs within genic regions (exons and introns), we repeated this 
analysis using only tsDMRs within intergenic regions, and the results were similar 
(Supplementary Table 4). These data suggest that the epigenetic differences between tissues are 
more likely to be encoded by genomic sequences retained over evolutionary time than in species-
specific sequences. 
Having identified orthologous regions of rat tsDMRs in the genomes of mouse and 
human, we wanted to examine DNA methylation patterns of these regions in each respective 
species and in their matching tissue types. Thus, we generated and collected published DNA 
methylomes of samples with matching tissue types for mouse and human (Supplementary 
Table 1). As expected, rat tsDMRs exhibited strong hypomethylation in their respective tissue 
types (Figure 1B, left column). Their orthologous regions in mouse and human also exhibited a 
tissue-specific pattern—they enriched for hypomethylation in tissues in which their rat 
counterparts were hypomethylated, but not in tissues in which their rat counterparts were 
hypermethylated (Figure 1B, middle and right columns). However, the majority of the 
orthologous regions of rat tsDMRs in the other two species remain hypermethylated (Figure 
1B). Consequently, this data allowed us to estimate how often a rat tsDMR was epigenetically 
conserved (EC) in mouse, human, or both (Methods). We found that at least 27% (blood), 37% 
(brain), and 27% (sperm) of rat tsDMRs were EC in mouse, and at least 11% (blood), 13% 
(brain), and 11% (sperm) of rat tsDMRs were EC in human (Table 1). Among these, at least 6% 
(blood), 6% (brain), and 5% (sperm) of rat tsDMRs were EC across all three species. These 
results were all statistically significant (Table 1). 
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4.3.2 Epigenetically conserved tsDMRs exhibit distinct genomic and 
epigenomic features as compared to epigenetically non-conserved tsDMRs 
Having categorized rat tsDMRs with orthologous regions based on their conserved 
epigenetic pattern in mouse and human (EC vs. epigenetically non-conserved (ENC)), we 
investigated genomic and epigenomic features of each tsDMR category. First, we calculated the 
distance between each rat tsDMR and the nearest gene transcription start site (TSS) to create a 
distribution for each tissue and species. When we compared rat and mouse, we found that EC 
tsDMRs of blood and sperm, but not those of brain, were enriched in regions near TSSs over the 
randomly selected genomic feature-matched background (Figure 2A). In contrast, we found a 
depletion of ENC tsDMRs near the TSS compared to the genome feature-matched background. 
Instead, ENC tsDMRs showed enrichment 2-5Kb from the TSS for blood and brain and at all 
other distances further from the TSS (other than >100 Kb) for all three tissues (Figure 2A). A 
similar pattern was observed for the rat and human comparison (Supplementary Figure 5A). 
Direct comparison of distance from the TSS to either EC or ENC tsDMRs was performed and in 
all, except the rat-mouse EC to ENC comparison, rat regions that were EC were closer to TSSs 
than their ENC counterparts (Supplementary Table 5). These results were further confirmed by 
an analysis of tsDMRs’ association with different genomic features (including promoters, exons, 
introns, intergenic regions, and CGIs) (Figure 2B and Supplementary Figure 5B). The EC 
mouse and human orthologous regions also showed increased proximity to known TSSs. No 
such enrichment was found in the ENC group (Supplementary Figure 6). Both, EC and ENC 
tsDMRs were more enriched for non-CGI promoters than CGI containing promoters, but the fold 
enrichment of EC tsDMRs over the background for non-CGI promoters was significantly higher 
than that of ENC tsDMRs (Supplementary Figure 7). Since genes associated with non-CGI 
promoters tend to have more tissue- or developmental stage-restricted expression patterns270, our 
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result is consistent with the expectation that the epigenetic patterning in these genes would be 
shared in a tissue-specific manner across evolutionary time. 
 We next asked if EC tsDMRs and ENC tsDMRs have different chromatin signatures. To 
this end, we collected published histone modification profiles (H3K4me1, H3K4me3, H3K27ac, 
and H3K27me3) for comparable mouse and human tissues (Supplementary Table 1) and 
computed the fractions of tsDMRs that overlap with each histone modification mark (Table 2). 
We found a striking difference between EC and non-conserved tsDMRs when analyzed in the 
context of histone marks that indicate transcriptional activity (Table 2).  
The EC tsDMRs exhibited much higher enrichment of transcriptionally active histone 
marks (H3K4me1, H3K4me3, and H3K27ac) in their respective tissue as compared to the ENC 
tsDMRs. To illustrate this, we plotted the average histone modification signals over rat tsDMRs 
in orthologous regions in the mouse genome (Figure 2C) and in the human genome 
(Supplementary Figure 8). For example, in mouse blood, EC blood tsDMRs showed 
enrichment, for both enhancer (H3K4me1 and H3K27ac) and promoter (H3K4me3) marks, with 
stronger enrichment for enhancers. In contrast, in mouse brain, EC brain tsDMRs were enriched 
mainly for active enhancers (i.e. H3K27ac). EC sperm tsDMRs also showed relative enrichment 
for both enhancer and promoter histone marks in mouse sperm.  
 The ENC tsDMRs did not enrich for any of the active histone marks. In addition, no 
enrichment was observed for the repressive mark H3K27me3 in either EC tsDMRs or ENC 
tsDMRs (Figure 2C). Examination of human histone modification data for the blood and brain 
revealed a somewhat similar pattern (Supplementary Figures. 8). This pattern was further 
confirmed by examining the chromatin state annotation of the human orthologous regions of the 
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rat tsDMRs, using chromHMM271. Using chromatin states defined by the nine ENCODE cell 
lines272, we found that human orthologous regions of rat tsDMRs (HO-tsDMRs) were enriched 
for regulatory elements including enhancers and promoters. The enrichment was much more 
dramatic in EC regions than ENC regions (Figure 2D). Taken together, this data underscores the 
functional potential of epigenetic conservation. 
4.3.3 Epigenetic conservation is associated with genetic conservation 
To determine the driving forces that maintain epigenetic conservation, we examined the 
overall sequence conservation of rat tsDMRs. First, we asked how often tsDMRs overlap with 
genetically conserved elements defined by the UCSC phastCons nine-way vertebrate elements 
track123. Compared to feature-matched expectation, all categories of tsDMRs were highly 
enriched for conserved elements (Figure 3A). Strikingly, EC tsDMRs contained statistically 
more genetically conserved elements than ENC tsDMRs did (Figure 3B). This pattern was 
substantiated by directly comparing the rat phastCons scores of EC tsDMRs and ENC tsDMRs 
(Figure 3C) 123: EC tsDMRs exhibited higher sequence conservation than ENC tsDMRs (Figure 
3C). Concerned that genomic sequences associated with genes might be conserved for other 
reasons (i.e. coding potential), we repeated this analysis using only tsDMRs within intergenic 
regions and the results were similar (Supplementary Figure 9). Thus far, our analysis revealed 
that epigenetic conservation is strongly associated with genetic conservation, but that genetic 
conservation does not account for all epigenetic conservation.  
 To further elucidate the relationship between genetic conservation and epigenetic 
conservation, we ranked tsDMRs based on their average phyloP scores122 and partitioned them 
into groups of 100 (Methods). phyloP scores can be interpreted as probability of selection and 
conservation, where positive values represent conservation and negative values mean fast-
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evolving, thus allowing for detection of sites under negative or positive selection. For any given 
phyloP score range, we asked if tsDMRs were more or less likely to be EC (Figure 3D). This 
analysis confirmed that genetically conserved tsDMRs, i.e., those whose DNA sequences were 
under negative selection, were more likely to be EC. Interestingly, tsDMRs under positive 
selection had a slightly increased likelihood of being EC when compared to those with neutrally 
evolving sequences.  
4.3.4 Epigenetic conservation can be explained by conservation of TF binding 
sites 
Our analyses thus far have suggested that primary sequence conservation is strongly 
associated with epigenetic conservation. However, the association is far from linear as there are 
many regions with discordant genetic and epigenetic conservation, i.e., genetically conserved but 
ENC tsDMRs, or genetically non-conserved but EC tsDMRs. Previous studies suggested that 
tissue-specific DMRs are regulatory elements that are enriched for TF binding motifs158,273. 
Thus, tissue-specific DNA binding factors could be another force that drives epigenetic 
conservation. To understand how the evolution of TFBSs might have regulated tissue 
specification via regulating DNA methylation, we investigated the association between tissue-
specific TFBSs and epigenetic conservation of tsDMRs.  
 We first asked if tsDMRs were enriched for tissue-specific TF binding motifs over the 
GC% content match background sequences that were randomly selected by the motif discovery 
algorithm. Using HOMER206, we identified the most significantly over-represented motifs within 
rat blood, brain, and sperm tsDMRs (Methods). Indeed, many of the identified motifs were 
associated with TFs relevant to the specific tissues (Figure 4A). For example, the most enriched 
sequence motifs in blood tsDMRs were those of the ETS TF family, which are master regulators 
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of hematopoiesis274 and involved in the pathology of diseases of the blood275. Specific factors 
include PU.1, which activates gene expression during myeloid and B-lymphoid cell 
development276,277 and Erg, which is required for platelet adhesion and regulation of 
hematopoiesis278. Similarly, in brain tsDMRs, motifs of TFs important for neuronal functions 
were highly enriched. Among these, Lhx3 is required for pituitary development and motor 
neuron specification279,280 and NF1 is essential in specifying brain-specific gene expression281. 
The pattern in sperm was not as strong as those in blood and brain, presumably due to the 
relative lack of annotated sperm-specific TF binding motifs.  
We next assessed if these TF motifs were also enriched in the orthologous sequences of 
tsDMRs in mouse and human. Overall, we observed that the same sequence motifs were 
enriched in the orthologous sequences of respective rat tsDMRs in both mouse and human, but to 
a lesser degree than in the rat tsDMRs (Figure 4A). Interestingly, when we compared the 
enrichment of the same set of motifs over the Homer selected background in orthologous 
sequences that were EC versus those that were ENC, we found high enrichment levels in the EC 
orthologous sequences, but low enrichment levels in the ENC orthologous sequences (Figure 
4B). Taken together, these data suggest that TF binding motifs are strongly correlated with 
epigenetic conservation282. 
4.3.5 Evolutionary dynamics of tsDMRs 
Our epigenomic data spans three common tissue types across three mammalian species. 
This data not only allows us to identify EC tsDMRs, but also gives us an opportunity to 
investigate the evolutionary dynamics of some of these tsDMRs. We focused our analysis on rat 
tsDMRs for which we can identify three-way orthologous regions in mouse and human 
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(Methods) and examined the epigenomic configuration of these regions in the context of the 
three species. 
 Overall, we identified 24,592 rat tsDMRs that shared three-way orthology with mouse 
and human. Of these, 2,796 were EC across all three species (Group 1, blood: 309 out of 2,859; 
brain: 402 out of 4,746; sperm: 2,085 out of 16,987). 6,205 were EC between rat and mouse, but 
not human (Group 2, blood: 611; brain: 1,551; sperm: 4,043), and 2,114 were EC between rat 
and human, but not mouse (Group 3, blood: 235; brain: 360; sperm: 1,519). The remaining 
11,972 tsDMRs were rat-specific and not EC in either mouse or human (Group 4) (Table 3). 
We compared the genomic distribution, sequence conservation, histone modification, and 
TFBS enrichment across these four groups of tsDMRs (Supplementary Figures 10-13). The 
results recapitulated the patterns we observed from the pairwise comparisons. In general, when 
compared to ENC tsDMRs, EC tsDMRs were closer to TSSs, were more enriched for active 
histone marks, contained more conserved sequences, and were more enriched for binding motifs 
of relevant TFs (Supplementary Figures 10-13).  
 These comparisons allowed us to examine patterns of evolutionary change within 
tsDMRs (Figure 5). Of the 2,796 EC tsDMRs across the three species, 1,661 were also 
genetically conserved as defined by PhastCons conserved elements (Methods). One such 
example was a brain specific hypomethylated DMR located in the fourth intron of Sez6 in the rat 
genome (chr10: 64007000-64007500). Sez6 is a brain-specific gene that encodes a protein 
related to seizures283. The orthologous regions of this tsDMR in mouse and human 
(Supplementary Table 6) were EC in each species, exhibiting hypomethylation in brain, and 
hypermethylation in blood and sperm. This brain tsDMR was located 35kb downstream of the 
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TSS in rat and mouse, and 38kb in human, and contained four predicted Lhx3 motifs in all three 
species. Motif sequence alignment suggested that the core motif, CTAATTAATT, was indeed 
conserved across the species. Thus, this analysis put Lhx3, a TF essential in brain function280, 
upstream of Sez6. Studies using mouse primary neurons associated Sez6 with pentylenetetrazol-
induced bursting activity, an attribute of neurons undergoing epileptic discharges283,284 Sez6 
mutation is also associated with febrile seizures in children285. These data are consistent with the 
hypothesis that brain tsDMRs that are epigenetically and genetically conserved should be 
functionally important in the tissue of interest (Figure 5A; Supplementary Table 6).  
 There were 1,135 tsDMRs that were EC, but genetically not conserved. Our genomic 
analysis suggested that conservation of TF binding could be a driving force of this phenomenon. 
Taking the Erg gene as an example, we identified an EC, blood-specific hypomethylated DMR 
3kb downstream of Erg gene’s TSS (Supplementary Table 6). Sequences of this tsDMR were 
not conserved across the three species, as indicated by the lack of high phyloP scores and lack of 
conserved elements (phastCons). Erg is an important regulator of differentiation for early 
hematopoietic cells286. Interestingly, we found that in all three species, there was an Erg motif 
within the EC tsDMR. However, the position of this motif shifted between rodents and human. A 
close examination of the primary sequence alignment revealed that rat and mouse shared a 
conserved Erg motif (consensus: ACAGGAAGTG), but in human, an AàG mismatch within 
the orthologous region of the rat motif sequence destroyed the Erg binding motif. Surprisingly, 
the human tsDMR had an Erg motif 84bp upstream from the rodent motif (Figure 5B 
Supplementary Table 6). This new binding site suggests an evolutionary event of TFBS 
turnover. Many studies have suggested that binding site turnover is a common, wide-spread 
phenomenon of gene regulatory network evolution287–289. We hypothesize that binding site 
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turnover potentially helped maintain the conserved epigenetic pattern, despite the lack of primary 
sequence conservation. 
 Of the 6,205 tsDMRs that were EC in rat and mouse, but not human, 2,915 were 
genetically conserved. Similarly, of the 2,114 tsDMRs that were EC in rat and human, but not 
mouse, 864 were genetically conserved. We sought to explain some of these phenomena.  
 We identified chr10:85389000-85389500 as a rat blood EC tsDMR in mouse. This region 
was in the intron of the Skap1 gene, which encodes a T-cell adaptor protein that regulates T-cell 
receptor signaling290. However, the human orthologous region was consistently highly 
methylated across the three tissues. The rodent tsDMR contained a conserved Fli1 motif, but the 
human orthologous region of the motif had a GàA mismatch, which destroyed the motif. By 
including the orthologous dog sequence as an outgroup, we found that the Fli1 motif is possibly 
gained (by substitution AàG) within the rodent branch, suggesting that this tsDMR represents a 
rodent-specific event likely driven by the Fli1 motif (Figure 5C; Supplementary Table 6).  
 We also identified chr1:213289000-213289500 as a rat blood tsDMR. This region is 
40kb downstream of the TSS of the Cd6 gene291. The human orthologous region was also a 
blood tsDMR, but the mouse orthologous region was consistently hypermethylated in all three 
tissues. Congruent with this pattern, we found a Fli1 motif in both rat and human orthologous 
tsDMRs, but not in the mouse orthologous region. The mouse and human sequence elements that 
aligned to the rat Fli1 motif (TCAGGAAGCC) both had the same substitution that disrupted the 
motif. The most parsimonious explanation was that the motif was a rat-specific gain. 357bp away 
from this site, but still within the human tsDMR, there was a Fli1 motif. Neither the sequences in 
the orthologous region in rat or mouse matched the Fli1 motif consensus sequence. Thus, the 
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epigenetic dynamics of this tsDMR did not correlate with sequence conservation, but rather they 
were correlated with a species-specific TFBS (Figure 5D; Supplementary Table 6).  
 Some of these ENC tsDMRs were associated with not only TFBS turnover, but also 
possibly tsDMR turnover. An interesting example was the blood tsDMR (rat, chr16:48707500-
48708000) in the intron of the Irf2 gene. Irf2 encodes interferon regulatory factor 2, a member of 
the interferon regulatory TF (IRF) family. The IRF family plays an important role in the immune 
system292. The orthologous region in mouse was also identified as a blood DMR, but in human, 
the orthologous region was hypermethylated in all three tissues. Motif analysis revealed that the 
rat and mouse orthologs shared the Fli1 motif, but the human orthologous sequence contained a 
5bp insertion, disrupting the Fli1 motif. By examining the surrounding regions in the human 
genome, we found a human blood tsDMR approximately 6kb upstream of the ENC human 
orthologous region of the rat tsDMR. This human tsDMR contained two predicted Fli1 motifs. 
Interestingly, the orthologous region of this human blood tsDMR in rat and mouse were not 
blood tsDMRs and did not have the Fli1 motif (Figure 5E; Supplementary Table 6). It is 
possible that the human tsDMR and rodent tsDMR are functionally equivalent. This example is 
suggestive of a tsDMR turnover event that was correlated with a TFBS turnover event. 
4.4 Discussion and Conclusions 
 Dynamic changes of DNA methylation play a key role in development and differentiation 
by defining tissue and cell type-specific epigenomes293. Although the mechanism of DNA 
methylation mediated epigenetic regulation is conserved across vertebrates109, the genome-wide 
conservation pattern of tissue-specific DNA methylation has not been thoroughly investigated. 
The genetic mechanism underlying epigenetic conservation is poorly understood.  
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 Our study extends the limited literature of Comparative Epigenomics113 and suggests a 
new paradigm for epigenetic conservation without genetic conservation through analysis of 
transcription factor binding sites. Previous comparative epigenomics studies investigated 
conserved epigenetic modifications of one tissue or cell type across species120. We expanded 
upon this framework and defined epigenetic conservation as conserved tissue-specific DNA 
methylation. Thus, our study is a cross-species comparison of the differences among epigenomes 
representing different tissue types.  
 By focusing on the dynamics of the DNA methylomes, we added strength to the notion 
that specific elements are important for specific tissue types. Consistent with recent 
discoveries130,273, these tissue-specific regulatory elements were often themselves tsDMRs. 
Compared to random genomic sequences, these tsDMRs were more likely to have orthologous 
counterparts in the three species we studied, indicating the importance of retaining these 
sequences. Analyses of the conservation pattern of these tsDMRs revealed several important 
principles. 
 First, tsDMRs were more likely to be EC than expected by chance. This was perhaps not 
too surprising, because tissue-specific gene expression is known to be conserved between species 
294. However, to our knowledge, this is the first study to define and quantify such epigenetic 
conservation. For example, we found that at a minimum between 11% and 37% of rat tsDMRs 
were EC in human or mouse depending on the tissue of interest. EC tsDMRs also exhibited 
conserved histone modifications, consistently supporting the regulatory roles of these tsDMRs. 
Perhaps most surprising was the result that the majority of tsDMRs were not EC. This is 
consistent with the idea that regulatory regions undergo rapid turnover, but could be confounded 
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by differing cell type frequencies and developmental time points across the samples used in this 
analysis. 
 Compared to ENC tsDMRs, EC tsDMRs were more likely to also be genetically 
conserved. This result suggests that sequence conservation was likely a primary driver of 
epigenetic conservation. Fast evolving sequences were also more likely to be EC. Sequence 
analysis discovered that EC tsDMRs were strongly enriched for binding motifs of TFs relevant to 
that tissue type, more so than tsDMRs that were not EC. This result suggests that TFBS played 
crucial roles in determining epigenetic conservation, consistent with the discovery that sequence-
specific DNA binding factors shape the landscape of DNA methylomes158,273 as well as DHSs295.  
 Importantly, TFBS turnover seemed to be associated with evolutionary dynamics of 
epigenetic conservation. Some tsDMRs were EC, but not genetically conserved. These tsDMRs 
often contained a binding site of a relevant TF, although the binding sites themselves did not 
align at orthologous positions between species. However, the presence of the binding site was 
indeed a conserved genetic event. In contrast, some tsDMRs were genetically conserved, but 
were not EC. Close examination of the primary sequence alignments revealed interesting 
examples in which genetic changes, that did not interrupt the overall conservation level, 
destroyed a binding site for a relevant TF. This hypothesis is consistent with a recent study 
showing that turnover of TF recognition elements was associated with the repurposing of DHSs 
295. 
 Our study has several limitations. Analysis of TFBS turnover is limited by two factors: 
first, all TFBSs are based on motif prediction; second, our knowledge on binding specificity of 
many TFs is quite incomplete. These inhibit us from addressing causality, i.e., whether 
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epigenetic conservation is indeed ‘determined’ by TF motif conservation or if it is just incidental 
to these factors, in this study. We expect future experiments will eventually establish causality. 
Mapping of orthologous tsDMRs was performed with a liftover requirement of 50% non-
reciprocal overlap, which could mask small regions of high conservation within larger DMR 
blocks. For this reason and others below, we believe all percentages presented throughout the 
paper represent an underestimation of the true epigenetic conservation of tsDMRs across the 
species studied. Additionally, a short highly conserved element may lie within a tsDMR and thus 
our annotation of genetically conserved tsDMRs may also be an underestimate. Although MRE-
seq is insensitive to non-CG methylation, MeDIP-seq is sensitive to this type of methylation. 
Since up to 25% of neuronal methylation may be in a non-CG context296, the proportion of non-
CG methylation could contribute to the genomic distribution of our brain DMRs and can not be 
directly accounted for in this analysis. The tissue samples were heterogeneous in cell type 
composition and our brain samples are not exactly matched for developmental stage. Thus, our 
analysis could not distinguish differences at tissue level from differences due to different cell 
type compositions or developmental stage. We believe these limitations could deflate the number 
of EC tsDMRs observed and inflate the number of ENC tsDMRs. However, by including three 
tissue types we were able to characterize differences in epigenetic conservation between tissues, 
which have previously been shown to be greater than differences between cell-types comprising 
any tissue130. For example, the genomic distribution of brain tsDMRs is different from that of 
blood and sperm. While for both blood and sperm we observed that tsDMRs tend to enrich for 
being closer to TSS of known genes, for brain we did not observe this pattern. Our histone 
modification analysis suggested that blood and sperm tsDMRs are enriched for both active 
enhancers and promoters, while brain is more enriched for active enhancer marks. Furthermore, 
97 
 
brain tsDMRs show more intermediate methylation in brain, while the tsDMRs in the other two 
tissues show low methylation in their respective tissue types. All of these data are in agreement 
with the hypothesis that the tissue specificity of the brain is mainly determined by enhancer 
activity. This is consistent with previous reports297 that brain specific DMRs are enriched for 
enhancers and depleted for CGIs and CGI-promoters. Our conclusions regarding genome-wide 
brain specific DNA methylation should not be greatly influenced by including different cell 
types from the brain. However, in our future studies, we expect to assess epigenetic conservation 
of specific cell types across species. Lastly, our study defined tsDMRs as regions of low 
methylation, since hypomethylation has previously been associated with tissue-specific gene 
ontology functions and accessible chromatin39,130,158. However, within this framework 
hypermethylated regions that could signify regulatory regions deactivated in a tissue-specific 
manner are not accounted for in this analysis. Additionally, it is well know that certain 
transcription factors interact with methylated CpGs298 with more recent studies examining this 
interaction for factors without a methyl-CpG binding domain299, thus hypermethylated regions 
could also signify regions with tissue-specific transcription factor interactions. Taken together, 
our study established that tissue-specific DNA methylation was conserved across species, and 
this epigenetic conservation was largely driven by genetic sequence conservation, including 
conserved TFBS. Our work provides a new paradigm for comparative epigenomics studies. We 
envision that future studies will include DNA methylomes from additional cell/tissue types and 
species, allowing us to better model epigenome evolution in the context of genome evolution. 
Such an understanding will contribute theories of how cellular differentiation evolved and how 
the epigenome contributes to cellular phenotype and identity. 
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DNA methylation underlies cell type-specificity through its regulation of gene 
expression. Although it is known that the overall pattern of genome-wide DNA methylation is 
conserved across many species, little is known about the genetic underpinnings of this epigenetic 
conservation. Here we compare genome-wide DNA methylomes of three tissues across three 
species. We find that orthologous regions of genomic regions with tissue-specific 
hypomethylation are much more likely to share this pattern than expected by chance and term 
this “epigenetic conservation”. Regions with epigenetic conservation are strongly associated with 
gene regulatory elements and active chromatin modifications. While primary sequence 
conservation underlies epigenetic conservation, maintenance and turnover of transcription factor 
binding sites is likely the driving force behind tissue-specific DNA methylation. 
4.5 Methods 
4.5.1 Animals 
 All experiments were approved by the Institutional Animal Care and Use Committee of 
Washington University in St. Louis and conducted in accordance with the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. For each of the three tissues, 
pooled samples from fifteen adult rats (60 days old) were obtained. 
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Sprague Dawley outbred rats (originally obtained from Harlan Sprague Dawley Inc., 
Indianapolis, Indiana, USA (now Envigo)) were used for this study. Animals were bred in the 
Animal Facilities at the Division of Comparative Medicine, Washington University School of 
Medicine. All experiments were approved by the Institutional Animal Care and Use Committee 
of the Washington University in St. Louis and conducted in accordance with the National 
Institutes of Health Guidelines for the Care and Use of Laboratory Animals.  
4.5.2 Processing MeDIP-seq and MRE-seq data 
 H3K4me1, H3K4me3, H3K27ac and H3K27me3 ChIP-seq data for relevant tissue types 
were downloaded from the Gene Expression Omnibus (GEO) database300. Mapped read density 
was generated from aligned sequencing reads using in-house Perl scripts. Read density 
overlapping tsDMRs and the extensions to their upstream/downstream regions were extracted at 
50-bp resolution as Reads Per Kilobase of transcript per Million mapped reads (RPKM) values. 
4.5.3 Processing histone modification data 
 All experiments were approved by the Institutional Animal Care and Use Committee of 
Washington University in St. Louis and conducted in accordance with the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals. For each of the three tissues, 
pooled samples from fifteen adult rats (60 days old) were obtained. 
4.5.4 Processing whole-genome bisulfite sequencing data  
 Whole-genome bisulfite sequencing (WGBS) data for mouse and human sperm were 
downloaded from the GEO database (Mouse sperm accession number: GSE49623; Human 
sperm accession number: GSE30340). Downloaded human WGBS data was in hg18, thus we 
converted the aligned data to hg19 coordinates using the UCSC Liftover package121. If the new 
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coordinates in the hg19 assembly overlapped with hg19 CpG sites, they were retained for 
downstream analysis. 
4.5.5 Defining tissue-specific hypomethylated DMRs 
 The M&M package130 was used to identify DMRs between tissue types. All DMRs are 
based on a default genomic window size of 500bp, which has been previously used in many 
studies130,133,261. The selection of DMRs for downstream analysis was based on the following 
criteria: 1) DMR q-values were <1e-5 and 2) for each tissue type, only hypomethylated DMRs 
(as defined below) in that tissue were retained. 
 MethylCRF263 scores predicted by the methylCRF algorithm served as another layer of 
filtering criteria. Scores were first averaged over all CpGs within a M&M DMR and M&M 
DMRs that meet either the following criteria were retained for the downstream analysis: (1) the 
methylCRF score in the tissue type in which the M&M DMR was identified as hypomethylated 
should be < 0.3, and the methylCRF score in the other two tissue types should be both ≥ 0.3; or 
(2) the methylCRF score in the tissue type in which the M&M DMR was identified as 
hypomethylated is ≥ 0.3 and ≤ 0.7 (intermediately methylated), and the methylCRF in the other 
two tissue types are both > 0.7 (hypermethylated). 
4.5.6 Obtaining genomic distribution-matched control set 
 The rat (rn4) genome was divided into 500bp non-overlapping windows, and for each 
window, genomic feature association was obtained. Similarly, the genomic feature associations 
of tsDMRs were obtained. For each set of tsDMRs associated with a certain genomic feature, the 
same number of rat 500bp windows was selected from a random genomic feature matched set. 
Each rat tsDMR or 500bp region is defined as being associated with a genomic feature 
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(promoter, exon, 3’utr, 5’utr, CGI, etc.) only if more than 50% of the nucleotides in the 
tsDMR/500bp region overlapped with that genomic feature. 
4.5.7 Mapping orthologous regions 
 The rat (rn4) genome was divided into approximately 5 million 500bp non-overlapping 
regions, and rat tsDMRs were identified. The orthologous regions of rat tsDMRs in mouse 
(mm9) and human (hg19) genomes were identified using UCSC liftover chain files. We required 
at least 50% non-reciprocal overlap of the original sequence in rat to the species (mouse or 
human) of interest with an upper bound of 1000bp for the orthologous region. 
4.5.8 Defining three-way orthologous regions 
 First, mouse orthologous regions of rat tsDMRs (MO-tsDMRs) were identified (Mapping 
orthologous regions). Second, HO-tsDMRs were determined utilizing the same pipeline. Third, 
human orthologous regions of MO-tsDMRs (HO of MO-tsDMRs) were determined utilizing the 
same pipeline. Fourth, HO-tsDMRs were compared to the HO of MO-tsDMRs. For a HO-
tsDMR and a HO of MO-tsDMR that corresponded to the same rat tsDMR, we required them to 
have ≥ 90% overlap. Fifth, the HO-tsDMRs that meet the description in step 4 were obtained and 
the corresponding MO-tsDMRs and rat tsDMRs are considered as 3-way orthologous regions. 
4.5.9 Defining epigenetic conservation 
 Epigenetic conservation was defined as the maintenance of a methylation pattern at 
certain loci within a certain tissue among the species that were examined. For instance, if a 
500bp region in rat was defined as a rat blood tsDMR (i.e., the region is hypomethylated in rat 
blood and methylated in rat brain and rat sperm) and if the orthologous region of this rat blood 
tsDMR in mouse and human showed the same tissue-specific methylation pattern 
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(hypomethylated in blood and hypermethylated in brain and sperm), then this rat blood tsDMR 
was defined as an EC blood tsDMR in rat, mouse, and human.  
 In mouse and human, the methylation data available for all 6 samples were 
methylCRF/WGBS, thus single CpG resolution whole-genome DNA methylation was used to 
identify tsDMRs. For orthologous regions of rat tsDMRs, only the orthologous regions with CpG 
dinucleotides were retained. For each orthologous region, average methylation was calculated as 
the sum of methylation level at individual CpGs divided by the number of CpGs in that region. 
The definition of epigenetic conservation was based on a method described in Sproul et al. 2012 
where sites were defined as methylated if their methylation level was greater than 0.7, 
unmethylated if they had average methylation values less than 0.3, and otherwise intermediately 
methylated301. We assigned a categorical value to each of the three methylation statuses: 
unmethylated=0, intermediately methylated=1, methylated=2. Based on this categorization, if an 
orthologous region had a 0 methylation status in the target tissue, and 1 or 2 in the other two 
tissues, or, if the methylation status was 1 in the target tissue, and 2 in both of the other two 
tissue types, the region was defined as EC. In all other cases, (for example an orthologous region 
with a 2 methylation status in the target tissue, and 1 or 2 in the other two tissues) the 
orthologous region is defined as ENC.   
4.5.10 Calculating the distance to the TSS 
 RefGene annotations were downloaded from the UCSC Genome Browser302,303. The 
closest TSS to a tsDMR was defined as the TSS with shortest distance to the start of the tsDMR 
irrespective of strand.  
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4.5.11 Genomic features 
 RepeatMasker annotations, CGIs, and refGene features (including 5’UTRs, exons, and 
3’UTRs) were downloaded from the UCSC Genome Browser. Promoters were defined as 2.5 kb 
around the most 5’ TSS (2kb upstream and 0.5 kb downstream from TSS) of any refGene record. 
Intergenic regions were defined as regions between neighboring refGene loci. 
4.5.12 Calculating genetic conservation at tsDMRs 
 The nine-way phastCons conserved elements file in rn4 format was downloaded from the 
UCSC Genome Browser. Using bedtools209, tsDMRs were overlapped with the conserved 
element track. Genetic conservation was defined when ≥ 20% of a tsDMR overlapped with 
elements in the nine-way track; otherwise the tsDMR was defined as genetically not conserved. 
4.5.13 Calculating epigenetic conservation enrichment 
 Forty-six-way human (hg19) vertebrate phyloP scores and 30-way mouse (mm9) 
vertebrate phyloP scores were downloaded from the UCSC Genome Browser. Since there were 
no phyloP score files for rat (rn4), we used human vertebrate phyloP scores for the rat-human 
comparison and mouse vertebrate phyloP scores for the rat-mouse comparison. Each 500bp 
window in rat was divided into ten 50bp windows, and their orthologous regions in mouse and 
human were determined. For the rat-mouse comparison, a phyloP score was computed for every 
base from 30 vertebrate genomes, and an average phyloP score was computed for each mouse 
region orthologous to the rat 50bp region. The same was done for the rat-human comparison. For 
each species pair, these genomic segments (orthologous regions of rat tsDMRs) were divided 
into 100 equal-sized sets with increasing average phyloP scores. The first set with the smallest 
phyloP scores are defined as the fastest-changing DNA sequences. The last set with the largest 
phyloP scores are the most conserved which are under purifying selection. In the rat-mouse 
comparison, a 50bp rat tsDMR was determined to be EC if the mouse orthologous region was 
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marked by the same DNA methylation pattern across the three tissue types (described in 
Defining epigenetic conservation). For each of the 100 sets, quantitative epigenetic 
conservation was calculated as the number of rat tsDMRs that were EC between rat and mouse 
divided by the total number of rat tsDMRs belonging to that set. Rat-human comparisons were 
done similarly. 
4.5.14 Motif analysis 
 For each region set of interest, we determined all known motifs that were present within 
the regions. Motif matching was performed using HOMER206. For the rat-mouse comparison, 
two motif analyses were done: one analysis was of the rat tsDMRs with mouse orthologous 
regions and the other was of the corresponding mouse orthologous sequences. The top 10 
significant motifs (based on p-value) within rat tsDMRs were obtained and were used for 
downstream motif analysis. To determine if these motifs played a role in epigenetic 
conservation, we further divided the tsDMRs/ orthologous regions into two subsets: the EC 
tsDMRs and their orthologous regions in mouse/human as well as the ENC tsDMRs and their 
orthologous regions in mouse/human. We performed HOMER analysis again on the top 10 
tissue-specific motifs and obtained their fold change enrichment over the background among 
each of the four groups of tsDMRs/ orthologous regions. In order to further determine the 
contribution of these motifs to the tsDMR conservation across species, we examined the genomic 
location of each motif occurrence. 
4.5.15 Data Availability 
All data from this study have been submitted to the NCBI Gene Expression Omnibus 
database (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE63527. 
Supplementary Tables, Table 1 lists GEO IDs for all datasets used within this study.  
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4.8 Figures & Tables 
 
 
Figure 1. Rat tissue-specific DMRs (tsDMRs) and their orthologous regions in mouse and human. (A) 
Numbers of rat tissue-specific hypomethylated tsDMRs (Methods) (middle purple panel), and percentage of rat 
tsDMRs with orthologous regions in mouse (left panel) and human (right panel) genomes, respectively. A chi-square 
test was performed to obtain p-values by comparing tsDMRs with genomic annotation matched random control 
regions in each respective tissue type. P-values were corrected for multiple testing using the Benjamini–Hochberg 
FDR method. (B) Genome-wide methylation profile of rat tsDMRs and orthologous regions in mouse and human. 
The left column shows the methylation profiles of rat tsDMRs in each of the three rat tissue types; the middle 
column shows the methylation profiles of mouse orthologous regions of rat tsDMRs in each of the mouse tissue 
types; and the right column shows the methylation profile of human orthologous regions of rat tsDMRs in each of 




Figure 2. Epigenetically conserved rat tsDMRs and epigenetically non-conserved rat tsDMRs show distinct 
patterns. (A) Distribution of the distance between rat tsDMRs that are Epigenetically Conserved (EC) in mouse (top 
panel) and Epigenetically non-conserved (ENC) in mouse (bottom panel) to the nearest TSS. The horizontal dashed 
black line denotes no enrichment over the background. The background was a set of genomic distribution-matched 
rat regions. The y-axis represents the fold enrichment of orthologous rat tsDMRs over the background. A chi-square 
test was performed to generate the p-values. P-values were corrected for multiple testing using Benjamini–Hochberg 
FDR method. (B) Genomic distribution of rat tsDMRs that are EC in mouse (top panel) and ENC in mouse (bottom 
panel). The background regions were chosen as described in (A). A chi-square test was performed to generate the p-
values. P-values were corrected for multiple testing using the Benjamini–Hochberg FDR method. (C) Average 
histone modification signal density at 50bp resolution over a 10-kb window centered on mouse orthologous regions 
of rat tsDMRs that are EC (left column) and ENC (right column) in mouse blood (top row), mouse brain (middle 
row), and mouse sperm (bottom row). (D) ChromHMM regulatory function annotation of human orthologous 
regions of rat blood tsDMRs (top left panel), rat brain tsDMRs (top right panel), EC and non-conserved rat blood 
tsDMRs (bottom left panel), and EC and non-conserved rat brain tsDMRs (bottom right panel). In all panels, the 
annotation of the human orthologous regions for randomly chosen rat regions was included. The background regions 




Figure 3. Epigenetically conserved tsDMRs and epigenetically non-conserved tsDMRs show distinct genetic 
conservation. (A) Percentage of rat tsDMRs that are genetically conserved. A pre-defined list of rat-conserved 
elements was determined using the Hidden Markov model from the UCSC Genome Browser. A rat tsDMR was 
defined as “genetically conserved” if at least 20% of the rat tsDMR region overlapped with genetically conserved 
elements (Methods). The number of genetically conserved tsDMRs is indicated above the bars for each tissue type. 
For each tissue type, a genomic annotation matched random control set was chosen. A chi-square test was performed 
to obtain p-values. P-values were corrected for multiple testing using the Benjamini–Hochberg FDR method. (B) 
Percentage of EC rat tsDMRs mapped in mouse that overlap with genetically conserved rat elements (in red) and the 
percentage of ENC rat tsDMRs mapped in mouse that overlap with genetically conserved rat elements (in green). A 
chi-square test was performed to obtain the p-values. P-values were corrected for multiple testing using the 
Benjamini–Hochberg FDR method. (C) Distribution of phastCons scores of EC rat tsDMRs and ENC rat tsDMRs in 
mouse. A Wilcoxon test was performed to obtain p-values. P-values were corrected for multiple testing using the 
Benjamini–Hochberg FDR method. (D) Epigenetic conservation (Y-axis) and genetic conservation as defined by 




Figure 4. TF motif analysis of rat tsDMRs and their orthologous regions in mouse and human. (A) Heatmaps 
representing the enrichment of transcription factor binding motifs for brain and blood tsDMRs the orthologous 
regions of these tsDMRs. Left panel: motif enrichment for rat-mouse comparison; right panel: motif enrichment for 
rat-human comparison. (B) Motif enrichment (fold change) of the top 10 TFBSs in rat blood (top row) and rat brain 
(bottom row) (as defined by the HOMER enrichment), separated by their epigenetic conservation status (Methods). 
First two columns: rat-mouse comparison; last two columns: rat-human comparison. A t-test was performed to 




Figure. 5. Evolutionary dynamics of tsDMRs and transcription factor binding sites. WashU EpiGenome 
Browser304 views of tsDMRs in rat and the orthologous regions in mouse and human. The following tracks are 
displayed: rat: rat DNA methylation (methylCRF) for blood, brain, and sperm, phastCons conserved elements, 
TFBSs, and refSeq gene annotation; mouse: mouse DNA methylation (methylCRF/WGBS) for blood, brain, and 
sperm, 30-way vertebrate phyloP score, TFBSs, and refSeq gene annotation; and human: human DNA methylation 
(methylCRF/WGBS) for blood, brain, and sperm, 46-way vertebrate phyloP score, TFBSs, and refSeq gene 
annotation. Rat tsDMRs and their orthologous regions in mouse and human are highlighted in pink rectangles. The 
predicted TF motifs are represented by the vertical red bars. (A) Genome browser view of a rat brain DMR and its 
mouse and human orthologous regions located in the intronic region of the Sez6 gene. (B) Genome browser view of 
a rat blood DMR and its mouse and human orthologous regions located in an intronic region of the Erg gene. (C) 
Genome browser view of a rat blood DMR and its mouse and human orthologous regions located in an intronic 
region of the Skap1 gene. (D) Genome browser view of a rat blood DMR and its orthologous regions in mouse and 
human located in the downstream region of the Cd6 gene. (E) Genome browser view of a rat blood DMR and its 





Supplementary Figure 1. Genome-wide methylation distribution across the three tissue types in the three 
species. (A) Distribution of the average methylation level in 500bp non-overlapping windows in the rat genome and 
their orthologous regions in the mouse and human genome for each tissue type. Each panel indicates the methylation 
distribution of a specific tissue type (indicated to the right of the panels) in a specific species (indicated above the 
panels). The x-axis represents the methylation level (%) from 0 to 100, with 0 meaning unmethylated and 100 
meaning methylated. For mouse and human sperm samples, WGBS data was used to calculate the average 
methylation at each mouse or human orthologous regions of the rat 500bp regions since MeDIP-seq and MRE-seq 
data was not available. For the other seven samples, methylCRF was used to estimate the methylation level at single 
CpG resolution. (B) Average methylation level across different gene features. Gene features were annotated using 
the UCSC gene annotations. For every gene, each gene feature, e.g., promoters, was divided into 30 sub-regions of 
equal size and the average methylation score (WGBS for mouse and human sperm and methylCRF for the other 
seven samples) was calculated for each sub-region. The methylation scores were averaged across all genes and 






Supplementary Figure 2. Genomic distribution and locations of rat tsDMRs. (A) Distribution of the distance 
between rat tsDMRs and the nearest TSS. An annotation-matched control set was selected for each tissue based on 
the genomic distribution of the tsDMRs in each tissue type. The horizontal dashed black line denotes no enrichment 
over the background. The y-axis represents the enrichment of rat tsDMRs located within different distance range 
groups relative to the background distribution. A Chi-square test was performed to obtain p-values. P-values were 
corrected for multiple testing using the Benjamini–Hochberg FDR method. (B) Genomic distribution of rat tsDMRs. 
The y-axis represents the enrichment of rat tsDMRs associated with different genomic features relative to the 
background genomic distribution. A Chi-square test was performed to obtain p-values. P-values were corrected for 
multiple testing using the Benjamini–Hochberg FDR method. (C) Percentage of rat tsDMRs located in different 






Supplementary Figure 3. Views of TE copies in LTR subfamilies that are significantly enriched for rat sperm 
tsDMRs. Displayed tracks include methyl tracks for DNA methylation for rat blood, brain, and sperm, the 
repeatMasker track, and the chromosome track. The rat sperm tsDMRs are highlighted in pink rectangles. The 
height of the bars in the methyl tracks indicates the methylation level. (A) Genome browser views of three 
RMER3D2 subfamily copies that show sperm specific hypomethylation. (B) Genome browser views of three 






Supplementary Figure. 4. Percentage of rat regions in different genomic features. Percentage of rat tsDMRs (in 
white) vs. genomic distribution-matched control set (in black) in different genomic features in blood (top panel), 






Supplementary Figure 5. Genomic distribution of epigenetically conserved and non-conserved tsDMRs in rat 
and human. (A) Distribution of the distance between rat tsDMRs that are epigenetically conserved in human (top 
row) and epigenetically non-conserved in human (bottom row) to the nearest TSS. An annotation-matched control 
set was selected for each tissue based on the genomic distribution of the tsDMRs in each tissue type. The y-axis 
represents the fold enrichment of rat tsDMRs over the background. The horizontal dashed black line denotes no 
enrichment over the background. (B) Genomic distribution of rat tsDMRs that are epigenetically conserved in 
human (top row) and epigenetically non-conserved in human (bottom row). The background regions were chosen 
the same way as described in (A). A Chi-square test was performed to obtain p-values. P-values were corrected for 






Supplementary Figure 6. Genomic distribution of mouse and human orthologous regions of epigenetically 
conserved and non-conserved tsDMRs. (A) Distribution of the distance between mouse orthologous regions of rat 
tsDMRs that are epigenetically conserved in mouse (top row) and epigenetically non-conserved in mouse (bottom 
row) to the nearest TSS. The y-axis represents the fold enrichment of mouse orthologous regions of rat tsDMRs over 
the background. The horizontal dashed black line denotes no enrichment over the background. (B) Genomic 
distribution of mouse orthologous regions of rat tsDMRs that are epigenetically conserved in mouse (top row) and 
epigenetically non-conserved in mouse (bottom row). In panels (C) and (D), human genomic regions that were 
orthologous to the rat genome were used instead of mouse genomic regions. A Chi-square test was performed to 






Supplementary Figure 7. Genomic distribution of epigenetically conserved and non-conserved tsDMRs 
associated with promoters in rat and human. (A) Genomic distribution of rat promoter tsDMRs (CpG-promoters 
vs. non-CpG promoters) that are epigenetically conserved in mouse (top row) and epigenetically non-conserved in 
mouse (bottom row). (B) Genomic distribution of rat promoter tsDMRs (CpG-promoters vs. non-CpG promoters) 
that are epigenetically conserved in human (top row) and epigenetically non-conserved in human (bottom row). A 
Chi-square test was performed to obtain p-values. P-values were corrected for multiple testing using the Benjamini–






Supplementary Figure 8. Histone modification signatures at human orthologous regions of rat tsDMRs. 
Average histone modification signal density at 50-bp resolution over a 10-kb window centered on human 
orthologous regions of rat tsDMRs that are epigenetically conserved (left column) and epigenetically non-conserved 






Supplementary Figure 9. Epigenetically conserved and epigenetically non-conserved rat intergenic tsDMRs 
show distinct genetic conservation. (A) Percentage of rat intergenic tsDMRs that are genetically conserved. The 
number of genetically conserved intergenic tsDMRs is indicated above the bars for each tissue type. For each tissue 
type, a genomic annotation matched random control set was chosen. A Chi-square test was performed to obtain p-
values. P-values were corrected for multiple testing using the Benjamini–Hochberg FDR method. (B) Percentage of 
EC intergenic rat tsDMRs in mouse that overlap with genetically conserved rat elements (in red) and the percentage 
of ENC rat intergenic tsDMRs in mouse that overlap with genetically conserved rat elements (in green). A Chi-
square test was performed to obtain the p-values. P-values were corrected for multiple testing using the Benjamini–
Hochberg FDR method. (C) Comparison of phastCons score distributions of EC rat intergenic tsDMRs and ENC rat 
intergenic tsDMRs in mouse. A Wilcoxon test was performed to obtain p-values. P-values were corrected for 







Supplementary Figure 10. Epigenetic conservation status of tsDMRs shows distinct genomic distributions. 
The four epigenetic conservation statuses are: Group 1: rat tsDMRs that are EC across rat, mouse, and human (RMH 
EC); Group 2: rat tsDMRs that are EC in rat and mouse, but not in human (RM EC); Group 3: rat tsDMRs that are 
EC in rat and human, but not in mouse (RH EC); Group 4: rat tsDMRs that are ENC in either mouse or human 
(RMH ENC). (A) Distribution of the distance between rat tsDMRs in each of the four epigenetic conservation 
categories and the nearest TSS. The four panels from top to bottom represent the distribution of distance in Group 1, 
Group2, Group 3, and Group 4, respectively. The horizontal dashed black line denotes no enrichment over the 
background. An annotation-matched control set was selected for each tissue based on the genomic distribution of the 
tsDMRs in each tissue type. (B) Genomic distribution of rat tsDMRs in each of the four epigenetic conservation 
categories. The order of the panels is the same as (A). The background regions were chosen the same way as 
described in (A). A Chi-square test was performed to obtain p-values. P-values were corrected for multiple testing 






Supplementary Figure 11. Histone modification signatures at mouse and human orthologous regions of rat 
tsDMRs. The four epigenetic conservation groups were defined in Supplementary Figures, Figure 10. Upper 
panels: average histone modification signal density at 50-bp resolution over a 10-kb window centered on mouse 
orthologous regions of rat tsDMRs in each of the four epigenetic conservation categories (RMH EC, column 1; RM 
EC, column 2; RH EC, column 3; and RMH ENC, column 4), in mouse blood (first row), mouse brain (second row) 
and mouse sperm (third row). Lower panels: average histone modification signal density at 50-bp resolution over a 
10-kb window centered on human orthologous regions of rat tsDMRs in each of the four epigenetic conservation 
categories (RMH EC, column 1; RM EC, column 2; RH EC, column 3; and RMH ENC, column 4), in human blood 







Supplementary Figure 12. Epigenetic conservation status of tsDMRs shows distinct genetic conservation. The 
four epigenetic conservation groups were defined as described in Supplementary Figures, Figure 10. PhastCons 
score distributions of rat tsDMRs in each of the four epigenetic conservation categories. A Wilcoxon-test was 
performed to obtain p-values for the RMH-EC vs. RMH-ENC comparison. P-values were corrected for multiple 








Supplementary Figure 13. Epigenetic conservation status of tsDMRs shows distinct transcription factor 
binding. The four groups were defined in Supplementary Figures, Figure 10. (A) Heatmap representing the 
enrichment of transcription factor binding motifs for the tsDMRs identified in each tissue and for the mouse and 
human orthologous regions of these tsDMRs. Each row represents a motif, and the corresponding transcription 
factor for selected motifs are labeled on the left. (B) Motif enrichment (fold change) of the top 10 TF motifs in rat 
blood tsDMRs and the corresponding mouse and human orthologous regions (top row) and rat brain tsDMRs and the 
corresponding mouse and human orthologous regions (bottom row), for each epigenetic conservation category 





Table 1. tsDMRs by epigenetic conservation status (2-way analysis). The percentage in parenthesis is calculated 
as the number of epigenetically conserved tsDMRs divided by the number of tsDMRs for each tissue type. A 
hypergeometric test was performed to determine if the epigenetic conservation was significant. The number of 
‘observed’ epigenetically conserved tsDMRs is indicated in the ‘EC’ column. The number of ‘expected’ 
epigenetically conserved tsDMRs was determined by randomly selecting 40,000 rat regions and examining the 
number of these randomly picked regions that were epigenetically conserved between rat and mouse/human.  
EC = Epigenetically conserved    ENC = Epigenetically non-conserved 
Rat-Mouse 
Tissue EC ENC p-value 
Blood 1,477 (27%) 3,583 <4.94e-324 
Brain 2,508 (37%) 4,037 <4.94e-324 
Sperm 11,149 (27%) 22,040 <4.94e-324 
Rat-Human 
Blood 629 (11%) 2,786 <4.94e-324 
Brain 872 (13%) 4,424 <4.94e-324 
Sperm 4,345 (11%) 15,263 2.52E-266 
 
*A hypergeometric test was performed to obtain p-values. P-values were corrected for multiple testing using the 
Benjamini–Hochberg FDR method. 
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Table 2. Summary of overlap between histone mark peaks and mouse and human orthologous regions of rat 
tsDMRs. Overlap between a histone mark peak and a mouse/human orthologous region was defined if the 
orthologous region contained the summit of the histone mark peak.  
Mouse 
Blood 
  # tsDMRs H3K4me1 H3K4me3 H3K27ac H3K27me3 
EC 1,477 181 146 193 5 
ENC 3,583 282 86 145 16 
p-value   8.77E-07 5.67E-31 1.54E-31 0.587 
Brain 
EC 2,508 826 70 551 18 
ENC 4,037 801 44 269 19 
p-value   9.85E-33 3.15E-07 6.73E-74 0.195 
Sperm 
EC 11,149 3,690 1,889 559 334 
ENC 22,040 1,941 555 314 155 
p-value   0 0 5.62E-83 3.02E-60 
Human 
Blood 
EC 629 311 138 221 24 
ENC 2,786 346 77 197 117 
p-value   1.84E-100 1.57E-71 8.21E-84 0.662 
Brain 
EC 872 272 207 250 33 
ENC 4,424 992 429 710 180 
p-value   2.82E-08 2.09E-31 9.40E-19 0.696 
 
*A chi-square test was performed to obtain p-values. P-values were corrected for multiple testing using Benjamini–
Hochberg FDR method. 
Table 3. Rat tsDMRs with various epigenetic conservation status (3-way analysis) 
RMH EC = epigenetically conserved rat tsDMRs across rat, mouse, and human; 
RM EC = epigenetically conserved rat tsDMRs in rat and mouse, but not human;  
RH EC = epigenetically conserved rat tsDMRs in rat and human, but not mouse;  
RMH ENC = rat tsDMRs that are epigenetically not conserved in either mouse or human. 
Tissue RMH EC RM EC RH EC RMH ENC 
Blood 309 611 235 1576 
Brain 402 1551 360 2251 




Supplementary Table 1: Datasets used in this study. (A) MeDIP-seq datasets. (B) MRE-seq datasets. (C) Whole-
genome bisulfite sequencing datasets. (D) Histone modification ChIP-seq datasets. 
A: MeDIP-seq datasets 




Blood Whole Blood GSM1551778 Wang lab 
Brain Whole Brain GSM1551779 Wang lab 
Sperm Sperm GSM1551780 Wang lab 
Mouse 
Blood Whole Blood GSM1551781 Wang lab 
Brain Cultured Neuron GSM1299110 Wang lab 
Human 
Blood Blood PBMC, TC003 GSM543023 Public 
Brain Prefrontal cortex grey matter SRX019264 Public 
 
B: MRE-seq datasets 




Blood Whole Blood GSM1551782 Wang lab 
Brain Whole Brain GSM1551783 Wang lab 
Sperm Sperm GSM1551784 Wang lab 
Mouse 
Blood Whole Blood GSM1551785 Wang lab 
Brain Cultured Neuron GSM1299111 Wang lab 
Human 
Blood Blood PBMC, TC003 GSM543009 Public 
Brain Prefrontal cortex grey matter SRX019323 Public 
 
C: Whole Genome Bisulfite sequencing datasets  





Mouse Sperm Mature Sperm GSE49623 Public 





D: Histone modification ChIP-seq datasets  





Thymus, Histone H3K4me1 GSM1000102 Public 
Thymus, Histone H3K4me3 GSM1000101 Public 
Thymus, Histone H3K27ac GSM1000103 Public 
Thymus, Histone H3K27me3 GSM1000144 Public 
Thymus, ChIP-Seq Input GSM1000204 Public 
Thymus, ChIP-Seq Input GSM918705 Public 
Brain 
Whole Brain, Histone H3K4me1 GSM1000096 Public 
Whole Brain, Histone H3K4me3 GSM1000095 Public 
Whole Brain, Histone H3K27ac GSM1000094 Public 
Whole Brain, Histone H3K27me3 GSM1000143 Public 
Whole Brain, ChIP-Seq Input GSM918752 Public 
Whole Brain, ChIP-Seq Input GSM1000098 Public 
Sperm 
Testis, Histone H3K4me1 GSM1000078 Public 
Testis, Histone H3K4me3 GSM1000079 Public 
Testis, Histone H3K27ac GSM1000081 Public 
Testis, Histone H3K27me3 GSM1000145 Public 
Testis, ChIP-Seq Input GSM918751 Public 
Testis, ChIP-Seq Input GSM1000203 Public 
Human 
Blood 
Blood PBMC, H3K4me1 GSM1127143 Public 
Blood PBMC, H3K4me3 GSM1127126 Public 
Blood PBMC, H3K27ac GSM1127145 Public 
Blood PBMC, H3K27me3 GSM1127130 Public 
Blood PBMC, ChIP-Seq Input GSM1127151 Public 
Brain 
Hippocampus middle, H3K4me1 GSM916039 Public 
Hippocampus middle, H3K4me3 GSM916040 Public 
Hippocampus middle, H3K27ac GSM916035 Public 
Hippocampus middle, H3K27me3 GSM916038 Public 
Hippocampus middle, ChIP-Seq 








Supplementary Table 2: Summary of rat tsDMRs overlapping TEs. 




Blood 5,506 577 (10.48%) 
Brain 6,861 331 (4.82%) 
Sperm 40,971 8,018 (19.57%) 
*Random 40,000 13,648 (34.12%) 
 
*Random refers to a set of forty thousand 500bp rat regions randomly selected from the rat genome.  
 
Supplementary Table 3: Enrichment of TE subfamilies overlapping rat sperm tsDMRs. 
TE 
subfamily** TE family TE class 
TE tsDMRs 
in sperm 








RMER3D2 ERVK LTR 60 1 5.93E-19 88.616 
RMER17B ERVK LTR 71 4 2.12E-20 26.215 
RLTR17 ERVK LTR 177 10 5.20E-50 26.142 
RMER21A ERV1 LTR 27 2 7.80E-08 19.939 
RMER3D3 ERVK LTR 23 2 1.30E-06 16.985 
RLTR20B1 ERVK LTR 40 4 1.08E-10 14.769 
RMER3D4 ERVK LTR 28 3 1.42E-07 13.785 
LTR48 ERV1 LTR 9 1 0.00651954 13.292 
RNERVK22 ERVK LTR 17 2 9.01E-05 12.554 
MER57D ERV1 LTR 7 1 0.02675837 10.338 
 
*Background refers to the forty thousand 500bp regions randomly chosen from the rat genome. **TE subfamilies 








Supplementary Table 4: Summary of three-way orthologous rat tsDMRs 
All tsDMRs Rat tsDMRs Three-way orthologous tsDMRs 
Blood 5506 2859 (52%) 
*Blood-matched  1728 (31%) 
Brain 6861 4746 (69%) 
*Brain-matched  2405 (35%) 
Sperm 40971 16987 (41%) 
*Sperm-matched  12912 (32%) 
**Genome 
random 40000 10184 (25%) 
   
Intergenic 
tsDMRs Rat tsDMRs 
Three-way orthologous 
tsDMRs 
Blood 3197 1626 (51%) 
Blood-matched  728 (23%) 
Brain 3056 2213 (72%) 
Brain-matched  709 (23%) 
Sperm 30676 11653 (38%) 
Sperm-matched   6873 (22%) 
 
* Blood-matched regions are the control set that matches the genomic distribution of rat blood tsDMRs. The same is 
true for Brain-matched and Sperm-matched regions. **Genome random is a set of forty thousand 500bp rat regions 
that are randomly chosen from the rat genome.  
Supplementary Table 5: Rat EC and ENC tsDMR distance from the nearest TSS to the start of the tsDMR.  
Species 
Comparison Tissue 
EC Distance* to 
the TSS (Mean) 
ENC Distance* to 
the TSS (Mean) 
Wilcox p-value 
 (EC < ENC) one-
sided 
Rat-Mouse 
Blood 57,641.02 73,551.66 6.10E-17 
Brain 96,375.93 78,770.65 1 
Sperm 125,715.44 144,645.01 1.85E-77 
Rat-Human 
Blood 36,322.83 80,543.11 2.57E-41 
Brain 44,221.69 99,469.63 1.55E-46 
Sperm 129,020.98 146,713.12 4.29E-49 
 
* Distances are given as base pair units and are averaged across the full group of EC or ENC tsDMRs.   
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Supplementary Table 6: Genomic coordinates and motif sequences of the TF binding sites shown in the five 
examples.  
GC = Genetically conserved, GNC = Genetically non-conserved, RMH EC = Epigenetically conserved across rat, 
mouse, and human, RM EC = Epigenetically conserved in rat and mouse, but not human, RH EC = Epigenetically 
conserved in rat and human, but not mouse 
Category Motif Gene Species tsDMR/ orthologous  region coordinates Motif sequence 
GC 
Lhx3 Sez6 
Rat chr10: 64007000-64007500 
CCCTAATTAT, 



























CCAGGGAGCA   
[84bp] 
CAGGAAGGAA 
            
GC 
Fli1 Skap1 
Rat chr10:85389000-85389500 GAAGGAAGTG 
RM EC Mouse chr11:96503962-96504467 GAAGGAAGTG 
  
Human chr17:46321342-46321848 GAAGGAAATG 
Dog chr9:27844513-27845025 GAAGGAAATG 
            
GC 
Fli Cd6 Rat chr1:213289000-213289500  
TCAGGAAGCC 
RH EC [ 357bp]    










[357bp]   
CACTTCCGCC 






















Sequences highlighted in red are the DNA sequences that are not TF binding motifs. Nucleotides highlighted in red 




Chapter 5: Conclusions and Future 
Directions 
 
Renee L. Sears 
133 
 
5.1 Significance  
In this dissertation I present advancements to the field of epigenetics in the context of 
understanding differences among neural cell types and the relative conservation of epigenetic 
regulatory regions across species.  
 Our evolving epigenome work establishes a new a framework for epigenetic comparisons 
among human, rat, and mouse that is extendible to other species. Tissue-specific hypo-DMRs are 
more likely than expectation to be genetically conserved across species and are more likely to 
maintain their tissue-specific hypomethylation in compared species. A significant portion, but 
not majority, of tissue-specific DMRs are epigenetically conserved and we attribute this 
phenomenon to regulatory region turnover among species. Careful examination at the sequence 
level reveals motif instances with hypomethylation that are tissue-specific and epigenetically 
conserved, but not genetically conserved as the actual instance of the TF motif shifts to a new 
location from species to species, i.e. a turnover event.  
 Our neural datasets represent the first mouse in vivo full transcriptome analysis of motor 
neurons through RNA-Seq, the first ATAC-Seq datasets of these cell types in mouse in vivo, and 
the first whole genome profiling of DNA methylation of mouse in vivo motor neurons and 
oligodendrocytes (astrocytes have previously been profiled as S100b+ nuclei92) to our 
knowledge. We define cell type-specific gene sets, open chromatin regions, and DNA 
methylation patterns. Thousands of circular RNAs are identified, some with putative cell type-
specific expression, and hundreds that have not been previously annotated. ATAC-Seq data is 
used to not only define motifs of interest, but also to identify putative distal cell type-specific 
open chromatin regions that might act as enhancers and clustered putative enhancers. We identify 
oligodendrocyte-specific clustered putative enhancers upstream of Qk that overlap the deletion in 
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quakingviable mutant mice and could account for the phenotype seen (including oligodendroglial 
defects). Samples are obtained for both males and females allowing comparison of all three 
assays between sexes resulting in interesting findings on chromosome X, but no differences on 
autosomes. Lastly, we find that while glia hypo-DMRs are the largest class of hypo-DMRs there 
are thousands of hypo-DMRs that separate astrocytes and oligodendrocytes along with their 
mCH profiles; implying that there are both shared and cell type-specific epigenetic patterns 
between these cell types.    
 Importantly, we have created two resources that we anticipate will be applicable to future 
research and our work is extendible to all bacTRAP lines. For the astrocyte (Aldh1l1), 
oligodendrocyte (Cnp), and motor neuron (ChAT) bacTRAP mouse lines I have created male and 
females GFP+ mESC lines that when differentiated into the appropriate cell types should be able 
to undergo FACS/FANS. I anticipate that these cells can be used to first profile in vivo versus in 
vitro transcriptional and epigenetic profiles and then to further refine differentiation methods. 
Given that in neural differentiation often more than one cell type is present in the culture, these 
lines will allow for easier cell type-specific isolation. Secondly, we have created a large public 
database of the tracks created from our neural cell type epigenome study through the WashU 
Epigenome Browser. We have also integrated reprocessed epigenetic data from S100B+ nuclei 
(astrocytes; GSE47966) and PV, VIP, and excitatory neurons (GSE63137). Processed data 
available includes aligned RNA-Seq tracks, circular RNA tracks, pairwise differentially 
expressed genes, aligned ATAC-Seq tracks, ATAC-Seq peaks, differentially accessible regions, 
CpG methylation tracks, non-CpG methylation tracks, methylation region tracks (unmethylated 
regions, lowly methylated regions, and DNA Methylation Valleys), differentially methylated 
regions, sex-specific differentially accessible regions, and sex-specific differentially methylated 
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regions. At present the hub contains 88 tracks, 76 of which are new data and 12 of which 
represent re-processed DNA methylation data. The hub can be extended to include newer studies 
and used for direct comparison by researchers. In the process of creating this datahub I have 
helped shape the modernized WashU Epigenome Browser140 by suggesting modifications to 
existing infrastructure, creating new track types, and extensively implementing clearer and more 
complete documentation than existed for the previous build of the Browser. 
5.2 Future Directions 
5.2.1  Regulation of Qk 
 Our discovery of a very large hypomethylated region in the gene body of Qk and multiple 
upstream oligodendrocyte-specific ATAC-Seq peaks could directly influence a follow-up study 
on the regulation of Qk. Additionally, there is evidence that oligodendrocytes in quakingviable 
(qkV) mice lack QKI-6 and QKI-7 and also experience a reduction of QKI-5 based on the 
severity of dysmyelinated tracts191. As a first step, qkV mice can be obtained and crossed to the 
Cnp bacTRAP line. After obtaining homozygotes for the qkV deletion that are also GFP+, 
oligodendrocytes can be specifically extracted using a density gradient and targeted BS-Seq can 
be employed to ascertain if the large oligodendrocyte-specific DMV is perturbed due to the qkV 
deletion. Putative oligodendrocyte-specific enhancers could each be deleted from our Cnp 
bacTRAP line using CRISPR technology. Each line would undergo three additional assays; 1) 
phenotypic assessment for presence of seizures, tremors, male sterility, and oligodendroglial 
defects as previously described189–191, 2) targeted bisulfite sequencing of the Qk gene body to 
assess disruption of the large DMV (if it was previously found to be perturbed in the qkV 
deletion), and 3) assessment of presence of the three Qk isoforms in wildtype as compared to our 
new lines either through qPCR, RNA-Seq (ideally long-read sequencing as the only difference in 
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the isoforms is the 3’ end), or through immunolabeling of the unique carboxy tails as previously 
published191. In this manner we can appraise the individual utility and response to enhancer 
perturbation in a well-defined mouse line both at a sequencing and phenotypic level.  
5.2.2  Cell Type Specificity of Circular RNAs  
 A relatively straightforward protocol and analysis could be used to verify the circular 
RNAs found in our mouse astrocyte, oligodendrocyte, motor neuron, and mESC RNA-Seq. 
Briefly, primers are designed as a divergent primer pair so that they will not amplify linear RNA, 
total RNA is isolated, linear RNA is degraded with RNase R, cDNA is created, and PCR is 
performed with SYBR Green for quantification305. Using this protocol, cell type specificity of 
our reported ciRNAs and those previously published150 could be determined leading to further 
study of their function in specific cell types instead of tissues. Gleaning the normal function of a 
ciRNA would later inform analysis on ciRNA’s role in disease and utility as biomarkers147,306.  
5.2.3  Central Nervous System Epigenetics 
As a fantastic example of cellular diversity, the CNS consists of hundreds of cell types21 
many with changing gene expression in different regions, over development, and in disease307. In 
an ideal world it would be possible to profile each of these cells in a region-specific manner as a 
future aim of our study, but I will propose more modest follow-up experiments and analysis 
below. It would be beneficial to profile H3K27ac in our cell types and then categorize regions 
with H3K27ac, hypomethylation, and open chromatin as active cell type-specific enhancers308. It 
is my belief that cell type-specific enhancers could be of great value to disease models as a 
mutation seen in bulk tissue with no obvious genetic function could then be ascribed to specific 
cell types. I will focus my next three analysis plans on astrocytes (Aldh1l1 bacTRAP mice), but 
these could be extended to oligodendrocytes and motor neurons as well.  
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Three experimental paths include epigenetically profiling astrocytes in a region-specific 
method, during aging, and in a disease model. An innovative study (John Lin et al. 2017) further 
delineated astrocytes into five subtypes via FACS with specific antibodies in the Aldh1l1-GFP 
reporter mouse and performed RNA-Seq for these five subtypes across olfactory bulb, cortex, 
and brainstem. They found that different subtypes were associated with different gene sets, 
functions such as synapse formation, and molecular profiles consistent with glioblastoma 
subtypes309. Using this new FACS based method; we could capture different subtypes of 
astrocytes across multiple regions of the CNS and then epigenetically profile them. It would be 
interesting to see if ATAC-Seq and DNA methylation data cluster subtypes or region-specific 
data together and if this was congruent with RNA-Seq data. One would expect that if our 
astrocyte population was a mix of subtypes with large differences in mCG then I would see 
regions of intermediate methylation, but these were not found in my previous analysis. Perhaps 
small percentages changes in mCG belie the expression changes seen between subtypes or 
regions. Another thought-provoking hypothesis that could be tested is whether astrocyte subtypes 
have differential usage of mCH, if this usage changes between regions, and if either subtype or 
region proportions are not the same between males and females, which could account for the 
higher mCH seen in our male astrocyte samples.  
 Aging is known to affect the epigenome, indeed certain CpGs can reliably serve as a 
DNA Methylation “Clock” to estimate the age of an individual310. Chromatin and transcription 
changes point to an induction of immune system response recurrently across tissues311. Synapse-
regulating genes are repressed and immune pathway genes are increased in astrocytes during 
aging leading to cells that resemble reactive astrocytes and creating an environment permissive 
to neuronal damage307. Do epigenetic shifts in open chromatin or DNA methylation underlie 
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immune and synapse-regulating gene expression changes? Are synapse-regulating genes 
repressed in all astrocyte subtypes or just in the subtype that was enriched for synapse gene 
expression (population C, John Lin et al. 2017)? By implementing a system with mice at three 
different time points, five subtypes, and multiple regions researchers could interrogate the shared 
and specific aging epigenome. Additionally, with at least three time points researchers could 
look for small changes over time (such as 10% mCG difference from young to middle age 
followed by another 10% from middle age to old). This would give the community a better 
understanding of how specific cell types or subtypes are tied to disease through overlap with 
enhancers that are cell type-specific and impacted by mutations. Lastly, as a more direct test, 
mouse models of disease state (such as Alzheimer’s Disease) can be crossed with bacTRAP lines 
to isolate specific cell types through normal development and disease state. We could then work 
towards differentiating between what is normally seen in aging and what is specific to the 
disease state.  
5.2.4  Epigenetics in vivo versus in vitro  
I have already created mouse embryonic stem cell lines from the astrocyte, 
oligodendrocyte, and motor neuron bacTRAP lines. In principal these should allow for easy 
extraction of these specific cell types once terminally differentiated through FANS/FACS. 
Examples such as directed differentiation of human ESCs to cardiomyocytes and their 
subsequent integration into rats with cardiac infraction312 and the partial recovery of 
hemiparkinsonian rats after transplantation of in vitro differentiated dopaminergic neurons313 
highlight the potential medical value of in vitro differentiation systems. However, the persistent 
failure of in vitro systems for drug discovery and transplantable cells226 can be attributed, in part 
to our incomplete understanding of normal in vivo cells and the assumption that in vitro systems 
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faithfully model these cells. First, we need to understand how epigenetic patterns differ in vitro 
versus in vivo and then assess the meaning or importance of this divergence. Our system presents 
a unique opportunity because the genomic background of our cells is identical to our in vivo 
generated data. 
An overarching goal of an in vivo versus in vitro comparison is to identify epigenetic 
events in vitro that are necessary and sufficient to drive a cultured cell towards the total 
phenotype of a comparable in vivo cell type. A high bar is necessary for defining a fully 
functioning in vitro differentiated cell type; the ultimate test of this is whether an in vitro derived 
cell type can be transplanted into an animal and behave identically to its in vivo counterpart. We 
hypothesize that there are two types of events in in vivo cells as they undergo terminal 
differentiation; 1) driving epigenetic events that when perturbed disrupt normal functions of the 
cell type or result in incomplete maturation and 2) passenger epigenetic events that when 
perturbed do not result in abnormal cell type activity. This hypothesis is motivated by a few 
studies that directly assay epigenetic conditions in vitro131,227–229 and a study that finds iPSCs 
have an epigenetic memory impacting their differentiation potential314. Does hypermethylation of 
in vitro cells131 impact their ability to form fully functioning differentiated cell types? Are 
patterns reflective of an epigenetic memory of initial cell type314 really indicative of cell type 
driving epigenetic patterns that are never lost? 
 Through careful re-reading and analysis of published figures I have found, perchance, an 
unexpected trend of in vitro cells clustering away from related tissues and instead clustering with 
other in vitro cells. Varley et al. 201393 cluster variable CpG methylation using RRBS data, 
highlighting hypermethylation in cancer cell lines, but also demonstrating that primary cells 
cluster away from tissues for mCG. This phenomenon is also seen in H1 derived neurons for 
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H3Kme3 in active promoters as while they cluster closely with fetal brain and brain germinal 
matrix they are more related to several hESCs and hESC-derived cells than other brain regions 
(e.g. hippocampus)1. Is this clustering indicative of incomplete differentiation? Could it be 
indicative of a shared culture environment? Are hESC-derived cell types missing driving 
epigenetic events? 
 A more recent study shows gradual erasure of the fibroblast epigenetic identity in miR-
9/9*-124-induced neurons indicated by opening of neuronal-related promoter loci and closure of 
fibroblast-related promoter loci315. The authors then differentiate the induced neurons into motor 
neurons (Moto-miNs) and compare their expression profiles to that of in vivo mouse motor 
neurons finding a significant overlap in genes enriched, but fall short of comparing epigenomic 
profiles as human motor neurons are not easily obtainable315. Lastly, an exciting paper155 did 
directly compare DNA methylomes and transcriptomes of cerebral organoids to fetal brain 
finding that epigenomic signatures in vivo were conserved in the system. However, the authors 
do find that for mCG cerebral organoids cluster away from cortex samples likely due to 
hypomethylation of pericentromeric regions in vitro. Visual inspection of their reported cerebral 
organoid hypo-DMRs (Luo et al. 2016, Figure 5) reveals more marked hypomethylation in fetal 
cortex than cerebral organoids155. Is the additional hypomethylation in fetal cortex necessary for 
cortex function or simply a passenger epigenetic pattern? A researcher could spend a career 
systematically categorizing which epigenetic patterns were necessary to create specific cell types 
and thus we address three potential directions for this section.  
First, using all three of our transgenic mESC lines cell types we can analyze global 
differences that are shared among cell types when in vivo data is compared to in vitro data. 
Indeed, hypermethylation has been observed in cells differentiated in vitro131,227, high-CpG 
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density promoter mCG increases with passage number131, and global patterns of 5-
hydroxymethylcytosine are lost in culture228,229. These are important to characterize as culture-
specific changes could act as driving epigenetic events towards a tumor-like state158,230,231, but 
experimental protocol changes232 could be used to mitigate these changes in turn leading to 
cultures better representing in vivo state. We might also expect a certain mis-maintenance of 
mESC-state that includes preservation of mCAG methylation and lowered mCAC methylation. 
mESC-like epigenetic patterns could conceivably indicate that while the morphological and 
transcription identity of the cells in question seems to match expectation their epigenomes are 
still immature. This type of information could be used to re-think protocols in the context of 
ending differentiation when certain epigenetic signatures of mESCs are lost instead of when cell 
type-specific marker expression is gained.   
Second, after eliminating epigenetic patterns that are shared between our three cell types, 
we can determine cell type-specific epigenetic mis-regulation in vivo versus in vitro. Clear 
divergences within regions close to cell type-specific genes and enhancers found in the in vivo 
portion of my dissertation are of immediate interest. An immediate goal of this future direction 
would be to identify in vitro epigenetic disruptions and work towards modified protocols that 
eliminate these cell type-specific disruptions. Small changes in culture systems can greatly affect 
epigenetic profiles; the addition of Vitamin C to mESCs causes demethylation at CGIs resulting 
in a blastocyst-like state232 while culturing ESCs with serum or serum and kinase inhibitors leads 
to hypermethylated and hypomethylated states respectively158,231.  
Third, an in vitro model might incompletely model an in vivo system due to variation in 
proportions of cell types or subtypes that do not mirror in vivo percentages. It would be 
interesting to see if after in vitro differentiation we could isolate all astrocyte subtypes as 
142 
 
previously classified309 or if one or two subtypes prevailed. If we could isolate all five subtypes, 
which regional proportions and expression patterns do the in vitro differentiated astrocytes 
match? Are there specific changes to the culture system that can be made to either 1) selectively 
acquire a specific sub-population of astrocytes or 2) selectively acquire expression patterns most 
like a particular CNS region?   
As a long-term goal, more relevant and identically behaving cultured cell types should 
lead to better transplantation results in model organisms and ultimately inform human disease 
care. It is essential to understand the normal cell state, how cells are globally perturbed in vitro, 
and how specific in vitro cell types differ from their in vivo counterparts. With this in mind, 
future studies can work towards 1) reconfiguring and using protocols that deliver in vitro cells 
that epigenetically match their in vivo counterparts, 2) defining epigenetic changes crucial for a 
specific cell fate, and 3) assessing different in vitro differentiated cells in the context of 
transplantation studies.  
5.2.5  Epigenome Evolution 
One of the biggest limitations of our previous study134 was the comparison of 
incompletely matched tissues (whole brain versus cultured neuron versus prefrontal cortex) 
across species. Given that cell types within the same tissue, as exemplified by our brain astrocyte 
and oligodendrocyte epigenetic maps, can vary greatly, studies across species need tight 
matching of input samples to draw broad conclusions. While not completely feasible for all 
species, it should be possible to have matched in vivo comparisons for human, mouse, and rat for 
cell types with cell type-specific antigens expressed on the cell surface that can be isolated via 
FACS. With this setup in mind we could: 1) reassess the percent of epigenetically conserved 
hypo-DMRs between species to see if different cell types have vast differences in EC hypo-
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DMRs, 2) assess the paradigm that promoter elements are more conserved than enhancers119, and 
3) see if rapid enhancer evolution tracks with percent EC hypo-DMRs. Perhaps liftover is too 
stringent of a tool and instead what is important is a proximal gene guided analysis in which the 
sequence level conservation of a regulatory element is not important. For example, in Qk our 
mouse oligodendrocytes have a large hypo-DMR over Qk’s gene body along with several Pacrg 
intronic hypo-DMRs. Perhaps what is important here is 1) having a promoter-associated hypo-
DMR, 2) having several upstream hypo-DMRs, and possibly 3) that the putative mouse enhancer 
hypo-DMRs share motifs with the upstream hypo-DMRs in human. At the gene level, RNA-Seq 
could be very valuable as we could specifically target our analysis towards: 1) cell type-specific 
genes that are shared between species with the parallel expectation of shared epigenetic patterns 
and 2) cell type-specific genes in species A that are not expressed or cell type-specific in species 
B with the expectation that there are epigenetic changes within the cell type between species or 
that the epigenetic pattern in species B is now shared across more than one cell type, 
respectively.  
5.3 Summary  
Here we profile gene expression, open chromatin, and DNA methylation in motor neurons, 
astrocytes, and oligodendrocytes from the mouse CNS along with DNA methylation from three 
tissues in three species. We create a data resource available as a public data hub through the 
WashU Epigenome Browser140 and three cell lines for in vitro follow-up studies. I suggest two 
specific follow-up studies based on the potential oligodendrocyte-specific Qk enhancers and 
circular RNAs discovered in our neural epigenome atlas paper. I also explore future directions in 
regard to studies in cell type-specific neural epigenomics, in vivo versus in vitro epigenomics, 
and comparative evolutionary epigenome mapping.   
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A.1 Astrocyte Expressed Gene Set 
Supplementary Table 1. Astrocyte Expressed Gene Set. Genes with the gene id, chromosome, start, stop, gene 
type, strand, and gene name. Each gene had at least 4-fold higher expression in all pairwise comparisons. 
Gene ID Chromosome Start Stop Type Strand Gene Name 
ENSMUSG00000029309.7 chr5 104079110 104113733 protein coding - Sparcl1 
ENSMUSG00000007097.14 chr1 172271708 172298064 protein coding - Atp1a2 
ENSMUSG00000022037.15 chr14 65968482 65981547 protein coding + Clu 
ENSMUSG00000027447.6 chr2 148871721 148875576 protein coding - Cst3 
ENSMUSG00000005089.15 chr2 102658658 102790784 protein coding + Slc1a2 
ENSMUSG00000026424.8 chr1 135160233 135167681 protein coding - Gpr37l1 
ENSMUSG00000041329.13 chr11 69599735 69605829 protein coding - Atp1b2 
ENSMUSG00000037852.8 chr8 64592541 64693054 protein coding - Cpe 
ENSMUSG00000005360.14 chr15 8634123 8710764 protein coding - Slc1a3 
ENSMUSG00000061808.3 chr18 20665249 20674324 protein coding + Ttr 
ENSMUSG00000006205.13 chr7 130936202 130985660 protein coding + Htra1 
ENSMUSG00000004892.13 chr3 87987530 88000230 protein coding - Bcan 
ENSMUSG00000028517.8 chr4 105157346 105232764 protein coding + Plpp3 
ENSMUSG00000030307.8 chr6 114131240 114249952 protein coding + Slc6a11 
ENSMUSG00000030310.10 chr6 114282634 114317532 protein coding + Slc6a1 
ENSMUSG00000023913.17 chr17 43568268 43612201 protein coding + Pla2g7 
ENSMUSG00000020591.11 chr12 16653483 16660227 protein coding + Ntsr2 
ENSMUSG00000045092.8 chr3 115710432 115715072 protein coding - S1pr1 
ENSMUSG00000030605.15 chr7 79133767 79149060 protein coding - Mfge8 
ENSMUSG00000030428.16 chr7 4119529 4136708 protein coding + Ttyh1 
ENSMUSG00000031980.9 chr8 124556533 124569706 protein coding - Agt 
ENSMUSG00000024411.9 chr18 15389393 15403684 protein coding - Aqp4 
ENSMUSG00000028128.13 chr3 121723536 121735048 protein coding + F3 
ENSMUSG00000068748.7 chr6 22875501 23052916 protein coding + Ptprz1 
ENSMUSG00000031808.7 chr8 71568881 71586708 protein coding + Slc27a1 
ENSMUSG00000054252.17 chr5 33721723 33737068 protein coding + Fgfr3 
ENSMUSG00000040055.9 chr14 57123302 57133611 protein coding - Gjb6 
ENSMUSG00000032181.7 chr9 75643188 75684056 protein coding - Scg3 
ENSMUSG00000060961.14 chr5 88886817 89239653 protein coding + Slc4a4 
ENSMUSG00000036949.16 chr2 14388315 14494977 protein coding + Slc39a12 
ENSMUSG00000030495.12 chr7 35186384 35201114 protein coding + Slc7a10 
ENSMUSG00000004558.15 chr14 51905270 51913488 protein coding - Ndrg2 
ENSMUSG00000043496.7 chr6 53815467 53820830 protein coding - Tril 
ENSMUSG00000055254.15 chr13 58808280 58937027 protein coding + Ntrk2 
ENSMUSG00000097156.7 chr3 88206812 88229959 lincRNA + RP23-168E14.7 
ENSMUSG00000022122.15 chr14 103814624 103844402 protein coding - Ednrb 
ENSMUSG00000020333.17 chr11 54304201 54364752 protein coding + Acsl6 
ENSMUSG00000029570.5 chr5 140607319 140615545 protein coding + Lfng 
ENSMUSG00000035805.13 chr15 88955883 88979007 protein coding - Mlc1 
ENSMUSG00000063297.7 chr7 54835614 55268885 protein coding + Luzp2 
ENSMUSG00000026249.10 chr1 79794196 79858696 protein coding - Serpine2 
ENSMUSG00000010064.15 chr9 107650633 107667374 protein coding - Slc38a3 
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ENSMUSG00000006522.17 chr14 30908571 30923760 protein coding - Itih3 
ENSMUSG00000025666.16 chrX 81070704 81097872 protein coding + Tmem47 
ENSMUSG00000033998.9 chr8 125995169 126030685 protein coding + Kcnk1 
ENSMUSG00000035237.7 chr8 105939550 105943382 protein coding - Lcat 
ENSMUSG00000030029.14 chr6 94604533 94700145 protein coding - Lrig1 
ENSMUSG00000023951.17 chr17 46016992 46032369 protein coding - Vegfa 
ENSMUSG00000046312.4 chr4 41495603 41503076 protein coding - RP23-100C7.2 
ENSMUSG00000000202.9 chr11 114791216 114795897 protein coding - Btbd17 
ENSMUSG00000036565.7 chr5 140620577 140649031 protein coding - Ttyh3 
ENSMUSG00000020044.13 chr10 86300371 86349506 protein coding + Timp3 
ENSMUSG00000015224.10 chr4 96568428 96591578 protein coding - Cyp2j9 
ENSMUSG00000052387.15 chr19 22139118 22989884 protein coding + Trpm3 
ENSMUSG00000020734.13 chr11 115249168 115267243 protein coding - Grin2c 
ENSMUSG00000030235.17 chr6 141524385 141570177 protein coding + Slco1c1 
ENSMUSG00000048148.18 chr8 72646710 72717876 protein coding + Nwd1 
ENSMUSG00000025283.15 chrX 155213131 155216449 protein coding - Sat1 
ENSMUSG00000014361.5 chr2 128698955 128802894 protein coding + Mertk 
ENSMUSG00000002341.8 chr8 70093084 70120873 protein coding - Ncan 
ENSMUSG00000039533.8 chr5 142562357 142608800 protein coding - Mmd2 
ENSMUSG00000017390.15 chr11 78322967 78327781 protein coding + Aldoc 
ENSMUSG00000022112.14 chr14 115092249 116525179 protein coding + Gpc5 
ENSMUSG00000032281.11 chr9 54604876 54661870 protein coding - Acsbg1 
ENSMUSG00000038094.15 chr16 29396027 29544864 protein coding - Atp13a4 
ENSMUSG00000024978.10 chr19 55069733 55099451 protein coding - Gpam 
ENSMUSG00000075012.4 chr2 102449365 102452499 protein coding - Fjx1 
ENSMUSG00000021340.13 chr13 24943151 24992501 protein coding + Gpld1 
ENSMUSG00000025555.14 chr14 121035563 121283744 protein coding + Farp1 
ENSMUSG00000067786.16 chr2 157560077 157562522 protein coding + Nnat 
ENSMUSG00000032482.9 chr9 110243782 110262576 protein coding + Cspg5 
ENSMUSG00000022658.10 chr16 45711229 45724608 protein coding - Tagln3 
ENSMUSG00000042613.9 chr3 89436705 89450952 protein coding + Pbxip1 
ENSMUSG00000033763.14 chr8 110725725 110739935 protein coding + Mtss1l 
ENSMUSG00000034463.4 chr14 65919393 65953935 protein coding - Scara3 
ENSMUSG00000048960.13 chr1 10993464 11303681 protein coding + Prex2 
ENSMUSG00000020932.14 chr11 102887335 102897200 protein coding - Gfap 
ENSMUSG00000021508.11 chr13 56288642 56296551 protein coding - Cxcl14 
ENSMUSG00000030088.15 chr6 90550788 90600203 protein coding + Aldh1l1 
ENSMUSG00000021750.15 chr14 8296273 8309779 protein coding - Fam107a 
ENSMUSG00000016194.14 chr1 193221633 193264075 protein coding - Hsd11b1 
ENSMUSG00000013275.9 chr1 131827976 131848865 protein coding + Slc41a1 
ENSMUSG00000007682.6 chr12 90724551 90738438 protein coding - Dio2 
ENSMUSG00000022132.15 chr14 118787907 118875489 protein coding + Cldn10 
ENSMUSG00000036790.5 chrX 66649317 66661393 protein coding + Slitrk2 
ENSMUSG00000020614.13 chr11 109672925 109722256 protein coding - Fam20a 
ENSMUSG00000026185.8 chr1 72857931 72874884 protein coding - Igfbp5 
ENSMUSG00000019872.13 chr10 57794373 57811830 protein coding + Smpdl3a 
ENSMUSG00000036560.14 chr7 31059341 31070935 protein coding + Lgi4 
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ENSMUSG00000029084.5 chr5 43868552 43912375 protein coding + Cd38 
ENSMUSG00000073424.9 chr17 32685626 32703352 protein coding + Cyp4f15 
ENSMUSG00000019437.17 chr11 78178650 78181909 protein coding + Tlcd1 
ENSMUSG00000024039.14 chr17 31612622 31637199 protein coding - Cbs 
ENSMUSG00000003526.11 chr16 18060356 18090203 protein coding - Prodh 
ENSMUSG00000035104.14 chr6 82041622 82093099 protein coding + Eva1a 
ENSMUSG00000042249.11 chr5 112910481 113015791 protein coding - Adrbk2 
ENSMUSG00000030111.9 chr6 121636227 121679227 protein coding + A2m 
ENSMUSG00000061740.8 chr15 82370526 82380257 protein coding - Cyp2d22 
ENSMUSG00000021364.16 chr13 41182380 41220405 protein coding - Elovl2 
ENSMUSG00000021379.2 chr13 48261227 48266026 protein coding + Id4 
ENSMUSG00000038679.16 chr15 50654751 50890041 protein coding - Trps1 
ENSMUSG00000028957.12 chr4 151003651 151044665 protein coding - Per3 
ENSMUSG00000027737.10 chr3 49892525 50443614 protein coding - Slc7a11 
ENSMUSG00000024347.16 chr18 35964829 36014715 protein coding + Psd2 
ENSMUSG00000036885.14 chr3 62338343 62462221 protein coding + Arhgef26 
ENSMUSG00000038594.9 chr10 53273442 53379947 protein coding - Cep85l 
ENSMUSG00000021943.7 chr14 33923586 33937983 protein coding + Gdf10 
ENSMUSG00000033720.12 chr6 85213048 85333422 protein coding - Sfxn5 
ENSMUSG00000067279.2 chr19 36731736 36736653 protein coding - Ppp1r3c 
ENSMUSG00000031596.15 chr8 40862395 40922308 protein coding + Slc7a2 
ENSMUSG00000031639.12 chr8 45395664 45410619 protein coding - Tlr3 
ENSMUSG00000001260.10 chr5 70751046 70842617 protein coding - Gabrg1 
ENSMUSG00000059336.14 chr18 78100090 78142119 protein coding - Slc14a1 
ENSMUSG00000052430.15 chr3 141837135 142169425 protein coding - Bmpr1b 
ENSMUSG00000037509.20 chr1 34678187 34813309 protein coding + Arhgef4 
ENSMUSG00000044674.6 chr5 4753838 4758035 protein coding - Fzd1 
ENSMUSG00000027570.15 chr2 180597789 180622189 protein coding + Col9a3 
ENSMUSG00000048332.13 chr3 53041527 53261679 protein coding + Lhfp 
ENSMUSG00000051497.15 chr11 110968032 111027968 protein coding + Kcnj16 
ENSMUSG00000040957.15 chr18 11839219 11945626 protein coding + Cables1 
ENSMUSG00000048001.7 chr4 154960922 154962371 protein coding + Hes5 
ENSMUSG00000027962.14 chr3 116109948 116129688 protein coding - Vcam1 
ENSMUSG00000060548.13 chr14 60963874 61046490 protein coding - Tnfrsf19 
ENSMUSG00000050288.6 chr11 102604395 102608058 protein coding + Fzd2 
ENSMUSG00000038156.16 chr7 113765997 114043370 protein coding + Spon1 
ENSMUSG00000027574.15 chr2 180934771 180954699 protein coding - Nkain4 
ENSMUSG00000078234.6 chr4 139960219 139968026 protein coding - Klhdc7a 
ENSMUSG00000070532.5 chr1 169929928 169934413 protein coding + Ccdc190 
ENSMUSG00000020889.11 chr11 98767931 98775333 protein coding - Nr1d1 
ENSMUSG00000030317.8 chr6 115241891 115252205 protein coding - Timp4 
ENSMUSG00000020334.6 chr11 53983122 54028090 protein coding - Slc22a4 
ENSMUSG00000019232.14 chr3 130617447 130637521 protein coding + Etnppl 
ENSMUSG00000036833.16 chr2 24976032 25054057 protein coding + Pnpla7 
ENSMUSG00000002602.16 chr7 25757272 25788705 protein coding - Axl 
ENSMUSG00000025537.12 chr5 129863420 129879083 protein coding - Phkg1 
ENSMUSG00000022899.8 chr16 36750177 36784962 protein coding - Slc15a2 
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ENSMUSG00000051515.9 chr7 93079864 93081867 protein coding + Fam181b 
ENSMUSG00000078202.3 chr2 25180757 25183339 protein coding + Nrarp 
ENSMUSG00000079484.12 chr2 30266528 30282149 protein coding + Phyhd1 
ENSMUSG00000015085.8 chr2 25395873 25401321 protein coding + Entpd2 
ENSMUSG00000039519.6 chr3 18071949 18243338 protein coding - Cyp7b1 
ENSMUSG00000021702.7 chr13 92751589 92794818 protein coding - Thbs4 
ENSMUSG00000031760.9 chr8 94152606 94154146 protein coding + Mt3 
ENSMUSG00000053861.1 chr18 74065101 74065584 protein coding + Gm9925 
ENSMUSG00000031788.14 chr8 95099827 95142547 protein coding - Kifc3 
ENSMUSG00000020644.9 chr12 25093798 25097140 protein coding - Id2 
ENSMUSG00000055782.9 chr15 91145870 91191799 protein coding - Abcd2 
ENSMUSG00000079056.12 chr2 127456497 127521370 protein coding - Kcnip3 
ENSMUSG00000032702.16 chr19 25236974 25434496 protein coding + Kank1 
ENSMUSG00000030276.19 chr6 113389259 113414569 protein coding + Ttll3 
ENSMUSG00000022687.12 chr16 44485048 44558897 protein coding - Boc 
ENSMUSG00000095139.2 chr4 22482779 22488366 protein coding - Pou3f2 
ENSMUSG00000038855.10 chr1 180330484 180424802 protein coding + Itpkb 
ENSMUSG00000027333.18 chr2 131491763 131525922 protein coding + Smox 
ENSMUSG00000020122.16 chr11 16752202 16918158 protein coding + Egfr 
ENSMUSG00000010529.6 chr12 111484608 111485823 protein coding - RP23-41J14.5 
ENSMUSG00000029093.14 chr5 36017179 36398139 protein coding - Sorcs2 
ENSMUSG00000024620.11 chr18 61045149 61085061 protein coding + Pdgfrb 
ENSMUSG00000044037.15 chr9 110880173 110900530 protein coding + Als2cl 
ENSMUSG00000026173.15 chr1 74542887 74567794 protein coding + Plcd4 
ENSMUSG00000020601.8 chr12 15791726 15816922 protein coding - Trib2 
ENSMUSG00000067242.11 chr19 38264535 38312214 protein coding + Lgi1 
ENSMUSG00000031610.3 chr8 57455922 57477585 protein coding + Scrg1 
ENSMUSG00000000567.5 chr11 112782223 112787760 protein coding + Sox9 
ENSMUSG00000036570.14 chr7 31051677 31055708 protein coding - Fxyd1 
ENSMUSG00000039007.10 chr15 33083128 33594552 protein coding + Cpq 
ENSMUSG00000021010.8 chr12 53248676 54072175 protein coding + Npas3 
ENSMUSG00000039934.12 chr5 21186288 21291723 protein coding + Gsap 
ENSMUSG00000034853.16 chr4 106744554 106804998 protein coding - Acot11 
ENSMUSG00000044197.8 chr5 139378219 139396415 protein coding + Gpr146 
ENSMUSG00000025350.15 chr10 128913592 128919297 protein coding - Rdh5 
ENSMUSG00000032014.6 chr9 43221234 43239911 protein coding - Oaf 
ENSMUSG00000029810.15 chr6 48833817 48841374 protein coding - Tmem176b 
ENSMUSG00000022537.17 chr16 30513690 30550578 protein coding - Tmem44 
ENSMUSG00000052957.8 chr13 60174404 60177365 protein coding - Gas1 
ENSMUSG00000020021.4 chr10 94036000 94145339 protein coding + Fgd6 
ENSMUSG00000050423.11 chr13 35958838 35970388 protein coding + Ppp1r3g 
ENSMUSG00000030287.15 chr6 146108298 146502178 protein coding - Itpr2 
ENSMUSG00000004902.7 chr6 120773577 120794336 protein coding + Slc25a18 
ENSMUSG00000049999.4 chr2 178411205 178414472 protein coding - Ppp1r3d 
ENSMUSG00000024558.12 chr18 73928485 74064929 protein coding - Mapk4 
ENSMUSG00000066026.14 chr4 144893076 144928209 protein coding + Dhrs3 
ENSMUSG00000027452.11 chr2 150618104 150668258 protein coding - Acss1 
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ENSMUSG00000041577.5 chr1 133910303 133921414 protein coding - Prelp 
ENSMUSG00000038233.9 chr9 121950987 121980209 protein coding + Fam198a 
ENSMUSG00000030093.7 chr6 91363980 91411363 protein coding - Wnt7a 
ENSMUSG00000019359.14 chrX 100729941 100738894 protein coding + Gdpd2 
ENSMUSG00000022562.15 chr15 76296600 76307245 protein coding - Oplah 
ENSMUSG00000108111.1 chr6 90486392 90519480 lincRNA + RP24-457L7.3 
ENSMUSG00000022505.9 chr16 10281748 10313968 protein coding - Emp2 
ENSMUSG00000047090.13 chr10 128800035 128804370 protein coding - Tmem198b 
ENSMUSG00000028364.15 chr4 63959784 64047015 protein coding - Tnc 
ENSMUSG00000039835.16 chr10 18318984 18533892 protein coding + Nhsl1 
ENSMUSG00000026697.10 chr1 162639154 162649693 protein coding + Myoc 
ENSMUSG00000026614.6 chr1 185454847 185468762 protein coding + Slc30a10 
ENSMUSG00000043671.14 chr7 35685164 35754454 protein coding - Dpy19l3 
ENSMUSG00000060477.14 chr6 113638466 113695026 protein coding + Irak2 
ENSMUSG00000020828.13 chr11 70540305 70558110 protein coding + Pld2 
ENSMUSG00000016239.11 chrX 36328352 36362341 protein coding + Lonrf3 
ENSMUSG00000018500.2 chr11 62248983 62266453 protein coding + Adora2b 
ENSMUSG00000021613.9 chr13 89539795 89611652 protein coding + Hapln1 
ENSMUSG00000036356.15 chr8 68356780 68735146 protein coding - Csgalnact1 
ENSMUSG00000036192.15 chr19 18930604 19111196 protein coding - Rorb 
ENSMUSG00000050721.9 chr9 65554383 65580040 protein coding - Plekho2 
ENSMUSG00000096014.1 chr8 12395294 12400126 protein coding + Sox1 
ENSMUSG00000044033.16 chr2 77009901 77170635 protein coding - Ccdc141 
ENSMUSG00000053004.9 chr6 114397935 114483296 protein coding + Hrh1 
ENSMUSG00000032648.14 chr19 6384398 6398459 protein coding + Pygm 
ENSMUSG00000031875.7 chr8 104340317 104347672 protein coding + Cmtm3 
ENSMUSG00000031925.17 chr9 13297956 13709388 protein coding + Maml2 
ENSMUSG00000041423.16 chr3 88364583 88368541 protein coding + Paqr6 
ENSMUSG00000022382.15 chr15 85535436 85582473 protein coding - Wnt7b 
ENSMUSG00000018822.7 chr19 42197970 42202252 protein coding - Sfrp5 
ENSMUSG00000034353.14 chr1 91179821 91225196 protein coding + Ramp1 
ENSMUSG00000079494.2 chr6 85817217 85820972 protein coding - Cml5 
ENSMUSG00000108255.1 chr6 53819973 53822150 lincRNA + RP23-446E21.6 
ENSMUSG00000068299.11 chr6 85899050 85904884 protein coding - RP23-448G18.4 
ENSMUSG00000035283.4 chr19 56722371 56724862 protein coding + Adrb1 
ENSMUSG00000030004.6 chr6 85830387 85832082 protein coding - Nat8 
ENSMUSG00000021760.4 chr13 113042758 113046386 protein coding - Gpx8 
ENSMUSG00000003420.8 chr7 45092989 45103851 protein coding - Fcgrt 
ENSMUSG00000027188.8 chr2 102550011 102643041 protein coding + Pamr1 
ENSMUSG00000033880.11 chr11 118392750 118402092 protein coding - Lgals3bp 
ENSMUSG00000042793.13 chr1 134983300 135105276 protein coding - Lgr6 
ENSMUSG00000040740.7 chr4 141618823 141623821 protein coding - Slc25a34 
ENSMUSG00000023367.14 chr6 48841511 48845869 protein coding + Tmem176a 
ENSMUSG00000062480.11 chr17 12923832 12940402 protein coding - Acat3 
ENSMUSG00000047361.16 chr1 59516263 59634509 protein coding + RP24-147G7.1 
ENSMUSG00000025352.6 chr10 128882294 128891718 protein coding - Gdf11 
ENSMUSG00000025780.7 chr2 10153570 10256529 protein coding + Itih5 
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ENSMUSG00000046352.7 chr14 57098599 57104702 protein coding - Gjb2 
ENSMUSG00000024292.14 chr17 32905070 32917342 protein coding - Cyp4f14 
ENSMUSG00000079436.3 chr1 87386362 87394729 protein coding - Kcnj13 
ENSMUSG00000026586.16 chr1 163245118 163313710 protein coding - Prrx1 
ENSMUSG00000097023.8 chr7 79500116 79534403 lincRNA + RP23-207N5.1 
ENSMUSG00000050666.14 chr14 32856755 32939491 protein coding + Vstm4 
ENSMUSG00000004328.15 chr7 17031506 17062427 protein coding - Hif3a 
ENSMUSG00000033965.10 chrX 103697413 103821983 protein coding - Slc16a2 
ENSMUSG00000095930.1 chr13 119710093 119755882 protein coding - Nim1k 
ENSMUSG00000016624.15 chr15 84785380 84856049 protein coding - Phf21b 
ENSMUSG00000069763.3 chr11 90030347 90036508 protein coding + Tmem100 
ENSMUSG00000020950.10 chr12 49382882 49386861 protein coding + Foxg1 
ENSMUSG00000064246.10 chr1 134182175 134190181 protein coding + Chil1 
ENSMUSG00000072941.5 chr5 52363790 52371418 protein coding + Sod3 
ENSMUSG00000048939.13 chr16 29231850 29378732 protein coding - Atp13a5 
ENSMUSG00000019874.11 chr10 57784880 57788450 protein coding + Fabp7 
ENSMUSG00000001240.13 chr11 101246027 101248250 protein coding + Ramp2 
ENSMUSG00000020805.14 chr11 72241988 72266659 protein coding - Slc13a5 
ENSMUSG00000020037.15 chr10 84756061 84906538 protein coding + Rfx4 
ENSMUSG00000048583.16 chr7 142650765 142666816 protein coding - Igf2 
ENSMUSG00000063415.12 chr6 84571413 84593908 protein coding - Cyp26b1 
ENSMUSG00000026227.11 chr1 86045862 86055456 protein coding + AC102506.1 
ENSMUSG00000020656.16 chr12 24572282 24617391 protein coding + Grhl1 
ENSMUSG00000002688.8 chr12 50341230 50649098 protein coding - Prkd1 
ENSMUSG00000028838.11 chr4 134356371 134372558 protein coding - Extl1 
ENSMUSG00000029070.9 chr4 155839725 155844088 protein coding + Mxra8 
ENSMUSG00000059049.14 chr4 82897919 83052339 protein coding - Frem1 
ENSMUSG00000008540.11 chr6 138140315 138156755 protein coding + Mgst1 
ENSMUSG00000025911.14 chr1 9547947 9577970 protein coding + Adhfe1 
ENSMUSG00000078349.2 chr4 156203303 156205151 protein coding + AW011738 
ENSMUSG00000035686.8 chr7 97412937 97417730 protein coding - Thrsp 
ENSMUSG00000034164.17 chr11 5106264 5152257 protein coding - Emid1 
ENSMUSG00000106951.1 chr5 148990055 148995223 lincRNA - RP23-134H19.3 
ENSMUSG00000028028.11 chr3 127670309 127780527 protein coding - Alpk1 
ENSMUSG00000091387.2 chr13 96924688 96950906 protein coding + Gcnt4 
ENSMUSG00000097881.7 chr1 121087404 121178441 lincRNA + Celrr 
ENSMUSG00000099696.6 chr9 46913492 46927366 lincRNA + RP24-247B20.1 
ENSMUSG00000047992.10 chr18 84720241 84740436 protein coding + Fam69c 
ENSMUSG00000113186.1 chr13 44185759 44216487 lincRNA - RP24-496E14.1 
ENSMUSG00000049690.15 chr1 125913619 126830632 protein coding - Nckap5 
ENSMUSG00000051910.13 chr7 115470871 116038744 protein coding - Sox6 
ENSMUSG00000058488.7 chr5 150952606 150993817 protein coding + Kl 
ENSMUSG00000037490.5 chr10 22645010 22704285 protein coding + Slc2a12 
ENSMUSG00000026200.13 chr1 75199346 75210778 protein coding - Glb1l 
ENSMUSG00000029307.7 chr5 104202612 104214102 protein coding + Dmp1 
ENSMUSG00000060703.12 chr2 60251992 60284488 protein coding - Cd302 
ENSMUSG00000079057.4 chr8 45304943 45333216 protein coding - Cyp4v3 
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ENSMUSG00000055541.17 chr7 4003401 4063204 protein coding - Lair1 
ENSMUSG00000048747.14 chr4 97568132 97690736 protein coding - RP23-313O9.1 
ENSMUSG00000031111.16 chrX 49782535 49797749 protein coding - Igsf1 
ENSMUSG00000023259.16 chr9 108854036 108912558 protein coding + Slc26a6 
ENSMUSG00000029843.4 chr6 35267956 35308131 protein coding - Slc13a4 
ENSMUSG00000034361.10 chr8 94532989 94570531 protein coding + Cpne2 
ENSMUSG00000041540.16 chr6 143828424 144209568 protein coding - Sox5 
ENSMUSG00000063428.8 chr10 40630010 40674915 protein coding + Ddo 
ENSMUSG00000100009.6 chr1 98589516 98607384 lincRNA + RP24-62C22.1 
ENSMUSG00000044164.2 chr13 43615709 43670945 protein coding + Rnf182 
ENSMUSG00000036814.13 chr9 123634769 123678885 protein coding - Slc6a20a 
ENSMUSG00000040181.14 chr1 162829560 162866610 protein coding - Fmo1 
ENSMUSG00000031209.14 chrX 96455358 96574485 protein coding + Heph 
ENSMUSG00000056854.4 chrX 110814279 110817207 protein coding + Pou3f4 
ENSMUSG00000022665.14 chr16 45093611 45127924 protein coding + Ccdc80 
ENSMUSG00000051590.9 chr1 127815270 127855031 protein coding - Map3k19 
ENSMUSG00000061517.8 chr14 118233231 118237030 protein coding - Sox21 
ENSMUSG00000048424.17 chr15 8968425 9066551 protein coding + Ranbp3l 
ENSMUSG00000087574.1 chr11 88718644 88728893 lincRNA + RP23-393B19.1 
ENSMUSG00000064036.15 chr18 73859384 73879134 protein coding + Mro 
ENSMUSG00000020061.17 chr10 88518278 88605152 protein coding - Mybpc1 
ENSMUSG00000045608.7 chr15 95623562 95655960 protein coding - Dbx2 
ENSMUSG00000060445.11 chr2 178345292 178407685 protein coding - Sycp2 
ENSMUSG00000023800.15 chr17 3326572 3519397 protein coding + Tiam2 
ENSMUSG00000042096.15 chr5 114003702 114025682 protein coding + Dao 
ENSMUSG00000026077.15 chr1 39194211 39363236 protein coding + Npas2 
ENSMUSG00000000693.10 chr6 83034172 83052562 protein coding + Loxl3 
ENSMUSG00000023885.8 chr17 14665499 14694262 protein coding - Thbs2 
ENSMUSG00000114860.1 chr13 48239053 48262591 lincRNA - RP23-344L21.1 
ENSMUSG00000040146.9 chr9 21971526 21989446 protein coding - Rgl3 
ENSMUSG00000047419.5 chr13 93040712 93144724 protein coding - Cmya5 
ENSMUSG00000002459.17 chr1 4909575 5070285 protein coding - Rgs20 
ENSMUSG00000027661.4 chr2 165503786 165519917 protein coding + Slc2a10 
ENSMUSG00000041559.7 chr1 134037253 134048277 protein coding + Fmod 
ENSMUSG00000022388.14 chr15 88913897 88954410 protein coding - Ttll8 
ENSMUSG00000073988.13 chr4 20008006 20030785 protein coding + Ttpa 
ENSMUSG00000027765.6 chr3 61002794 61008982 protein coding + P2ry1 
ENSMUSG00000026471.14 chr1 155127877 155146783 protein coding - Mr1 
ENSMUSG00000044337.5 chr1 90203979 90216751 protein coding + Ackr3 
ENSMUSG00000039239.14 chr1 186622791 186705989 protein coding - Tgfb2 
ENSMUSG00000097867.1 chr16 24391611 24393588 lincRNA - Lppos 
ENSMUSG00000097789.2 chr7 84528953 84583531 protein coding + RP23-121N17.2 
ENSMUSG00000040841.5 chr7 19094593 19098549 protein coding + Six5 
ENSMUSG00000105352.4 chr5 64477013 64482465 lincRNA + RP23-195B3.5 
ENSMUSG00000112054.1 chr12 45466272 45546677 lincRNA + RP23-123J19.1 
ENSMUSG00000089840.1 chr14 57112505 57115883 protein coding - RP24-448F1.2 
ENSMUSG00000040147.14 chrX 16709281 16817366 protein coding - Maob 
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ENSMUSG00000052942.13 chr19 28258850 28680077 protein coding - Glis3 
ENSMUSG00000030108.14 chr6 121300226 121337733 protein coding + Slc6a13 
ENSMUSG00000111443.1 chr9 83346158 83353978 lincRNA + RP23-72A20.11 
ENSMUSG00000107815.1 chr7 3378120 3390080 lincRNA - RP23-449F12.6 
ENSMUSG00000027168.21 chr2 105668899 105697364 protein coding + Pax6 
ENSMUSG00000023249.15 chr9 106470321 106476949 protein coding - Parp3 
ENSMUSG00000032942.14 chr7 100472990 100486432 protein coding + Ucp3 
ENSMUSG00000028631.7 chr4 120696137 120747248 protein coding - Kcnq4 
ENSMUSG00000022949.9 chr16 92498133 92541243 protein coding + Clic6 
ENSMUSG00000108778.1 chr7 73185743 73189446 lincRNA + RP24-136L4.5 
ENSMUSG00000030771.17 chr7 112368307 112413106 protein coding + Micalc1 
ENSMUSG00000039410.16 chr4 154316124 154636866 protein coding - Prdm16 
ENSMUSG00000043631.8 chr13 49504809 49532789 protein coding + Ecm2 
ENSMUSG00000046688.14 chr3 127789804 127798389 protein coding + Tifa 
ENSMUSG00000100111.2 chr7 29568902 29573928 lincRNA - RP23-228M12.4 
ENSMUSG00000019789.9 chr10 30832358 30842801 protein coding - Hey2 
ENSMUSG00000031616.7 chr8 77663030 77724436 protein coding - Ednra 
ENSMUSG00000032744.4 chr4 123233555 123249875 protein coding + Heyl 
ENSMUSG00000036972.14 chr9 91368969 91389348 protein coding + Zic4 
ENSMUSG00000068428.6 chr16 26957235 26989974 protein coding - Gmnc 
ENSMUSG00000009614.16 chr2 27188392 27247266 protein coding - Sardh 
ENSMUSG00000000247.11 chr2 38339280 38369733 protein coding + Lhx2 
ENSMUSG00000031283.16 chrX 143285673 143394262 protein coding - Chrdl1 
ENSMUSG00000021848.16 chr14 48657676 48673819 protein coding - Otx2 
ENSMUSG00000019803.11 chr10 42561962 42583632 protein coding - Nr2e1 
ENSMUSG00000022219.10 chr14 55754049 55758458 protein coding - Cideb 
ENSMUSG00000025932.14 chr1 14168953 14310235 protein coding - Eya1 
ENSMUSG00000037686.6 chr12 112106678 112127559 protein coding + Aspg 
ENSMUSG00000033207.6 chr19 23302608 23448322 protein coding - Mamdc2 
ENSMUSG00000079495.2 chr6 85808023 85820954 protein coding - RP24-478I22.6 
ENSMUSG00000046618.7 chr2 38931977 38963753 protein coding + Olfml2a 
ENSMUSG00000070337.4 chr11 97332108 97352016 protein coding - Gpr179 
ENSMUSG00000024899.6 chr19 32620004 32667187 protein coding + Papss2 
ENSMUSG00000004872.15 chr1 78101266 78197134 protein coding - Pax3 
ENSMUSG00000022146.12 chr15 6813576 6874969 protein coding - Osmr 
ENSMUSG00000041272.11 chr4 6686352 6990799 protein coding - Tox 
ENSMUSG00000036292.14 chr16 43980349 44063345 protein coding - Gramd1c 
ENSMUSG00000075593.10 chr5 138264920 138272840 protein coding - Gal3st4 
ENSMUSG00000022383.13 chr15 85735563 85802819 protein coding + Ppara 
ENSMUSG00000028125.14 chr3 122044442 122180061 protein coding + Abca4 
ENSMUSG00000026674.9 chr1 169972306 170110561 protein coding - Ddr2 
ENSMUSG00000048108.13 chr6 116679062 116716913 protein coding - Tmem72 
ENSMUSG00000057143.15 chr7 104338753 104353362 protein coding - Trim12c 
ENSMUSG00000035948.13 chr10 106933516 107123668 protein coding - Acss3 




A.2 Oligodendrocyte Expressed Gene Set 
Supplementary Table 2. Oligodendrocyte Expressed Gene Set. Genes with the gene id, chromosome, start, stop, 
gene type, strand, and gene name. Each gene had at least 4-fold higher expression in all pairwise comparisons. 
Gene ID Chromosome Start Stop Type Strand Gene Name 
ENSMUSG00000031425.15 chrX 136822670 136839733 protein coding + Plp1 
ENSMUSG00000015090.13 chr2 25466708 25470046 protein coding - Ptgds 
ENSMUSG00000006651.8 chr7 30434981 30445535 protein coding - Aplp1 
ENSMUSG00000032554.15 chr9 103204000 103230444 protein coding - Trf 
ENSMUSG00000025203.5 chr19 44293675 44306864 protein coding + Scd2 
ENSMUSG00000037625.7 chr3 31149919 31164324 protein coding + Cldn11 
ENSMUSG00000036634.15 chr7 30899175 30914832 protein coding - Mag 
ENSMUSG00000027375.14 chr2 127633225 127656695 protein coding - Mal 
ENSMUSG00000022425.16 chr15 54838900 54920018 protein coding - Enpp2 
ENSMUSG00000076439.12 chr17 37010742 37023398 protein coding - Mog 
ENSMUSG00000006782.16 chr11 100574903 100581728 protein coding + Cnp 
ENSMUSG00000022548.14 chr16 31296191 31314808 protein coding - Apod 
ENSMUSG00000032854.12 chr3 125865270 125938619 protein coding - Ugt8a 
ENSMUSG00000026944.18 chr2 25428702 25448540 protein coding + Abca2 
ENSMUSG00000022044.14 chr14 66344303 66361680 protein coding + Stmn4 
ENSMUSG00000026879.14 chr2 35282379 35307892 protein coding + Gsn 
ENSMUSG00000022892.11 chr16 84949684 85173766 protein coding - App 
ENSMUSG00000068923.14 chr3 88744699 88775164 protein coding - Syt11 
ENSMUSG00000027858.13 chr3 102734528 102772292 protein coding + Tspan2 
ENSMUSG00000020331.9 chr10 79716633 79736108 protein coding + Hcn2 
ENSMUSG00000034714.9 chr11 114675430 114720977 protein coding + Ttyh2 
ENSMUSG00000033595.7 chr14 70530827 70538324 protein coding + Lgi3 
ENSMUSG00000031775.5 chr8 94674893 94696278 protein coding - Pllp 
ENSMUSG00000024597.10 chr18 57878677 57946821 protein coding + Slc12a2 
ENSMUSG00000030683.11 chr7 126950562 126970606 protein coding + Sez6l2 
ENSMUSG00000053024.14 chr1 132511781 132542939 protein coding - Cntn2 
ENSMUSG00000028399.18 chr4 75941237 76594299 protein coding - Ptprd 
ENSMUSG00000015714.11 chr3 95315083 95323599 protein coding + Cers2 
ENSMUSG00000041607.16 chr18 82475145 82585637 protein coding + Mbp 
ENSMUSG00000033579.16 chr8 111345140 111393824 protein coding - Fa2h 
ENSMUSG00000036503.13 chr3 57736061 57835233 protein coding + Rnf13 
ENSMUSG00000004894.10 chr3 88022060 88027478 protein coding - Hapln2 
ENSMUSG00000032412.8 chr9 96332654 96364442 protein coding - Atp1b3 
ENSMUSG00000039904.9 chr6 25665877 25690729 protein coding - Gpr37 
ENSMUSG00000026519.16 chr1 180942458 180975112 protein coding + Tmem63a 
ENSMUSG00000003934.5 chr11 69554091 69560205 protein coding - Efnb3 
ENSMUSG00000043448.13 chr11 59175567 59182826 protein coding - Gjc2 
ENSMUSG00000018171.9 chr11 86583864 86683836 protein coding - Vmp1 
ENSMUSG00000020486.18 chr11 87578423 87590539 protein coding + Sept4 
ENSMUSG00000048537.16 chr9 44686303 44735198 protein coding - Phldb1 
ENSMUSG00000073680.2 chr4 155781590 155785874 protein coding - Tmem88b 
ENSMUSG00000021703.9 chr13 92611090 92711947 protein coding + Serinc5 
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ENSMUSG00000003534.17 chr17 35681566 35704599 protein coding - Ddr1 
ENSMUSG00000040759.9 chr14 54936260 54939273 protein coding + Cmtm5 
ENSMUSG00000031990.15 chr9 27097383 27155393 protein coding - Jam3 
ENSMUSG00000061451.13 chr19 5079329 5085531 protein coding - Tmem151a 
ENSMUSG00000034488.14 chr13 88821471 89323223 protein coding + Edil3 
ENSMUSG00000068747.14 chr3 108284081 108361511 protein coding + Sort1 
ENSMUSG00000037419.9 chr9 14353989 14381242 protein coding - Endod1 
ENSMUSG00000024516.12 chr18 65800548 65817665 protein coding + Sec11c 
ENSMUSG00000019087.13 chrX 74297096 74304721 protein coding + Atp6ap1 
ENSMUSG00000047797.14 chrX 101383735 101385629 protein coding + Gjb1 
ENSMUSG00000001833.17 chr9 25252438 25308571 protein coding + Sept7 
ENSMUSG00000020811.16 chr11 71750979 71789647 protein coding + Wscd1 
ENSMUSG00000045087.8 chr9 21242911 21248443 protein coding - S1pr5 
ENSMUSG00000020376.16 chr11 50025345 50104758 protein coding + Rnf130 
ENSMUSG00000081534.3 chr15 97784354 97792692 protein coding + Slc48a1 
ENSMUSG00000025375.15 chr11 120007312 120047145 protein coding - Aatk 
ENSMUSG00000030849.18 chr7 130162450 130266263 protein coding - Fgfr2 
ENSMUSG00000024413.13 chr18 12189692 12236400 protein coding - Npc1 
ENSMUSG00000050121.8 chr19 41062473 41077113 protein coding - Opalin 
ENSMUSG00000033904.16 chr7 118712551 118737024 protein coding + Ccp110 
ENSMUSG00000020099.8 chr10 60762592 60831581 protein coding - Unc5b 
ENSMUSG00000078771.10 chr11 79526559 79530609 protein coding - Evi2a 
ENSMUSG00000029426.8 chr5 92441313 92505637 protein coding - Scarb2 
ENSMUSG00000028412.17 chr4 53440412 53622478 protein coding + Slc44a1 
ENSMUSG00000023827.8 chr17 12119283 12219645 protein coding + Agpat4 
ENSMUSG00000027215.13 chr2 93419110 93462502 protein coding - Cd82 
ENSMUSG00000037685.15 chr5 67618139 67847434 protein coding - Atp8a1 
ENSMUSG00000036098.15 chr19 10208271 10240748 protein coding - Myrf 
ENSMUSG00000046160.6 chr16 91269771 91271933 protein coding + Olig1 
ENSMUSG00000020841.5 chr11 76778423 76847018 protein coding - Cpd 
ENSMUSG00000062591.5 chr17 57080065 57087782 protein coding - Tubb4a 
ENSMUSG00000054364.5 chr12 8497660 8500009 protein coding - Rhob 
ENSMUSG00000034648.9 chr6 107529767 107570214 protein coding + Lrrn1 
ENSMUSG00000027199.14 chr2 122594466 122611303 protein coding - Gatm 
ENSMUSG00000032135.15 chr9 44134561 44142727 protein coding + Mcam 
ENSMUSG00000053475.5 chr2 52038008 52056686 protein coding + Tnfaip6 
ENSMUSG00000038077.7 chr6 126708331 126740674 protein coding - Kcna6 
ENSMUSG00000027674.16 chr3 32949407 33143082 protein coding - Pex5l 
ENSMUSG00000026442.14 chr1 132564689 132741797 protein coding - Nfasc 
ENSMUSG00000026109.14 chr1 50927518 51187270 protein coding + Tmeff2 
ENSMUSG00000037996.17 chr4 86983123 87230477 protein coding - Slc24a2 
ENSMUSG00000027298.17 chr2 119797732 119818104 protein coding + Tyro3 
ENSMUSG00000037280.12 chr15 100691812 100729376 protein coding - Galnt6 
ENSMUSG00000091735.2 chr9 106463961 106465938 protein coding - Gpr62 
ENSMUSG00000020604.13 chr11 109473373 109573330 protein coding + Arsg 
ENSMUSG00000035413.8 chr11 80810174 80822033 protein coding + Tmem98 
ENSMUSG00000074794.10 chr13 80883409 80896042 protein coding + Arrdc3 
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ENSMUSG00000041889.7 chr1 135371056 135375237 protein coding - Shisa4 
ENSMUSG00000038936.13 chr1 179668209 179687189 protein coding + Sccpdh 
ENSMUSG00000056966.7 chr5 137953460 137963098 protein coding - Gjc3 
ENSMUSG00000051041.7 chr7 107567445 107591094 protein coding + Olfml1 
ENSMUSG00000027562.12 chr3 14886427 14900770 protein coding + Car2 
ENSMUSG00000038668.14 chr4 58435254 58553553 protein coding - Lpar1 
ENSMUSG00000006403.13 chr1 171250420 171260637 protein coding + Adamts4 
ENSMUSG00000043067.15 chr9 24411775 24503140 protein coding - Dpy19l1 
ENSMUSG00000100147.2 chr1 182287989 182303325 lincRNA + RP24-131B6.1 
ENSMUSG00000006390.15 chr4 118428092 118432953 protein coding + Elovl1 
ENSMUSG00000038526.14 chr3 95897767 95904691 protein coding - Car14 
ENSMUSG00000066129.15 chr7 139894838 139914452 protein coding + Kndc1 
ENSMUSG00000036985.12 chrX 48171968 48208687 protein coding - Zdhhc9 
ENSMUSG00000023961.16 chr17 44096307 44105809 protein coding - Enpp4 
ENSMUSG00000051022.7 chr5 39613938 39644634 protein coding - Hs3st1 
ENSMUSG00000018166.8 chr10 128567522 128589652 protein coding - Erbb3 
ENSMUSG00000073982.11 chr7 102239122 102250123 protein coding - Rhog 
ENSMUSG00000022744.12 chr16 58727909 58734251 protein coding + Cldnd1 
ENSMUSG00000038695.13 chr7 44467979 44471662 protein coding + Josd2 
ENSMUSG00000020774.9 chr11 73304991 73329596 protein coding - Aspa 
ENSMUSG00000036529.17 chr15 89288235 89315311 protein coding - Sbf1 
ENSMUSG00000032517.16 chr9 120149706 120176091 protein coding + Mobp 
ENSMUSG00000022514.14 chr16 26581703 26725264 protein coding + Il1rap 
ENSMUSG00000038608.15 chr1 80501072 80758448 protein coding - Dock10 
ENSMUSG00000024030.6 chr17 31057697 31115777 protein coding + Abcg1 
ENSMUSG00000026830.9 chr2 58045112 58052864 protein coding - Ermn 
ENSMUSG00000074892.9 chr16 96280797 96319857 protein coding + B3galt5 
ENSMUSG00000041309.17 chr7 139581219 139582790 protein coding - Nkx6-2 
ENSMUSG00000050854.9 chr4 118540940 118543728 protein coding - Tmem125 
ENSMUSG00000019996.17 chr10 20148470 20281590 protein coding + Map7 
ENSMUSG00000019055.15 chr4 147909752 147936767 protein coding - Plod1 
ENSMUSG00000028962.14 chr5 24425231 24440950 protein coding + Slc4a2 
ENSMUSG00000046324.12 chr19 29608213 29648415 protein coding - Ermp1 
ENSMUSG00000021709.14 chr13 103818786 103920514 protein coding - Erbb2ip 
ENSMUSG00000040447.15 chr11 72451637 72489904 protein coding - Spns2 
ENSMUSG00000021573.15 chr13 74009418 74035753 protein coding + Tppp 
ENSMUSG00000020570.15 chr12 32953890 32979860 protein coding + Sypl 
ENSMUSG00000078532.9 chr4 130531617 130574173 protein coding - Nkain1 
ENSMUSG00000038264.8 chr9 57940112 57962865 protein coding + Sema7a 
ENSMUSG00000090213.1 chr2 167642607 167661556 protein coding - Tmem189 
ENSMUSG00000068290.11 chr2 130653959 130664659 protein coding - Ddrgk1 
ENSMUSG00000015850.11 chr3 95676200 95687917 protein coding - Adamtsl4 
ENSMUSG00000022270.16 chr15 25843179 25973687 protein coding + Retreg1 
ENSMUSG00000022742.5 chr16 58670207 58680391 protein coding + Cpox 
ENSMUSG00000037031.10 chr10 62185395 62231251 protein coding - Tspan15 
ENSMUSG00000042682.9 chr14 29968307 29975662 protein coding + Selk 
ENSMUSG00000069808.13 chr11 76202014 76209416 protein coding + Fam57a 
156 
 
ENSMUSG00000049807.16 chr11 97450159 97502400 protein coding + Arhgap23 
ENSMUSG00000021696.9 chr13 108214403 108285683 protein coding + Elovl7 
ENSMUSG00000021451.16 chr13 51701245 51793747 protein coding - Sema4d 
ENSMUSG00000050063.18 chr7 43824498 43832030 protein coding + Klk6 
ENSMUSG00000060716.7 chr12 79029162 79081655 protein coding + Plekhh1 
ENSMUSG00000024924.14 chr19 27217019 27254231 protein coding + Vldlr 
ENSMUSG00000030064.16 chr6 97286866 97617541 protein coding - Frmd4b 
ENSMUSG00000031385.14 chrX 73757098 73772514 protein coding + Plxnb3 
ENSMUSG00000091712.2 chr16 5147108 5187271 protein coding + Sec14l5 
ENSMUSG00000048707.9 chr2 25262617 25269885 protein coding + Tprn 
ENSMUSG00000041762.16 chr2 73341505 73386572 protein coding - Gpr155 
ENSMUSG00000004631.15 chr6 4674349 4747207 protein coding - Sgce 
ENSMUSG00000006301.17 chr1 74288246 74304405 protein coding - Tmbim1 
ENSMUSG00000017802.14 chr11 101096321 101119893 protein coding - Fam134c 
ENSMUSG00000047037.5 chr7 55977566 56019954 protein coding - Nipa1 
ENSMUSG00000028059.15 chr3 88616516 88648052 protein coding + Arhgef2 
ENSMUSG00000032086.12 chr9 45838579 45864399 protein coding + Bace1 
ENSMUSG00000020231.15 chr10 76262735 76345291 protein coding - Dip2a 
ENSMUSG00000045404.16 chr12 99964498 100062682 protein coding + Kcnk13 
ENSMUSG00000019647.16 chr18 47245253 47368868 protein coding - Sema6a 
ENSMUSG00000014496.8 chr14 31698767 31830651 protein coding - Ankrd28 
ENSMUSG00000034586.14 chr11 115347706 115367756 protein coding - Hid1 
ENSMUSG00000045625.4 chr16 31933850 31946046 protein coding + Pigz 
ENSMUSG00000040268.17 chr7 130865897 130913302 protein coding + Plekha1 
ENSMUSG00000035235.13 chr14 61598246 61605946 protein coding + Trim13 
ENSMUSG00000033006.10 chr15 79154907 79165240 protein coding - Sox10 
ENSMUSG00000026748.13 chr2 16356303 16755839 protein coding + Plxdc2 
ENSMUSG00000044734.16 chr13 32842091 32851185 protein coding - Serpinb1a 
ENSMUSG00000005125.13 chr15 66929317 66969640 protein coding - Ndrg1 
ENSMUSG00000055717.13 chr14 103650227 103704907 protein coding + Slain1 
ENSMUSG00000017734.15 chr2 164486454 164493319 protein coding + Dbndd2 
ENSMUSG00000030616.15 chr7 90348698 90410439 protein coding + Sytl2 
ENSMUSG00000037166.5 chr7 29289307 29293801 protein coding + Ppp1r14a 
ENSMUSG00000001065.15 chr8 123254194 123269745 protein coding + Zfp276 
ENSMUSG00000029416.17 chr5 127595663 127617416 protein coding - Slc15a4 
ENSMUSG00000070639.5 chr5 105415774 105490074 protein coding + Lrrc8b 
ENSMUSG00000041205.7 chr16 20233309 20241358 protein coding - Map6d1 
ENSMUSG00000038173.15 chr8 46986886 47096762 protein coding + Enpp6 
ENSMUSG00000057614.6 chr5 18265134 18360355 protein coding - Gnai1 
ENSMUSG00000043456.16 chr7 37479103 37769962 protein coding - Zfp536 
ENSMUSG00000020183.11 chr10 117629499 117687352 protein coding + Cpm 
ENSMUSG00000021830.14 chr14 45133464 45220328 protein coding - Txndc16 
ENSMUSG00000044788.10 chr11 115279621 115297514 protein coding - Fads6 
ENSMUSG00000018167.10 chr11 98358367 98381099 protein coding + Stard3 
ENSMUSG00000019806.13 chr10 13647053 13868980 protein coding - Aig1 
ENSMUSG00000031918.16 chr9 13748409 13806481 protein coding + Mtmr2 
ENSMUSG00000060012.9 chr14 64652530 64809617 protein coding + Kif13b 
157 
 
ENSMUSG00000026170.6 chr1 74713573 74737892 protein coding + Cyp27a1 
ENSMUSG00000071176.10 chr8 14911662 15001085 protein coding + Arhgef10 
ENSMUSG00000032060.10 chr9 50751324 50756636 protein coding + Cryab 
ENSMUSG00000049439.13 chr1 60343322 60388060 protein coding + Cyp20a1 
ENSMUSG00000034265.7 chr17 5492599 5753891 protein coding + Zdhhc14 
ENSMUSG00000030747.5 chr7 99153657 99182719 protein coding - Dgat2 
ENSMUSG00000032537.15 chr9 101922127 102354693 protein coding - Ephb1 
ENSMUSG00000031605.8 chr8 64739674 64850017 protein coding - Klhl2 
ENSMUSG00000049721.14 chr11 3983635 3999326 protein coding + Gal3st1 
ENSMUSG00000064325.4 chr8 79965852 80058006 protein coding - Hhip 
ENSMUSG00000006931.15 chr11 100408455 100414836 protein coding - P3h4 
ENSMUSG00000069920.10 chr8 105252637 105255153 protein coding - B3gnt9 
ENSMUSG00000037754.13 chr2 158666732 158766334 protein coding + Ppp1r16b 
ENSMUSG00000031833.10 chr8 70778116 70796988 protein coding - Mast3 
ENSMUSG00000111994.1 chr10 72973302 73086705 lincRNA - RP23-291O3.1 
ENSMUSG00000018427.7 chr11 86936424 86993707 protein coding - Ypel2 
ENSMUSG00000020411.2 chr11 46148154 46166508 protein coding - Nipal4 
ENSMUSG00000028525.16 chr4 102254741 102607259 protein coding + Pde4b 
ENSMUSG00000032763.11 chr10 78574499 78584502 protein coding + Ilvbl 
ENSMUSG00000055945.7 chr17 8340738 8344112 protein coding + Prr18 
ENSMUSG00000030685.5 chr7 126928878 126945631 protein coding + Kctd13 
ENSMUSG00000029832.16 chr6 51432669 51458768 protein coding + Nfe2l3 
ENSMUSG00000020023.18 chr10 94514856 94590956 protein coding + Tmcc3 
ENSMUSG00000029592.11 chr5 114100314 114124720 protein coding + Usp30 
ENSMUSG00000052609.9 chr12 76533379 76579042 protein coding + Plekhg3 
ENSMUSG00000013523.13 chr2 170346990 170427845 protein coding - Bcas1 
ENSMUSG00000047996.16 chrX 78449612 78583896 protein coding - Prrg1 
ENSMUSG00000023805.16 chr17 5941279 6044290 protein coding + Synj2 
ENSMUSG00000024810.16 chr19 29925113 29960718 protein coding + Il33 
ENSMUSG00000069670.8 chr10 31689309 32890462 protein coding - Nkain2 
ENSMUSG00000026203.16 chr1 75236464 75245690 protein coding + Dnajb2 
ENSMUSG00000108569.1 chr7 134498190 134501160 lincRNA - RP23-44H21.1 
ENSMUSG00000038349.10 chr1 55405920 55754285 protein coding + Plcl1 
ENSMUSG00000039157.12 chr2 32535358 32569756 protein coding + Fam102a 
ENSMUSG00000049493.13 chr9 95752641 95845286 protein coding - Pls1 
ENSMUSG00000020758.15 chr11 115974708 116008412 protein coding + Itgb4 
ENSMUSG00000030701.17 chr7 100642891 100662414 protein coding - Plekhb1 
ENSMUSG00000075289.4 chr19 4164323 4175479 protein coding - Carns1 
ENSMUSG00000026447.16 chr1 133046011 133108687 protein coding + Pik3c2b 
ENSMUSG00000025584.17 chr7 81213595 81334533 protein coding + Pde8a 
ENSMUSG00000027792.11 chr3 73635807 73708415 protein coding - Bche 
ENSMUSG00000026317.7 chr8 14888110 14901720 protein coding + Cln8 
ENSMUSG00000034930.16 chr6 83137088 83152579 protein coding + Rtkn 
ENSMUSG00000074457.10 chr3 90537253 90543151 protein coding + S100a16 
ENSMUSG00000001786.14 chr10 86021971 86051873 protein coding + Fbxo7 
ENSMUSG00000110027.1 chr7 136268331 136282140 lincRNA + RP24-163K4.1 
ENSMUSG00000022602.14 chr15 74669082 74672570 protein coding - Arc 
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ENSMUSG00000075254.11 chr16 33684465 33771576 protein coding + Heg1 
ENSMUSG00000112168.1 chr10 72940237 72949792 lincRNA - RP23-291O3.2 
ENSMUSG00000038495.14 chr3 96104526 96161129 protein coding + Otud7b 
ENSMUSG00000043298.8 chr6 136829926 136835452 protein coding - Smco3 
ENSMUSG00000034839.5 chr9 60712988 60738801 protein coding + Larp6 
ENSMUSG00000073468.11 chr17 8311101 8327442 protein coding + Sft2d1 
ENSMUSG00000002910.11 chr8 70835128 70839720 protein coding - Arrdc2 
ENSMUSG00000037578.4 chr19 44147636 44192442 protein coding - Pkd2l1 
ENSMUSG00000032766.9 chr6 4003903 4008445 protein coding + Gng11 
ENSMUSG00000032087.10 chr9 45430290 45753712 protein coding + Dscaml1 
ENSMUSG00000018796.13 chr8 46471036 46536051 protein coding + Acsl1 
ENSMUSG00000045664.4 chr19 5917555 5924816 protein coding - Cdc42ep2 
ENSMUSG00000046523.5 chr14 75955008 75966206 protein coding + Kctd4 
ENSMUSG00000020696.18 chr11 82802448 82871210 protein coding - Rffl 
ENSMUSG00000024053.10 chr17 71252175 71310965 protein coding - Emilin2 
ENSMUSG00000066113.16 chr4 86053914 86428385 protein coding + Adamtsl1 
ENSMUSG00000033740.17 chr1 6487230 6860940 protein coding + St18 
ENSMUSG00000042066.15 chr1 132356314 132391281 protein coding - Tmcc2 
ENSMUSG00000034936.2 chr11 101665540 101667832 protein coding + Arl4d 
ENSMUSG00000052544.9 chr3 153198265 153725174 protein coding - St6galnac3 
ENSMUSG00000038871.5 chr6 34476206 34505613 protein coding + Bpgm 
ENSMUSG00000026888.14 chr2 64912475 65022782 protein coding - Grb14 
ENSMUSG00000011148.14 chr12 112620044 112641360 protein coding + Adssl1 
ENSMUSG00000029999.14 chr6 86195222 86275719 protein coding + Tgfa 
ENSMUSG00000027956.11 chr3 79812563 79842679 protein coding - Tmem144 
ENSMUSG00000022766.13 chr16 17331370 17343572 protein coding + Serpind1 
ENSMUSG00000035441.14 chr11 80482125 80780025 protein coding - Myo1d 
ENSMUSG00000086006.2 chr2 11339487 11344111 lincRNA + RP23-291L24.2 
ENSMUSG00000048782.15 chr7 114745765 114850380 protein coding + Insc 
ENSMUSG00000032841.15 chr2 101714284 101838980 protein coding - Prr5l 
ENSMUSG00000028995.14 chr5 23915276 24030690 protein coding - Fam126a 
ENSMUSG00000015354.8 chr9 95637600 95698096 protein coding + Pcolce2 
ENSMUSG00000041695.2 chr11 111066163 111076821 protein coding + Kcnj2 
ENSMUSG00000060843.11 chr10 63430097 65003667 protein coding + Ctnna3 
ENSMUSG00000026435.15 chr1 131962966 131982969 protein coding + Slc45a3 
ENSMUSG00000030788.16 chr7 110815145 110844402 protein coding - Rnf141 
ENSMUSG00000038732.15 chr13 30136488 30246717 protein coding + Mboat1 
ENSMUSG00000035493.10 chr13 56609585 56639358 protein coding + Tgfbi 
ENSMUSG00000027954.9 chr3 89271732 89281142 protein coding - Efna1 
ENSMUSG00000022604.18 chr16 55899887 55934855 protein coding - Cep97 
ENSMUSG00000029602.11 chr5 120648821 120679597 protein coding + Rasal1 
ENSMUSG00000010175.13 chr1 190118034 190170714 protein coding - Prox1 
ENSMUSG00000004035.12 chr3 107926333 107931817 protein coding - Gstm7 
ENSMUSG00000030994.15 chr7 134265778 134376828 protein coding - RP23-445H7.1 
ENSMUSG00000025597.13 chrX 114474332 114560829 protein coding + Klhl4 
ENSMUSG00000039913.12 chr2 136081103 136387960 protein coding - Pak7 
ENSMUSG00000039384.8 chr1 184034380 184075636 protein coding + Dusp10 
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ENSMUSG00000026121.13 chr1 36548638 36558349 protein coding - Sema4c 
ENSMUSG00000039328.11 chr8 31111819 31131482 protein coding + Rnf122 
ENSMUSG00000041377.12 chr6 120093349 120200339 protein coding + Ninj2 
ENSMUSG00000033192.5 chr8 92855338 92919279 protein coding + Lpcat2 
ENSMUSG00000096948.1 chr18 54990309 55079414 lincRNA + Gm4221 
ENSMUSG00000105891.4 chr3 102262404 102445132 lincRNA + RP23-63A19.1 
ENSMUSG00000081225.3 chr4 96099572 96141138 protein coding - Cyp2j12 
ENSMUSG00000030255.13 chr6 145931640 145965223 protein coding + Sspn 
ENSMUSG00000020150.13 chr10 80258150 80261012 protein coding - Gamt 
ENSMUSG00000038463.8 chr1 170644531 170682789 protein coding + Olfml2b 
ENSMUSG00000106317.1 chr3 105725900 105727147 lincRNA - RP24-500I24.6 
ENSMUSG00000074591.7 chr3 57664634 57692537 protein coding - Ankub1 
ENSMUSG00000033032.15 chr18 61730260 61786702 protein coding - Afap1l1 
ENSMUSG00000036908.16 chr19 3935185 3949340 protein coding + Unc93b1 
ENSMUSG00000027931.12 chr3 90450590 90465866 protein coding - Npr1 
ENSMUSG00000036545.8 chr11 50602083 50807573 protein coding + Adamts2 
ENSMUSG00000038642.10 chr3 95526785 95556403 protein coding + Ctss 
ENSMUSG00000063445.14 chr16 4710058 4719356 protein coding - Nmral1 
ENSMUSG00000002007.5 chrX 73774404 73778925 protein coding + Srpk3 
ENSMUSG00000037370.13 chr10 24637913 24712158 protein coding - Enpp1 
ENSMUSG00000015966.17 chr14 29996134 30008896 protein coding - Il17rb 
ENSMUSG00000022090.10 chr14 70164217 70177681 protein coding - Pdlim2 
ENSMUSG00000022639.14 chr16 50719293 50732773 lincRNA - Dubr 
ENSMUSG00000039529.8 chr18 64528978 64661000 protein coding - Atp8b1 
ENSMUSG00000039911.13 chr4 149896282 149955043 protein coding - Spsb1 
ENSMUSG00000029727.7 chr5 137892931 137921619 protein coding - Cyp3a13 
ENSMUSG00000079304.5 chr6 128375455 128385144 protein coding + RP23-114E15.3 
ENSMUSG00000030638.13 chr7 82173839 82307419 protein coding + Sh3gl3 
ENSMUSG00000055415.7 chr11 43151598 43262285 protein coding + Atp10b 
ENSMUSG00000056220.14 chr1 149829617 149961290 protein coding - Pla2g4a 
ENSMUSG00000071042.11 chr17 75435904 75529043 protein coding + Rasgrp3 
ENSMUSG00000044749.13 chr11 110176819 110251776 protein coding - Abca6 
ENSMUSG00000039316.14 chr17 49992256 50190674 protein coding - Rftn1 
ENSMUSG00000045629.7 chr18 61953074 62015715 protein coding + Sh3tc2 
ENSMUSG00000025429.8 chr18 77794544 77882007 protein coding + Pstpip2 
ENSMUSG00000022358.7 chr15 58175878 58214932 protein coding - Fbxo32 
ENSMUSG00000037946.11 chr13 49261553 49320311 protein coding - Fgd3 
ENSMUSG00000014198.15 chr11 100627542 100650693 protein coding - Zfp385c 
ENSMUSG00000041930.7 chr5 114568015 114613220 protein coding + Fam222a 
ENSMUSG00000026778.13 chr2 11172107 11301222 protein coding + Prkcq 
ENSMUSG00000030917.13 chr7 120102352 120120992 protein coding + Tmem159 
ENSMUSG00000018387.12 chr11 53457204 53467766 protein coding + Shroom1 
ENSMUSG00000024818.14 chr19 5877816 5885766 protein coding + Slc25a45 
ENSMUSG00000026418.16 chr1 135799401 135810989 protein coding + Tnni1 
ENSMUSG00000057337.13 chr10 60181531 60219260 protein coding - Chst3 
ENSMUSG00000015970.19 chr14 30009022 30040527 protein coding + Chdh 
ENSMUSG00000024395.8 chr18 31931324 31958619 protein coding + Lims2 
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ENSMUSG00000041460.14 chr6 119236525 119352407 protein coding + Cacna2d4 
ENSMUSG00000069899.3 chr11 46051353 46052311 protein coding - RP23-29H5.3 
ENSMUSG00000111110.1 chr9 43506550 43521004 lincRNA - RP23-421M6.1 
ENSMUSG00000054520.15 chr5 34525845 34563641 protein coding + Sh3bp2 
ENSMUSG00000110205.1 chr2 57982191 57986017 lincRNA - RP23-441D24.1 
ENSMUSG00000000791.9 chr8 70808448 70821424 protein coding + Il12rb1 
ENSMUSG00000017868.16 chr2 162987329 163014127 protein coding + Sgk2 
ENSMUSG00000097783.2 chr8 121421237 121428043 lincRNA + RP23-76C13.2 
ENSMUSG00000032265.14 chr9 85320438 85327348 protein coding - Fam46a 
ENSMUSG00000023267.10 chr4 33062998 33095865 protein coding + Gabrr2 
ENSMUSG00000031661.12 chr8 88521353 88594884 protein coding + Nkd1 
ENSMUSG00000044519.8 chr14 33967069 33978764 protein coding - Zfp488 
ENSMUSG00000034177.15 chr11 87663086 87735539 protein coding + Rnf43 
ENSMUSG00000054150.12 chr12 104929932 105009809 protein coding - Syne3 
ENSMUSG00000045954.7 chr1 51289125 51302960 protein coding + Sdpr 
ENSMUSG00000027358.6 chr2 133552158 133562885 protein coding + Bmp2 
ENSMUSG00000025727.8 chr17 25946386 25952565 protein coding - RP23-356J2.6 
ENSMUSG00000105966.1 chr3 102369161 102370937 lincRNA + RP24-409P22.1 
ENSMUSG00000006784.14 chr11 100545606 100572568 protein coding + Ttc25 
ENSMUSG00000112112.1 chr12 45094011 45162048 lincRNA + RP23-390F4.1 
ENSMUSG00000113088.1 chr12 111950516 111954152 lincRNA + RP23-123N23.4 
ENSMUSG00000030406.7 chr7 19156060 19166127 protein coding - Gipr 
ENSMUSG00000020689.4 chr11 104607999 104670476 protein coding + Itgb3 
ENSMUSG00000109598.1 chr7 135486028 135491315 lincRNA + RP23-226C6.3 
ENSMUSG00000026736.1 chr2 18998342 18999801 protein coding + 4930426L09Rik 
ENSMUSG00000032380.8 chr9 66158222 66272242 protein coding + Dapk2 
ENSMUSG00000023999.14 chr17 49615171 49909847 protein coding + Kif6 
ENSMUSG00000024885.8 chr19 3913492 3929761 protein coding - Aldh3b1 
ENSMUSG00000060284.7 chr15 102356605 102366968 protein coding - Sp7 
ENSMUSG00000029797.13 chr6 48448228 48501250 protein coding + Sspo 
ENSMUSG00000047515.8 chr6 136828842 136840662 protein coding + RP23-296J10.4 
ENSMUSG00000097405.1 chr17 25951471 25963610 protein coding + D630044L22Rik 
ENSMUSG00000087116.1 chr11 71647075 71658477 lincRNA - RP23-73C1.1 




A.3 Motor Neuron Expressed Gene Set 
Supplementary Table 3. Motor Neuron Expressed Gene Set. Genes with the gene id, chromosome, start, stop, 
gene type, strand, and gene name. Each gene had at least 4-fold higher expression in all pairwise comparisons. 
Gene ID Chromosome Start Stop Type Strand Gene Name 
ENSMUSG00000044349.15 chr2 158375637 158386145 protein coding + Snhg11 
ENSMUSG00000021268.17 chr12 109541004 109571726 lincRNA + Meg3 
ENSMUSG00000097767.8 chr5 112213227 112229395 lincRNA - Miat 
ENSMUSG00000100241.1 chr14 32462437 32464850 protein coding - Slc18a3 
ENSMUSG00000098061.1 chr12 109640340 109642351 lincRNA + RP23-204I16.2 
ENSMUSG00000023328.14 chr5 137288276 137294466 protein coding + Ache 
ENSMUSG00000033061.15 chr1 75272198 75278415 protein coding - Resp18 
ENSMUSG00000045573.9 chr4 4133530 4138477 protein coding - Penk 
ENSMUSG00000022054.11 chr14 68082589 68124846 protein coding - Nefm 
ENSMUSG00000022055.7 chr14 68083862 68089095 protein coding + Nefl 
ENSMUSG00000039126.10 chr19 16956117 17223932 protein coding + Prune2 
ENSMUSG00000097391.8 chr12 109729763 109749460 lincRNA + Mirg 
ENSMUSG00000033152.13 chr6 88842564 88875044 protein coding - Podxl2 
ENSMUSG00000087620.7 chrX 105348281 105391776 lincRNA - RP23-316B4.2 
ENSMUSG00000040035.14 chr2 118779718 118811293 protein coding + Disp2 
ENSMUSG00000023945.6 chr17 54273593 54299034 protein coding - Slc5a7 
ENSMUSG00000023484.14 chr15 99055173 99058978 protein coding + Prph 
ENSMUSG00000020396.8 chr11 4938753 4948064 protein coding - Nefh 
ENSMUSG00000016346.17 chr2 181075578 181135300 protein coding - Kcnq2 
ENSMUSG00000031644.19 chr8 60993194 61131346 protein coding + Nek1 
ENSMUSG00000020836.15 chr11 77462410 77470484 protein coding + Coro6 
ENSMUSG00000097736.8 chr9 122572498 122678965 lincRNA + RP23-361B11.2 
ENSMUSG00000041837.4 chr9 65346103 65359643 protein coding + Pdcd7 
ENSMUSG00000030500.6 chr7 51622005 51671119 protein coding + Slc17a6 
ENSMUSG00000031558.15 chr5 47983137 48307733 protein coding + Slit2 
ENSMUSG00000026452.15 chr1 134646680 134753149 protein coding + Syt2 
ENSMUSG00000059540.15 chr2 181680309 181688071 protein coding + Tcea2 
ENSMUSG00000026247.13 chr1 87147654 87156521 protein coding - Ecel1 
ENSMUSG00000110710.1 chr8 94322157 94328100 lincRNA + RP24-263E2.3 
ENSMUSG00000000263.15 chr11 55514237 55608198 protein coding - Glra1 
ENSMUSG00000098202.1 chr12 109695585 109702587 lincRNA + RP23-378G4.2 
ENSMUSG00000052581.13 chr6 80018876 80810143 protein coding + Lrrtm4 
ENSMUSG00000008489.18 chr4 91250762 91376496 protein coding - Elavl2 
ENSMUSG00000052852.8 chr6 71707560 71810710 protein coding + Reep1 
ENSMUSG00000104178.1 chr3 118434769 118435997 lincRNA + RP23-14P23.3 
ENSMUSG00000030110.13 chr6 118151744 118197718 protein coding - Ret 
ENSMUSG00000072812.4 chr12 112772433 112775254 protein coding - Ahnak2 
ENSMUSG00000022212.15 chr14 55510444 55517431 protein coding + Cpne6 
ENSMUSG00000040867.12 chr12 109032186 109068217 protein coding - Begain 
ENSMUSG00000046613.18 chr16 20591155 20605374 protein coding + Vwa5b2 
ENSMUSG00000025272.16 chrX 150645303 150657583 protein coding - Tro 
ENSMUSG00000004113.18 chr2 24603886 24763152 protein coding - Cacna1b 
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ENSMUSG00000086228.2 chr9 65361060 65380377 protein coding + Ubap1l 
ENSMUSG00000036760.7 chr15 72501088 72546340 protein coding - Kcnk9 
ENSMUSG00000056427.10 chr11 35121223 35708507 protein coding + Slit3 
ENSMUSG00000021647.7 chr13 99898488 99901091 protein coding - Cartpt 
ENSMUSG00000021919.8 chr14 32408202 32465957 protein coding - Chat 
ENSMUSG00000022842.17 chr16 20629827 20646476 protein coding + Ece2 
ENSMUSG00000028906.16 chr4 131923412 132075292 protein coding - Epb41 
ENSMUSG00000051111.16 chr13 95954593 96132577 protein coding - Sv2c 
ENSMUSG00000036502.14 chrX 38196572 38252439 protein coding - Tmem255a 
ENSMUSG00000006930.15 chr11 100347326 100356128 protein coding - Hap1 
ENSMUSG00000053693.16 chr8 84911902 84937359 protein coding - Mast1 
ENSMUSG00000025020.11 chr19 41600256 41743665 protein coding - Slit1 
ENSMUSG00000115293.1 chr16 20611600 20645915 protein coding + RP23-101H1.18 
ENSMUSG00000069072.9 chr3 31202857 31310378 protein coding - Slc7a14 
ENSMUSG00000057378.15 chr2 112631354 113217087 protein coding - Ryr3 
ENSMUSG00000050272.9 chr16 96592078 97170752 protein coding - Dscam 
ENSMUSG00000062991.7 chr8 31814550 32884029 protein coding - Nrg1 
ENSMUSG00000044024.15 chr18 37955138 37959179 protein coding + Rell2 
ENSMUSG00000043843.16 chr7 25306107 25316195 protein coding + Tmem145 
ENSMUSG00000024186.15 chr17 26202957 26211324 protein coding + Rgs11 
ENSMUSG00000006342.15 chr10 75636705 75643991 protein coding - Susd2 
ENSMUSG00000115956.1 chr2 74721977 74729160 protein coding + Hoxd4 
ENSMUSG00000040258.6 chr10 127525472 127534559 protein coding - Nxph4 
ENSMUSG00000024256.6 chr17 93199421 93205485 protein coding + Adcyap1 
ENSMUSG00000030000.10 chr6 86028703 86124409 protein coding + Add2 
ENSMUSG00000034059.13 chr2 84734057 84738655 protein coding + Ypel4 
ENSMUSG00000027584.16 chr2 181715015 181720985 protein coding + Oprl1 
ENSMUSG00000027966.20 chr3 114030539 114220718 protein coding + Col11a1 
ENSMUSG00000045613.9 chr6 36388083 36528414 protein coding + Chrm2 
ENSMUSG00000027400.11 chr2 129686564 129699833 protein coding - Pdyn 
ENSMUSG00000038319.14 chr5 24319588 24351604 protein coding - Kcnh2 
ENSMUSG00000057182.14 chr2 65457117 65567627 protein coding - Scn3a 
ENSMUSG00000039539.13 chr8 37522553 38661508 protein coding - Sgcz 
ENSMUSG00000053137.7 chr15 89142486 89149628 protein coding - Mapk11 
ENSMUSG00000049265.7 chr5 30588169 30625271 protein coding + Kcnk3 
ENSMUSG00000046178.3 chr6 8948613 9249032 protein coding + Nxph1 
ENSMUSG00000057715.13 chr1 11414104 11975901 protein coding + AC103635.1 
ENSMUSG00000025400.11 chr10 127724477 127731768 protein coding + Tac2 
ENSMUSG00000062995.12 chr6 8630526 8778487 protein coding - Ica1 
ENSMUSG00000070695.4 chr1 115684755 116587323 protein coding + Cntnap5a 
ENSMUSG00000019890.4 chr10 102481755 102490486 protein coding - Nts 
ENSMUSG00000034098.14 chr3 76074269 76710019 protein coding + Fstl5 
ENSMUSG00000036699.12 chrX 36195903 36199158 protein coding + Zcchc12 
ENSMUSG00000062372.13 chr5 30367061 30461932 protein coding - Otof 
ENSMUSG00000046854.16 chr2 32575717 32583782 protein coding + Pip5kl1 
ENSMUSG00000036800.8 chr15 71431608 71727838 protein coding - Fam135b 
ENSMUSG00000021983.16 chr14 59638539 60197179 protein coding - Atp8a2 
163 
 
ENSMUSG00000034145.14 chr12 87026291 87090041 protein coding + Tmem63c 
ENSMUSG00000002012.13 chrX 73655993 73660117 protein coding - Pnck 
ENSMUSG00000040797.16 chr6 121372932 121473678 protein coding - Iqsec3 
ENSMUSG00000040856.17 chr12 109452848 109463336 protein coding + Dlk1 
ENSMUSG00000032968.4 chr1 75507076 75510366 protein coding + Inha 
ENSMUSG00000047507.12 chr17 25242658 25256364 protein coding - Baiap3 
ENSMUSG00000060314.13 chr7 140807448 140822178 protein coding - Zfp941 
ENSMUSG00000029219.10 chr5 73006882 73012955 protein coding + Slc10a4 
ENSMUSG00000036578.7 chr7 31042512 31051467 protein coding - Fxyd7 
ENSMUSG00000039728.15 chr7 49910145 49963856 protein coding + Slc6a5 
ENSMUSG00000067028.11 chr1 99772764 100484849 protein coding + Cntnap5b 
ENSMUSG00000042817.15 chr5 147330740 147400489 protein coding - Flt3 
ENSMUSG00000079277.9 chr2 74736514 74747915 protein coding + Hoxd3 
ENSMUSG00000070823.6 chr5 37154429 37229342 protein coding + RP23-339H11.2 
ENSMUSG00000029361.18 chr5 117841849 117958840 protein coding + Nos1 
ENSMUSG00000075316.11 chr2 66480079 66634952 protein coding - Scn9a 
ENSMUSG00000006711.15 chr13 24845134 24901270 protein coding + RP23-92G13.7 
ENSMUSG00000034997.5 chr14 74640839 74709494 protein coding + Htr2a 
ENSMUSG00000048483.6 chr12 86980762 86990430 protein coding - Zdhhc22 
ENSMUSG00000020042.15 chr10 85386813 85660292 protein coding + Btbd11 
ENSMUSG00000021587.5 chr13 75089825 75134861 protein coding + Pcsk1 
ENSMUSG00000039860.19 chr5 135818105 135874772 protein coding + Srrm3 
ENSMUSG00000022269.13 chr15 26309047 26409576 protein coding + March11 
ENSMUSG00000028780.13 chr5 17574280 17730268 protein coding + Sema3c 
ENSMUSG00000022860.14 chr16 78930947 78951733 protein coding + Chodl 
ENSMUSG00000026399.12 chr1 130439026 130462744 protein coding - Cd55 
ENSMUSG00000026837.15 chr2 27886424 28039514 protein coding + Col5a1 
ENSMUSG00000102752.1 chr1 170298198 170306332 protein coding - RP23-124N16.6 
ENSMUSG00000028051.10 chr3 89146073 89160196 protein coding - Hcn3 
ENSMUSG00000002771.12 chr7 45831882 45870429 protein coding - Grin2d 
ENSMUSG00000068151.7 chr7 61127995 61311721 lincRNA - AC132685.1 
ENSMUSG00000029994.17 chr6 86736839 86793584 protein coding - Anxa4 
ENSMUSG00000050830.17 chr11 11114222 11266638 protein coding + Vwc2 
ENSMUSG00000017400.10 chr11 98036622 98053462 protein coding - Stac2 
ENSMUSG00000036067.12 chr2 27021362 27027998 protein coding - Slc2a6 
ENSMUSG00000026494.12 chr1 178529124 178939200 protein coding + Kif26b 
ENSMUSG00000028963.1 chr4 150997096 151001810 protein coding + Uts2 
ENSMUSG00000022935.16 chr16 87895899 88290258 protein coding - Grik1 
ENSMUSG00000039313.14 chr9 89587215 89623125 protein coding - RP23-407B23.1 
ENSMUSG00000035576.13 chr2 162943473 162974522 protein coding + L3mbtl1 
ENSMUSG00000007030.8 chr17 35016578 35026741 protein coding + Vwa7 
ENSMUSG00000021098.14 chr12 72881108 72940774 protein coding - Six6os1 
ENSMUSG00000052551.16 chr13 8202865 8761530 protein coding + Adarb2 
ENSMUSG00000029544.16 chr5 115168688 115194381 protein coding - Cabp1 
ENSMUSG00000038623.9 chr7 81859000 81884071 protein coding + Tm6sf1 
ENSMUSG00000001520.12 chr6 128399765 128408932 protein coding + Nrip2 
ENSMUSG00000061702.10 chr7 25669138 25675166 protein coding - Tmem91 
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ENSMUSG00000029403.14 chr5 92006073 92043042 protein coding - Cdkl2 
ENSMUSG00000020312.12 chr10 79618651 79637918 protein coding - Shc2 
ENSMUSG00000048126.16 chr1 90765922 90843971 protein coding - Col6a3 
ENSMUSG00000027971.16 chr3 125404075 125728899 protein coding + Ndst4 
ENSMUSG00000050875.11 chr18 59062281 59076962 protein coding + AC132242.1 
ENSMUSG00000023064.4 chr14 34370273 34374789 protein coding - Sncg 
ENSMUSG00000030666.11 chr7 114718642 114723365 protein coding + Calcb 
ENSMUSG00000035745.9 chr10 79970714 79977190 protein coding + Grin3b 
ENSMUSG00000045348.16 chr5 137729898 137741607 protein coding - Nyap1 
ENSMUSG00000046287.7 chrX 73064786 73068191 protein coding + Pnma3 
ENSMUSG00000110246.1 chr8 50743290 50916997 lincRNA - RP23-127M7.1 
ENSMUSG00000020140.15 chr10 115450310 115587780 protein coding - Lgr5 
ENSMUSG00000009075.2 chr11 4736891 4746778 protein coding - Cabp7 
ENSMUSG00000028197.4 chr3 145292471 145552011 protein coding + Col24a1 
ENSMUSG00000053519.15 chr11 33629338 33843585 protein coding - Kcnip1 
ENSMUSG00000038048.8 chr17 57769569 58410355 protein coding + Cntnap5c 
ENSMUSG00000090061.9 chr5 63649107 63810546 protein coding + Nwd2 
ENSMUSG00000031659.13 chr8 88272402 88329962 protein coding + Adcy7 
ENSMUSG00000020701.12 chr11 82388899 82446332 protein coding + Tmem132e 
ENSMUSG00000089901.1 chr14 43925389 43933411 protein coding + RP23-78F6.3 
ENSMUSG00000068615.4 chr2 114009600 114013619 protein coding - Gjd2 
ENSMUSG00000027750.16 chr3 54361108 54391037 protein coding + Postn 
ENSMUSG00000044499.11 chr10 36506813 36834397 protein coding + Hs3st5 
ENSMUSG00000009292.18 chr10 77907721 77969854 protein coding - Trpm2 
ENSMUSG00000018507.16 chr11 62574537 62600515 protein coding + Trpv2 
ENSMUSG00000018589.8 chrX 165129016 165327393 protein coding - Glra2 
ENSMUSG00000036198.12 chrX 49470449 49500244 protein coding + Arhgap36 
ENSMUSG00000028876.7 chr4 124880898 124886930 protein coding + Epha10 
ENSMUSG00000001661.5 chr15 103009572 103011881 protein coding + Hoxc6 
ENSMUSG00000066438.6 chr12 80692590 80724214 protein coding + Plekhd1 
ENSMUSG00000041608.8 chr9 120539817 120568327 protein coding + Entpd3 
ENSMUSG00000050069.3 chr1 174833784 174921819 protein coding - Grem2 
ENSMUSG00000031870.16 chr9 8899832 8968611 protein coding + Pgr 
ENSMUSG00000078235.3 chr4 138394091 138396528 protein coding - Fam43b 
ENSMUSG00000031872.14 chr8 104170441 104219122 protein coding + Bean1 
ENSMUSG00000078117.2 chr9 8971790 8975773 protein coding + Gm16485 
ENSMUSG00000010476.14 chr7 137193672 137314445 protein coding - Ebf3 
ENSMUSG00000036913.15 chr8 124793091 124834704 protein coding + Trim67 
ENSMUSG00000024798.15 chr19 35958733 36057373 protein coding - Htr7 
ENSMUSG00000028214.13 chr4 11704456 11714752 protein coding + Gem 
ENSMUSG00000021675.4 chr13 95696852 95702739 protein coding + F2rl2 
ENSMUSG00000043441.5 chr3 62529076 62605140 protein coding - Gpr149 
ENSMUSG00000038257.9 chr8 55940508 56130070 protein coding + Glra3 
ENSMUSG00000062252.8 chr17 28575717 28583593 protein coding + Lhfpl5 
ENSMUSG00000028555.15 chr4 109407086 109444745 protein coding + Ttc39a 
ENSMUSG00000021998.16 chr14 75131553 75230842 protein coding + Lcp1 
ENSMUSG00000109121.1 chr7 60915549 60922910 lincRNA - RP24-236C17.2 
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ENSMUSG00000034810.7 chr2 66673424 66784914 protein coding - Scn7a 
ENSMUSG00000047415.12 chr12 100876681 100908198 protein coding - Gpr68 
ENSMUSG00000086825.1 chr1 130429780 130437191 lincRNA - AC111067.4 
ENSMUSG00000052520.7 chr4 96628772 96664154 protein coding - Cyp2j5 
ENSMUSG00000038112.15 chr9 39587509 39603687 protein coding - RP23-159L13.1 
ENSMUSG00000022485.3 chr15 103013814 103017429 protein coding + Hoxc5 
ENSMUSG00000001333.9 chr4 129287616 129308559 protein coding + Sync 
ENSMUSG00000028370.7 chr4 65124173 65357509 protein coding + Pappa 
ENSMUSG00000045648.15 chr1 70725714 70885397 protein coding + Vwc2l 
ENSMUSG00000031344.11 chrX 72825177 72842602 protein coding + Gabrq 
ENSMUSG00000091002.2 chr7 138208973 138397728 protein coding - Tcerg1l 
ENSMUSG00000049985.15 chr13 112288450 112384002 protein coding + Ankrd55 
ENSMUSG00000042425.18 chrX 140342262 140435467 protein coding + Frmpd3 
ENSMUSG00000057777.4 chr3 86545580 86548283 protein coding - Mab21l2 
ENSMUSG00000086602.1 chr15 89520095 89523677 lincRNA - AC137513.1 
ENSMUSG00000102692.1 chr3 83127947 83357209 protein coding + Dchs2 
ENSMUSG00000025905.13 chr1 5588492 5606131 protein coding + Oprk1 
ENSMUSG00000043219.9 chr6 52206287 52208722 protein coding - Hoxa6 
ENSMUSG00000000690.5 chr11 96292475 96301569 protein coding + Hoxb6 
ENSMUSG00000038253.6 chr6 52201753 52204587 protein coding - Hoxa5 
ENSMUSG00000031937.7 chr9 15239044 15259416 protein coding + Vstm5 
ENSMUSG00000033249.10 chr8 105269800 105275845 protein coding + Hsf4 
ENSMUSG00000047155.13 chr4 115106322 115134281 protein coding - Cyp4x1 
ENSMUSG00000022076.10 chr14 96102735 96519102 protein coding - Klhl1 
ENSMUSG00000028778.15 chr4 130130216 130139359 protein coding - Hcrtr1 
ENSMUSG00000032297.11 chr9 59578191 59607292 protein coding + Celf6 
ENSMUSG00000057098.14 chr11 44617316 45008091 protein coding + Ebf1 
ENSMUSG00000030043.11 chr6 82402474 82560104 protein coding + Tacr1 
ENSMUSG00000070687.11 chr4 136423523 136444398 protein coding + Htr1d 
ENSMUSG00000038236.8 chr6 52214497 52218711 protein coding - Hoxa7 
ENSMUSG00000042761.14 chr9 87144305 87184045 protein coding + Mrap2 
ENSMUSG00000099839.1 chr1 87142873 87146983 lincRNA - RP23-416O18.4 
ENSMUSG00000048763.11 chr11 96323325 96347930 protein coding + Hoxb3 
ENSMUSG00000001657.7 chr15 102990606 102993821 protein coding + Hoxc8 
ENSMUSG00000001988.9 chr7 16455720 16476780 protein coding - Npas1 
ENSMUSG00000033788.15 chr6 84008589 84211060 protein coding + Dysf 
ENSMUSG00000058400.13 chr3 36179423 36222313 protein coding - Qrfpr 
ENSMUSG00000032360.16 chr9 76225879 76323856 protein coding - Hcrtr2 
ENSMUSG00000043463.6 chrX 136858146 136868755 protein coding - Rab9b 
ENSMUSG00000050783.4 chr16 64924728 65105784 protein coding - Htr1f 
ENSMUSG00000036040.14 chr2 27079378 27108981 protein coding + Adamtsl2 
ENSMUSG00000071531.3 chr14 34185687 34201633 protein coding - Gprin2 
ENSMUSG00000032502.8 chr9 111561436 111690348 protein coding - Stac 
ENSMUSG00000025885.18 chr18 74442536 74771493 protein coding + Myo5b 
ENSMUSG00000047259.2 chr18 66857714 66860472 protein coding - Mc4r 
ENSMUSG00000056972.6 chr7 62377009 62381640 protein coding + Magel2 
ENSMUSG00000049122.17 chr4 74013441 74202214 protein coding + Frmd3 
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ENSMUSG00000093536.7 chr7 6398714 6432093 protein coding + Smim17 
ENSMUSG00000075270.11 chr2 75989911 76338774 protein coding - Pde11a 
ENSMUSG00000069132.3 chr2 23321245 23401973 protein coding + Nxph2 
ENSMUSG00000045731.6 chr14 65400672 65425472 protein coding - Pnoc 
ENSMUSG00000035279.8 chr7 4925784 4944826 protein coding + Ssc5d 
ENSMUSG00000060257.2 chr2 152081528 152095802 protein coding + Scrt2 
ENSMUSG00000039372.5 chr1 72427111 72536930 protein coding - March4 
ENSMUSG00000069911.10 chr11 34314821 34422640 protein coding + Fam196b 
ENSMUSG00000020354.15 chr11 46896252 47578965 protein coding - Sgcd 
ENSMUSG00000027102.4 chr2 74704614 74707933 protein coding + Hoxd8 
ENSMUSG00000038760.14 chr15 44196134 44235544 protein coding + Trhr 
ENSMUSG00000029919.5 chr6 65117292 65144908 protein coding - Hpgds 
ENSMUSG00000019853.6 chr10 18539497 18546076 protein coding - Hebp2 
ENSMUSG00000045777.14 chr7 142326109 142373753 protein coding - Ifitm10 
ENSMUSG00000038227.15 chr6 52223099 52227370 protein coding - Hoxa9 
ENSMUSG00000002633.4 chr5 28456814 28467256 protein coding - Shh 
ENSMUSG00000031355.16 chrX 169036610 169304435 protein coding + Arhgap6 
ENSMUSG00000012819.15 chr10 60302747 60696490 protein coding - Cdh23 
ENSMUSG00000071984.10 chr17 7738568 7804974 protein coding - Fndc1 
ENSMUSG00000045534.4 chr6 126532550 126535412 protein coding - Kcna5 
ENSMUSG00000028753.12 chr4 138565359 138624012 protein coding - Vwa5b1 
ENSMUSG00000026976.15 chr2 24420559 24475599 protein coding - Pax8 
ENSMUSG00000048617.16 chr8 84946990 84956603 protein coding + Rtbdn 
ENSMUSG00000041907.9 chr1 42952962 43035456 protein coding + Gpr45 
ENSMUSG00000050368.4 chr2 74691923 74695105 protein coding + Hoxd10 
ENSMUSG00000024553.7 chr18 82392495 82406777 protein coding - Galr1 
ENSMUSG00000091275.1 chr14 5939224 5961745 protein coding - RP23-314N18.4 
ENSMUSG00000000766.18 chr10 6758505 7038198 protein coding + Oprm1 
ENSMUSG00000074003.4 chr7 98440415 98477479 protein coding + Gucy2d 
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